```
FILE 'HOME' ENTERED AT 09:54:56 ON 30 JUL 2004

=> fil .bec
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,
       ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 09:55:13 ON 30 JUL 2004
ALL COPYRIGHTS AND RESTRICTIONS APPLY.  SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s aminopyrazolopyrimidine? or pyrazolopyrimidine? or (aminopyrazolo or
pyrazolo)(3w)pyrimidine?
FILE 'MEDLINE'
            50 AMINOPYRAZOLOPYRIMIDINE?
            87 PYRAZOLOPYRIMIDINE?
           140 AMINOPYRAZOLO
           852 PYRAZOLO
         27185 PYRIMIDINE?
           502 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L1         591 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'SCISEARCH'
            34 AMINOPYRAZOLOPYRIMIDINE?
           133 PYRAZOLOPYRIMIDINE?
            99 AMINOPYRAZOLO
          2284 PYRAZOLO
         20620 PYRIMIDINE?
           760 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L2         891 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'LIFESCI'
            12 AMINOPYRAZOLOPYRIMIDINE?
            31 PYRAZOLOPYRIMIDINE?
            14 AMINOPYRAZOLO
           145 PYRAZOLO
          5660 PYRIMIDINE?
            77 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L3         109 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOTECHDS'
             0 AMINOPYRAZOLOPYRIMIDINE?
             4 PYRAZOLOPYRIMIDINE?
             3 AMINOPYRAZOLO
            20 PYRAZOLO
           755 PYRIMIDINE?
            19 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L4          22 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOSIS'
            57 AMINOPYRAZOLOPYRIMIDINE?
           146 PYRAZOLOPYRIMIDINE?
           139 AMINOPYRAZOLO
          1751 PYRAZOLO
         21362 PYRIMIDINE?
           656 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L5         805 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
```

```
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'EMBASE'
            47 AMINOPYRAZOLOPYRIMIDINE?
           181 PYRAZOLOPYRIMIDINE?
           174 AMINOPYRAZOLO
          2292 PYRAZOLO
         17694 PYRIMIDINE?
           674 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L6         833 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'HCAPLUS'
           184 AMINOPYRAZOLOPYRIMIDINE?
          1402 PYRAZOLOPYRIMIDINE?
           409 AMINOPYRAZOLO
          5413 PYRAZOLO
         61580 PYRIMIDINE?
          1686 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L7        2301 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'NTIS'
             1 AMINOPYRAZOLOPYRIMIDINE?
             1 PYRAZOLOPYRIMIDINE?
             0 AMINOPYRAZOLO
             5 PYRAZOLO
           526 PYRIMIDINE?
             1 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L8           3 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'ESBIOBASE'
             2 AMINOPYRAZOLOPYRIMIDINE?
            28 PYRAZOLOPYRIMIDINE?
            10 AMINOPYRAZOLO
           290 PYRAZOLO
          4646 PYRIMIDINE?
           129 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L9         156 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOTECHNO'
            15 AMINOPYRAZOLOPYRIMIDINE?
            27 PYRAZOLOPYRIMIDINE?
            42 AMINOPYRAZOLO
           260 PYRAZOLO
          5965 PYRIMIDINE?
            85 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L10        119 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'WPIDS'
             2 AMINOPYRAZOLOPYRIMIDINE?
           126 PYRAZOLOPYRIMIDINE?
            50 AMINOPYRAZOLO
          2380 PYRAZOLO
         12648 PYRIMIDINE?
           515 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L11        596 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

TOTAL FOR ALL FILES
L12       6426 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
```

```
              O OR PYRAZOLO)(3W) PYRIMIDINE?

=> s l12 and src(4a)inhibit?
FILE 'MEDLINE'
         14361 SRC
       1117037 INHIBIT?
          1401 SRC(4A)INHIBIT?
L13        126 L1 AND SRC(4A)INHIBIT?

FILE 'SCISEARCH'
         13627 SRC
        907143 INHIBIT?
          1457 SRC(4A)INHIBIT?
L14         71 L2 AND SRC(4A)INHIBIT?

FILE 'LIFESCI'
          5412 SRC
        306371 INHIBIT?
           494 SRC(4A)INHIBIT?
L15         18 L3 AND SRC(4A)INHIBIT?

FILE 'BIOTECHDS'
           250 SRC
         48149 INHIBIT?
            27 SRC(4A)INHIBIT?
L16          1 L4 AND SRC(4A)INHIBIT?

FILE 'BIOSIS'
         14113 SRC
       1210047 INHIBIT?
          1736 SRC(4A)INHIBIT?
L17         70 L5 AND SRC(4A)INHIBIT?

FILE 'EMBASE'
         10619 SRC
       1006321 INHIBIT?
          1376 SRC(4A)INHIBIT?
L18         96 L6 AND SRC(4A)INHIBIT?

FILE 'HCAPLUS'
         14133 SRC
       1670645 INHIBIT?
          1707 SRC(4A)INHIBIT?
L19         82 L7 AND SRC(4A)INHIBIT?

FILE 'NTIS'
          2011 SRC
         20284 INHIBIT?
            10 SRC(4A)INHIBIT?
L20          0 L8 AND SRC(4A)INHIBIT?

FILE 'ESBIOBASE'
          7242 SRC
        382890 INHIBIT?
          1134 SRC(4A)INHIBIT?
L21         68 L9 AND SRC(4A)INHIBIT?

FILE 'BIOTECHNO'
          7046 SRC
        301415 INHIBIT?
           754 SRC(4A)INHIBIT?
L22         38 L10 AND SRC(4A)INHIBIT?

FILE 'WPIDS'
```

```
          821 SRC
       219315 INHIBIT?
          144 SRC(4A)INHIBIT?
L23         5 L11 AND SRC(4A)INHIBIT?

TOTAL FOR ALL FILES
L24       575 L12 AND SRC(4A) INHIBIT?

=> dup rem l24
PROCESSING COMPLETED FOR L24
L25       181 DUP REM L24 (394 DUPLICATES REMOVED)

=> d tot

L25   ANSWER 1 OF 181  BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
TI    Identifying therapeutic compound for treating Alzheimer's disease,
      involves providing Src protein and determining
      inhibitory effect of compound on Src activity;
         recombinant protein production for use in drug screening and disease
         therapy
AU    MERCKEN L; ZAMBRANO N; RUSSO T
AN    2004-14884  BIOTECHDS
PI    EP 1413887 28 Apr 2004

L25  ANSWER 2 OF 181  WPIDS  COPYRIGHT 2004 THOMSON DERWENT on STN
TI   Use of an inhibitor of vascular endothelial growth factor-mediated
     vascular permeability e.g. a pyrazolopyrimidine or
     4-anilino-3-quinolinecarbonitrile derivative to treat, prevent or reduce
     reperfusion injury or post-pump syndrome.
PI   WO 2004032709   A2 20040422 (200432)* EN   62    A61B000-00
        RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
            LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
            DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
            KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
            RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
            ZM ZW
IN   LORSORDO, D W

L25  ANSWER 3 OF 181     MEDLINE on STN                  DUPLICATE 2
TI   Mechanical strain on osteoblasts activates autophosphorylation of focal
     adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved
     in ERK activation.
SO   Journal of biological chemistry, (2004 Jul 16) 279 (29) 30588-99.
     Journal code: 2985121R. ISSN: 0021-9258.
AU   Boutahar Nadia; Guignandon Alain; Vico Laurence; Lafage-Proust
     Marie-Helene
AN   2004343375     IN-PROCESS

L25  ANSWER 4 OF 181     MEDLINE on STN                  DUPLICATE 3
TI   Activation of vascular endothelial growth factor receptor-3 and its
     downstream signaling promote cell survival under oxidative stress.
SO   Journal of biological chemistry, (2004 Jun 25) 279 (26) 27088-97.
     Journal code: 2985121R. ISSN: 0021-9258.
AU   Wang Jian Feng; Zhang Xuefeng; Groopman Jerome E
AN   2004305796     IN-PROCESS

L25  ANSWER 5 OF 181     MEDLINE on STN                  DUPLICATE 4
TI   Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation
     of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation
     and survival of multiple myeloma cells.
SO   Journal of biological chemistry, (2004 May 14) 279 (20) 21658-65.
     Journal code: 2985121R. ISSN: 0021-9258.
AU   Podar Klaus; Mostoslavsky Gustavo; Sattler Martin; Tai Yu-Tzu; Hayashi
```

Toshiaki; Catley Laurence P; Hideshima Teru; Mulligan Richard C; Chauhan Dharminder; Anderson Kenneth C
AN 2004234576 MEDLINE

L25 ANSWER 6 OF 181 MEDLINE on STN
TI Role of vav1- and src-related tyrosine kinases in macrophage activation by CpG DNA.
SO Journal of biological chemistry, (2004 Apr 2) 279 (14) 13809-16.
Journal code: 2985121R. ISSN: 0021-9258.
AU Stovall Stephanie H; Yi Ae-Kyung; Meals Elizabeth A; Talati Ajay J; Godambe Sandip A; English B Keith
AN 2004154652 MEDLINE

L25 ANSWER 7 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance.
SO Oncogene, (29 Apr 2004) 23/20 (3530-3540).
Refs: 47
ISSN: 0950-9232 CODEN: ONCNES
AU Vega M.I.; Huerta-Yepaz S.; Garban H.; Jazirehi A.; Emmanouilides C.; Bonavida B.
AN 2004224066 EMBASE

L25 ANSWER 8 OF 181 HCAPLUS COPYRIGHT 2004 ACS on STN
TI A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(10), 2613-2616
CODEN: BMCLE8; ISSN: 0960-894X
AU Borhani, David W.; Calderwood, David J.; Friedman, Michael M.; Hirst, Gavin C.; Li, Biqin; Leung, Adelaine K. W.; McRae, Brad; Ratnofsky, Sheldon; Ritter, Kurt; Waegell, Wendy
AN 2004:346273 HCAPLUS
DN 141:81914

L25 ANSWER 9 OF 181 MEDLINE on STN DUPLICATE 5
TI New **pyrazolo**[3,4-d]**pyrimidines** endowed with A431 antiproliferative activity and **inhibitory** properties of **Src** phosphorylation.
SO Bioorganic & medicinal chemistry letters, (2004 May 17) 14 (10) 2511-7.
Journal code: 9107377. ISSN: 0960-894X.
AU Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Mosti L; Menozzi G; Carraro F; Naldini A; Bernini C; Manetti F; Botta M
AN 2004212341 IN-PROCESS

L25 ANSWER 10 OF 181 MEDLINE on STN DUPLICATE 6
TI **Inhibition** of **SRC** tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2004 Apr 1) 10 (7) 2307-18.
Journal code: 9502500. ISSN: 1078-0432.
AU Duxbury Mark S; Ito Hiromichi; Zinner Michael J; Ashley Stanley W; Whang Edward E
AN 2004178445 IN-PROCESS

L25 ANSWER 11 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI SRC: Regulation, role in human carcinogenesis and pharmacological inhibitors.
SO Current Pharmaceutical Design, (2004) 10/15 (1745-1756).
Refs: 261
ISSN: 1381-6128 CODEN: CPDEFP
AU Tsygankov A.Y.; Shore S.K.
AN 2004219492 EMBASE

L25 ANSWER 12 OF 181 MEDLINE on STN
TI Hydrogen peroxide generation induces pp60src activation in human platelets: evidence for the involvement of this pathway in store-mediated calcium entry.
SO Journal of biological chemistry, (2004 Jan 16) 279 (3) 1665-75. Journal code: 2985121R. ISSN: 0021-9258.
AU Rosado Juan A; Redondo Pedro C; Salido Gines M; Gomez-Arteta Emilio; Sage Stewart O; Pariente Jose A
AN 2004018590 MEDLINE

L25 ANSWER 13 OF 181 MEDLINE on STN DUPLICATE 7
TI Combination of an **SRC** kinase **inhibitor** with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2004 Feb 15) 10 (4) 1545-55. Journal code: 9502500. ISSN: 1078-0432.
AU Boyd Douglas D; Wang Heng; Avila Hector; Parikh Nila U; Kessler Horst; Magdolen Victor; Gallick Gary E
AN 2004088380 IN-PROCESS

L25 ANSWER 14 OF 181 MEDLINE on STN DUPLICATE 8
TI Recruitment of the cross-linked opsonic receptor CD32A (FcgammaRIIA) to high-density detergent-resistant membrane domains in human neutrophils.
SO Biochemical journal, (2004 Aug 1) 381 (Pt 3) 919-28. Journal code: 2984726R. ISSN: 1470-8728.
AU Rollet-Labelle Emmanuelle; Marois Sebastien; Barbeau Kathy; Malawista Stephen E; Naccache Paul H
AN 2004367991 IN-PROCESS

L25 ANSWER 15 OF 181 MEDLINE on STN DUPLICATE 9
TI Carbachol regulation of rabbit ileal brush border Na+-H+ exchanger 3 (NHE3) occurs through changes in NHE3 trafficking and complex formation and is Src dependent.
SO Journal of physiology, (2004 May 1) 556 (Pt 3) 791-804. Journal code: 0266262. ISSN: 0022-3751.
AU Li Xuhang; Zhang Huiping; Cheong Alice; Leu Sharon; Chen Yueping; Elowsky Christian G; Donowitz Mark
AN 2004220162 IN-PROCESS

L25 ANSWER 16 OF 181 MEDLINE on STN DUPLICATE 10
TI Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells.
SO Biochemical journal, (2004 Mar 1) 378 (Pt 2) 559-67. Journal code: 2984726R. ISSN: 1470-8728.
AU Park Hee Boong; Golubovskaya Vita; Xu Lihui; Yang Xihui; Lee Jin Woo; Scully Sean 2nd; Craven Rolf Joseph; Cance William G
AN 2004092278 MEDLINE

L25 ANSWER 17 OF 181 MEDLINE on STN
TI Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils.
SO Journal of leukocyte biology, (2004 Aug) 76 (2) 433-40. Journal code: 8405628. ISSN: 0741-5400.
AU Ryckman Carle; Gilbert Caroline; De Medicis Rinaldo; Lussier Andre; Vandal Karen; Tessier Philippe A
AN 2004373913 IN-PROCESS

L25 ANSWER 18 OF 181 MEDLINE on STN DUPLICATE 11
TI Kappa-opioid receptor signals through Src and focal adhesion kinase to stimulate c-Jun N-terminal kinases in transfected COS-7 cells and human monocytic THP-1 cells.
SO Journal of pharmacology and experimental therapeutics, (2004 Jul) 310 (1)

301-10.
Journal code: 0376362. ISSN: 0022-3565.
AU Kam Angel Y F; Chan Anthony S L; Wong Yung H
AN 2004354345 IN-PROCESS

L25 ANSWER 19 OF 181 MEDLINE on STN DUPLICATE 12
TI Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event.
SO Biochemical journal, (2004 Jan 1) 377 (Pt 1) 249-55.
Journal code: 2984726R. ISSN: 1470-8728.
AU Cole Adam; Frame Sheelagh; Cohen Philip
AN 2003591495 MEDLINE

L25 ANSWER 20 OF 181 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event
SO BIOCHEMICAL JOURNAL, (1 JAN 2004) Vol. 377, Part 1, pp. 249-255.
Publisher: PORTLAND PRESS, 59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND.
ISSN: 0264-6021.
AU Cole A; Frame S; Cohen P (Reprint)
AN 2004:69341 SCISEARCH

L25 ANSWER 21 OF 181 MEDLINE on STN DUPLICATE 13
TI **Pyrazolo pyrimidine**-type **inhibitors** of **SRC** family tyrosine kinases promote ovarian steroid-induced differentiation of human endometrial stromal cells in vitro.
SO Biology of reproduction, (2004 Jan) 70 (1) 214-21.
Journal code: 0207224. ISSN: 0006-3363.
AU Maruyama Tetsuo; Yamamoto Yurie; Shimizu Aki; Masuda Hirotaka; Sakai Nozomi; Sakurai Rei; Asada Hironori; Yoshimura Yasunori
AN 2003604897 MEDLINE

L25 ANSWER 22 OF 181 MEDLINE on STN DUPLICATE 14
TI c-Src-dependent cross-talk between CEACAM6 and alphavbeta3 integrin enhances pancreatic adenocarcinoma cell adhesion to extracellular matrix components.
SO Biochemical and biophysical research communications, (2004 Apr 23) 317 (1) 133-41.
Journal code: 0372516. ISSN: 0006-291X.
AU Duxbury Mark S; Ito Hiromichi; Ashley Stanley W; Whang Edward E
AN 2004153947 MEDLINE

L25 ANSWER 23 OF 181 MEDLINE on STN DUPLICATE 15
TI Extracellular signal-regulated kinase 1/2 is required for the induction of group I metabotropic glutamate receptor-mediated epileptiform discharges.
SO Journal of neuroscience : official journal of the Society for Neuroscience, (2004 Jan 7) 24 (1) 76-84.
Journal code: 8102140. ISSN: 1529-2401.
AU Zhao Wangfa; Bianchi Riccardo; Wang Min; Wong Robert K S
AN 2004018984 MEDLINE

L25 ANSWER 24 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Signals mediating cleavage of intercellular adhesion molecule-1.
SO American Journal of Physiology - Cell Physiology, (2004) 287/1 56-1 (C55-C63).
Refs: 54
ISSN: 0363-6143 CODEN: AJPCDD
AU Tsakadze N.L.; Sen U.; Zhao Z.; Sithu S.D.; English W.R.; D'Souza S.E.
AN 2004259031 EMBASE

L25 ANSWER 25 OF 181 MEDLINE on STN DUPLICATE 16
TI Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia.

SO Journal of neuroscience : official journal of the Society for Neuroscience, (2004 Jan 7) 24 (1) 1-7.
Journal code: 8102140. ISSN: 1529-2401.
AU Suzuki Tomohisa; Hide Izumi; Ido Katsutoshi; Kohsaka Shinichi; Inoue Kazuhide; Nakata Yoshihiro
AN 2004019819 MEDLINE

L25 ANSWER 26 OF 181 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI Production and release of neuroprotective tumor necrosis factor by P2X(7) receptor-activated microglia
SO JOURNAL OF NEUROSCIENCE, (7 JAN 2004) Vol. 24, No. 1, pp. 1-7.
Publisher: SOC NEUROSCIENCE, 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA.
ISSN: 0270-6474.
AU Suzuki T; Hide I (Reprint); Ido K; Kohsaka S; Inoue K; Nakata Y
AN 2004:59016 SCISEARCH

L25 ANSWER 27 OF 181 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 17
TI Method of treatment of myocardial infarction using **Src** kinase **inhibitors**
SO U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 538,248.
CODEN: USXXCO
IN Cheresh, David A.; Paul, Robert; Eliceiri, Brian
AN 2003:532334 HCAPLUS
DN 139:95468

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003130209	A1	20030710	US 2002-298377	20021118
US 6685938	B1	20040203	US 1999-470881	19991222
WO 2004045563	A2	20040603	WO 2003-US37653	20031118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L25 ANSWER 28 OF 181 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of phosphorus-substituted pyrazolo- and pyrrolopyrimidines as therapeutic agents
SO PCT Int. Appl., 165 pp.
CODEN: PIXXD2
IN Shakespeare, William C.; Sawyer, Tomi K.; Metcalf, Chester A., III; Wang, Yihan; Bohacek, Regine; Sundaramoorthi, Rajeswari
AN 2003:5718 HCAPLUS
DN 138:56075

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003000187	A2	20030103	WO 2002-US19632	20020621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003114467 A1 20030619 US 2002-177563 20020621

L25 ANSWER 29 OF 181 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI New pyrazole compounds are protein kinase inhibitors, for treating e.g. cancer, diabetes, Alzheimer's disease, Parkinson's disease, AIDS-associated dementia, amyotrophic lateral sclerosis, multiple sclerosis.
PI US 2003055068 A1 20030320 (200377)* 154 A61K031-517
IN BEBBINGTON, D; CHARRIER, J; DAVIES, R; EVERITT, S; KAY, D; KNEGTEL, R; PATEL, S

L25 ANSWER 30 OF 181 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI **Src** family kinase **inhibitor** PP1 improves motor function by reducing edema after spinal cord contusion in rats.
SO Kuroiwa, T. [Editor, Reprint Author]; Baethmann, A. [Editor]; Czernicki, Z. [Editor]; Hoff, J. T. [Editor]; Ito, U. [Editor]; Katayama, Y. [Editor]; Marmarou, A. [Editor]; Mendelow, A. D. [Editor]; Reulen, H.-J. [Editor]. Acta Neurochir. Suppl., (2003) pp. 421-423. Brain edema 12. print.
Publisher: Springer-Verlag Wien KG, Sachsenplatz 4-6, A-1200, Vienna, Austria; Springer-Verlag New York Inc., 175 Fifth Avenue, New York, NY, 10010-7858, USA. Series: Acta Neurochirurgica Supplement.
Meeting Info.: 12th International Symposium on Brain Edema and Brain Tissue Injury. Hakone, Japan. November 10-13, 2002.
CODEN: ANCSBM. ISSN: 0065-1419. ISBN: 3-211-00919-1 (cloth).
AU Akiyama, C. [Reprint Author]; Yuguchi, T.; Nishio, M.; Fujinaka, T.; Taniguchi, M.; Nakajima, Y.; Yoshimine, T.
AN 2004:111907 BIOSIS

L25 ANSWER 31 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Oxidative Stress Reprograms Lipopolysaccharide Signaling via Src Kinase-dependent Pathway in RAW 264.7 Macrophage Cell Line.
SO Journal of Biological Chemistry, (28 Nov 2003) 278/48 (47834-47841). Refs: 33
ISSN: 0021-9258 CODEN: JBCHA3
AU Khadaroo R.G.; Kapus A.; Powers K.A.; Cybulsky M.I.; Marshall J.C.; Rotstein O.D.
AN 2003508826 EMBASE

L25 ANSWER 32 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 18
TI Integrin α(IIb)β(3)-dependent calcium signals regulate platelet-fibrinogen interactions under flow: Involvement of phospholipase Cγ2.
SO Journal of Biological Chemistry, (12 Sep 2003) 278/37 (34812-34822). Refs: 45
ISSN: 0021-9258 CODEN: JBCHA3
AU Goncalves I.; Hughan S.C.; Schoenwaelder S.M.; Yap C.L.; Yuan Y.; Jackson S.P.
AN 2003370786 EMBASE

L25 ANSWER 33 OF 181 MEDLINE on STN DUPLICATE 19
TI Src kinase mediates the regulation of phospholipase C-gamma activity by glycosphingolipids.
SO Journal of biological chemistry, (2003 Aug 15) 278 (33) 31419-25.
Journal code: 2985121R. ISSN: 0021-9258.
AU Shu Liming; Shayman James A
AN 2003392159 MEDLINE

L25 ANSWER 34 OF 181 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Platelet-derived growth factor induces the beta-gamma-secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway.

SO Journal of Biological Chemistry, (March 14 2003) Vol. 278, No. 11, pp. 9290-9297. print.
CODEN: JBCHA3. ISSN: 0021-9258.
AU Gianni, Davide; Zambrano, Nicola; Bimonte, Marida; Minopoli, Giuseppina; Mercken, Luc; Talamo, Fabio; Scaloni, Andrea; Russo, Tommaso [Reprint Author]
AN 2003:201742 BIOSIS

L25 ANSWER 35 OF 181 MEDLINE on STN DUPLICATE 20
TI Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation in T cells.
SO Journal of immunology (Baltimore, Md. : 1950), (2003 Jun 15) 170 (12) 6024-32.
Journal code: 2985117R. ISSN: 0022-1767.
AU Sharfe Nigel; Freywald Andrew; Toro Ana; Roifman Chaim M
AN 2003268264 MEDLINE

L25 ANSWER 36 OF 181 MEDLINE on STN DUPLICATE 21
TI The **Src**-selective kinase **inhibitor** PP1 also inhibits Kit and Bcr-Abl tyrosine kinases.
SO Journal of biological chemistry, (2003 Feb 14) 278 (7) 4847-53.
Journal code: 2985121R. ISSN: 0021-9258.
AU Tatton Louise; Morley Gary M; Chopra Rajesh; Khwaja Asim
AN 2003087957 MEDLINE

L25 ANSWER 37 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 22
TI Erratum: Bone-Targeted **Src** Kinase **Inhibitors**: Novel Pyrrolo- and **Pyrazolopyrimidine** Analogues (Bioorganic and Medicinal Chemistry Letters (2003) 13 (3063)).
SO Bioorganic and Medicinal Chemistry Letters, (15 Dec 2003) 13/24 (4519). ISSN: 0960-894X CODEN: BMCLE8
AU Sundaramoorthi R.; Shakespeare W.C.; Keenan T.P.; Metcalf III C.A.; Wang Y.; Mani U.; Merry T.; Liu S.; Bohacek R.S.; Narula S.S.; Dalgarno D.C.; Van Schravendijk M.R.; Violette S.M.; Liou S.; Adams S.; Ram M.K.; Keats J.A.; Weigle M.; Sawyer T.K.
AN 2003496614 EMBASE

L25 ANSWER 38 OF 181 MEDLINE on STN
TI Corrigendum to "Bone-Targeted **Src** Kinase **Inhibitors**: Novel Pyrrolo- and **Pyrazolopyrimidine** Analogues"[bioorg. Med. Chemical Lett. 13 (2003) 3063].
SO Bioorganic & medicinal chemistry letters, (2003 Dec 15) 13 (24) 4519.
Journal code: 9107377. ISSN: 0960-894X.
AU Sundaramoorthi Raji; Shakespeare William C; Keenan Terence P; Metcalf Chester A; Wang Yihan; Mani Ukti; Merry Taylor; Liu Shuangying; Bohacek Regine S; Narula Surinder S; Dalgarno David C; Van Schravendijk Marie Rose; Violette Shelia M; Liou Shuenn; Adams Susan; Ram Mary K; Keats Jeffrey A; Weigle Manfred; Sawyer Tomi K
AN 2003565519 IN-PROCESS

L25 ANSWER 39 OF 181 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI Bone-targeted **src** kinase **inhibitors**: Novel pyrrolo- and **pyrazolopyrimidine** analogues (vol 13, pg 3063, 2003)
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (15 DEC 2003) Vol. 13, No. 24, pp. 4519-4519.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND.
ISSN: 0960-894X.
AU Sundaramoorthi R (Reprint); Shakespeare W C; Keenan T P; Metcalf C A; Wang Y H; Mani U; Merry T; Liu S Y; Bohacek R S; Narula S S; Dalgarno D C; Van Schravendijk M R; Violette S M; Liou S; Adams S; Ram M K; Keats J A; Weigle M; Sawyer T K
AN 2003:1091901 SCISEARCH

L25 ANSWER 40 OF 181 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI (Correction of Previews 200300564392. Bone-targeted **Src** kinase **inhibitors**: Novel pyrrolo- and **pyrazolopyrimidine** analogues. Correction of author names.).
SO Bioorganic & Medicinal Chemistry Letters, (15 December 2003) Vol. 13, No. 24, pp. 4519. print.
CODEN: BMCLE8. ISSN: 0960-894X.
AU Sundaramoorthi, Raji [Reprint Author]; Shakespeare, William C.; Keenan, Terence P.; Metcalf, Chester A. III; Wang, Yihan; Mani, Ukti; Merry, Taylor; Liu, Shuangying; Bohacek, Regine S.; Narula, Surinder S.; Dalgarno, David C.; Van Schravendijk, Marie Rose; Violette, Shelia M.; Liou, Shuenn; Adams, Susan; Ram, Mary K.; Keats, Jeffrey A.; Weigle, Manfred; Sawyer, Tomi K.
AN 2004:271691 BIOSIS

L25 ANSWER 41 OF 181 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Bone-Targeted **Src** kinase **inhibitors**: novel pyrrolo- and **pyrazolopyrimidine** analogues. [Erratum to document cited in CA139:285654]
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(24), 4519
CODEN: BMCLE8; ISSN: 0960-894X
AU Sundaramoorthi, Raji; Shakespeare, William C.; Keenan, Terence P.; Metcalf, Chester A., III; Wang, Yihan; Mani, Ukti; Merry, Taylor; Liu, Shuangying; Bohacek, Regine S.; Narula, Surinder S.; Dalgarno, David C.; Van Schravendijk, Marie Rose; Violette, Shelia M.; Liou, Shuenn; Adams, Susan; Ram, Mary K.; Keats, Jeffrey A.; Weigle, Manfred; Sawyer, Tomi K.
AN 2003:928905 HCAPLUS

L25 ANSWER 42 OF 181 MEDLINE on STN DUPLICATE 23
TI Eosinophil major basic protein stimulates neutrophil superoxide production by a class IA phosphoinositide 3-kinase and protein kinase C-zeta-dependent pathway.
SO Journal of immunology (Baltimore, Md. : 1950), (2003 Oct 1) 171 (7) 3734-41.
Journal code: 2985117R. ISSN: 0022-1767.
AU Shenoy Neeta G; Gleich Gerald J; Thomas Larry L
AN 2003440997 MEDLINE

L25 ANSWER 43 OF 181 MEDLINE on STN DUPLICATE 24
TI Bone-targeted **Src** kinase **inhibitors**: novel pyrrolo- and **pyrazolopyrimidine** analogues.
SO Bioorganic & medicinal chemistry letters, (2003 Sep 15) 13 (18) 3063-6.
Journal code: 9107377. ISSN: 0960-894X.
AU Sundaramoorthi Raji; Shakespeare William C; Keenan Terence P; Metcalf Chester A 3rd; Wang Yihan; Mani Ukti; Taylor Merry; Liu Shuangying; Bohacek Regine S; Narula Surinder S; Dalgarno David C; van Schravandijk Marie Rose; Violette Sheila M; Liou Shuenn; Adams Susan; Ram Mary K; Keats Jeffrey A; Weigele Manfred; Sawyer Tomi K
AN 2003402621 MEDLINE

L25 ANSWER 44 OF 181 MEDLINE on STN DUPLICATE 25
TI Activation of cell adhesion kinase beta by mechanical stretch in vascular smooth muscle cells.
SO Endocrinology, (2003 Jun) 144 (6) 2304-10.
Journal code: 0375040. ISSN: 0013-7227.
AU Iwasaki Hiroaki; Yoshimoto Takanobu; Sugiyama Toru; Hirata Yukio
AN 2003223957 MEDLINE

L25 ANSWER 45 OF 181 MEDLINE on STN DUPLICATE 26
TI Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen.
SO Journal of biological chemistry, (2003 Jan 24) 278 (4) 2118-23.
Journal code: 2985121R. ISSN: 0021-9258.

AU Haynes M Page; Li Lei; Sinha Diviya; Russell Kerry S; Hisamoto Koji; Baron Roland; Collinge Mark; Sessa William C; Bender Jeffrey R
AN 2003040930 MEDLINE

L25 ANSWER 46 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Platelet adhesion to collagen and collagen-related peptide under flow: Roles of the α(2)β(1) integrin, GPVI, and Src tyrosine kinases.
SO Arteriosclerosis, Thrombosis, and Vascular Biology, (2003) 23/10 (1934-1940).
Refs: 41
ISSN: 1079-5642 CODEN: ATVBFA
AU Polanowska-Grabowska R.; Gibbins J.M.; Gear A.R.L.
AN 2003412972 EMBASE

L25 ANSWER 47 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI c-Src kinase activation regulates preprotachykinin gene expression and substance P secretion in rat sensory ganglia.
SO European Journal of Neuroscience, (2003) 18/7 (1719-1730).
Refs: 115
ISSN: 0953-816X CODEN: EJONEI
AU Igwe O.J.
AN 2003453032 EMBASE

L25 ANSWER 48 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 27
TI Regulation of vascular endothelial growth factor production by Leydig cells in vitro: The role of protein kinase A and mitogen-activated protein kinase cascade.
SO Biology of Reproduction, (1 May 2003) 68/5 (1663-1673).
Refs: 61
ISSN: 0006-3363 CODEN: BIREBV
AU Kaur Anand R.J.; Paust H.-J.; Altenpohl K.; Mukhopadhyay A.K.
AN 2003175984 EMBASE

L25 ANSWER 49 OF 181 MEDLINE on STN DUPLICATE 28
TI The role of the Ca2+-sensitive tyrosine kinase Pyk2 and Src in thrombin signalling in rat astrocytes.
SO Journal of neurochemistry, (2003 Mar) 84 (6) 1349-57.
Journal code: 2985190R. ISSN: 0022-3042.
AU Wang Hong; Reiser Georg
AN 2003103100 MEDLINE

L25 ANSWER 50 OF 181 MEDLINE on STN DUPLICATE 29
TI PTTH-stimulated ecdysone secretion is dependent upon tyrosine phosphorylation in the prothoracic glands of Manduca sexta.
SO Insect biochemistry and molecular biology, (2003 Dec) 33 (12) 1317-25.
Journal code: 9207282. ISSN: 0965-1748.
AU Smith Wendy; Priester Jennifer; Morais Jason
AN 2003522055 MEDLINE

L25 ANSWER 51 OF 181 MEDLINE on STN DUPLICATE 30
TI IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism.
SO Kidney international, (2003 Apr) 63 (4) 1249-55.
Journal code: 0323470. ISSN: 0085-2538.
AU Gruden Gabriella; Araf Shawanna; Zonca Silvia; Burt Davina; Thomas Stephen; Gnudi Luigi; Viberti Giancarlo
AN 2003215649 MEDLINE

L25 ANSWER 52 OF 181 MEDLINE on STN DUPLICATE 31
TI Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity.

SO Biochemical journal, (2003 Jun 15) 372 (Pt 3) 841-9.
Journal code: 2984726R. ISSN: 0264-6021.
AU Donella-Deana Arianna; Cesaro Luca; Sarno Stefania; Ruzzene Maria; Brunati Anna Maria; Marin Oriano; Vilk Greg; Doherty-Kirby Amanda; Lajoie Gilles; Litchfield David W; Pinna Lorenzo A
AN 2003258406 MEDLINE

L25 ANSWER 53 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 32
TI Intercellular signalling within vascular cells under high D-glucose involves free radical-triggered tyrosine kinase activation.
SO Diabetologia, (1 Jun 2003) 46/6 (773-783).
Refs: 53
ISSN: 0012-186X CODEN: DBTGAJ
AU Schaeffer G.; Levak-Frank S.; Spitaler M.M.; Fleischhacker E.; Esenabhalu V.E.; Wagner A.H.; Hecker M.; Graier W.F.
AN 2003281373 EMBASE

L25 ANSWER 54 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 33
TI Fgr but not Syk tyrosine kinase is a target for β(2) integrin-induced c-Cbl-mediated ubiquitination in adherent human neutrophils.
SO Biochemical Journal, (1 Mar 2003) 370/2 (687-694).
Refs: 41
ISSN: 0264-6021 CODEN: BIJOAK
AU Melander F.; Andersson T.; Dib K.
AN 2003114177 EMBASE

L25 ANSWER 55 OF 181 MEDLINE on STN DUPLICATE 34
TI Dual-specific **Src** and Abl kinase **inhibitors**, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
SO Blood, (2003 Jan 15) 101 (2) 664-72.
Journal code: 7603509. ISSN: 0006-4971.
AU Warmuth Markus; Simon Nicola; Mitina Olga; Mathes Ruth; Fabbro Doriano; Manley Paul W; Buchdunger Elisabeth; Forster Karin; Moarefi Ismail; Hallek Michael
AN 2003021595 MEDLINE

L25 ANSWER 56 OF 181 MEDLINE on STN DUPLICATE 35
TI Src kinase activity is required for avoidance memory formation and recall.
SO Behavioural pharmacology, (2003 Dec) 14 (8) 649-52.
Journal code: 9013016. ISSN: 0955-8810.
AU Bevilaqua L R M; Rossato J I; Medina J H; Izquierdo I; Cammarota M
AN 2003584063 MEDLINE

L25 ANSWER 57 OF 181 MEDLINE on STN DUPLICATE 36
TI Chemical anoxia of tubular cells induces activation of c-Src and its translocation to the zonula adherens.
SO American journal of physiology. Renal physiology, (2003 Mar) 284 (3) F488-97.
Journal code: 100901990. ISSN: 0363-6127.
AU Sinha Diviya; Wang Zhiyong; Price Valerie R; Schwartz John H; Lieberthal Wilfred
AN 2003046920 MEDLINE

L25 ANSWER 58 OF 181 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2003050821 ESBIOBASE
TI Chemical anoxia of tubular cells induces activation of c-Src and its translocation to the zonula adherens
AU Sinha D.; Wang Z.; Price V.R.; Schwartz J.H.; Lieberthal W.
CS W. Lieberthal, Renal Section, Evans Biomedical Research Ctr., 650 Albany St., Boston, MA 02118, United States.

E-mail: wliebert@bu.edu
SO American Journal of Physiology - Renal Physiology, (01 MAR 2003), 284/3 53-3 (F488-F497), 53 reference(s)
CODEN: AJPPFK ISSN: 0363-6127
DT Journal; Article
CY United States
LA English
SL English

L25 ANSWER 59 OF 181 MEDLINE on STN DUPLICATE 37
TI Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation.
SO Molecular pharmacology, (2003 Aug) 64 (2) 447-55.
Journal code: 0035623. ISSN: 0026-895X.
AU Yang Ming; Zhang Hongmei; Voyno-Yasenetskaya Tatyana; Ye Richard D
AN 2003361768 MEDLINE

L25 ANSWER 60 OF 181 MEDLINE on STN
TI **Src** family kinase **inhibitor** PP1 improves motor function by reducing edema after spinal cord contusion in rats.
SO Acta neurochirurgica. Supplement, (2003) 86 421-3.
Journal code: 100962752. ISSN: 0065-1419.
AU Akiyama C; Yuguchi T; Nishio M; Fujinaka T; Taniguchi M; Nakajima Y; Yoshimine T
AN 2004052494 MEDLINE

L25 ANSWER 61 OF 181 MEDLINE on STN
TI Pp60c-src mediates ERK activation/nuclear localization and PAI-1 gene expression in response to cellular deformation.
SO Journal of cellular physiology, (2003 Jun) 195 (3) 411-20.
Journal code: 0050222. ISSN: 0021-9541.
AU Samarakoon Rohan; Higgins Paul J
AN 2003185628 MEDLINE

L25 ANSWER 62 OF 181 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin-6- induced proliferation and survival of multiple myeloma cells.
SO Blood, (November 16 2003) Vol. 102, No. 11, pp. 368b. print.
Meeting Info.: 45th Annual Meeting of the American Society of Hematology. San Diego, CA, USA. December 06-09, 2003. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
AU Podar, Klaus [Reprint Author]; Mostoslavsky, Gustavo; Tai, Yu-Tzu [Reprint Author]; Sattler, Martin [Reprint Author]; Hayashi, Toshiaki [Reprint Author]; Catley, Laurence P. [Reprint Author]; Hideshima, Teru [Reprint Author]; Mulligan, Richard C.; Chauhan, Dharminder [Reprint Author]; Anderson, Kenneth C. [Reprint Author]
AN 2004:184543 BIOSIS

L25 ANSWER 63 OF 181 MEDLINE on STN DUPLICATE 38
TI Regulation of K-Cl cotransport by Syk and Src protein tyrosine kinases in deoxygenated sickle cells.
SO Pflugers Archiv : European journal of physiology, (2003 May) 446 (2) 232-8.
Journal code: 0154720. ISSN: 0031-6768.
AU Merciris P; Claussen W J; Joiner C H; Giraud F
AN 2003217994 MEDLINE

L25 ANSWER 64 OF 181 MEDLINE on STN DUPLICATE 39
TI **Inhibition** of tyrosine kinase **Src** suppresses pancreatic cancer invasiveness.
SO Surgery, (2003 Aug) 134 (2) 221-6.
Journal code: 0417347. ISSN: 0039-6060.
AU Ito Hiromichi; Gardner-Thorpe James; Zinner Michael J; Ashley Stanley W;

Whang Edward E
AN 2003408443 MEDLINE

L25 ANSWER 65 OF 181 MEDLINE on STN DUPLICATE 40
TI Involvement of G(i) proteins and Src tyrosine kinase in TNFalpha production induced by lipopolysaccharide, group B Streptococci and Staphylococcus aureus.
SO Cytokine, (2003 Jun 7) 22 (5) 126-33.
Journal code: 9005353. ISSN: 1043-4666.
AU Fan Hongkuan; Teti Giuseppe; Ashton Sarah; Guyton Kelly; Tempel George E; Halushka Perry V; Cook James A
AN 2003344872 MEDLINE

L25 ANSWER 66 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Inactivation of **Src** family kinases **inhibits** angiogenesis in vivo: Implications for a mechanism involving organization of the actin cytoskeleton.
SO Experimental Cell Research, (15 Nov 2003) 291/1 (70-82).
Refs: 55
ISSN: 0014-4827 CODEN: ECREAL
AU Kilarski W.W.; Jura N.; Gerwins P.
AN 2003441072 EMBASE

L25 ANSWER 67 OF 181 MEDLINE on STN
TI The pp60c-**Src inhibitor** PP1 is non-competitive against ATP.
SO FEBS letters, (2003 Feb 27) 537 (1-3) 47-52.
Journal code: 0155157. ISSN: 0014-5793.
AU Karni Rotem; Mizrachi Sarit; Reiss-Sklan Ella; Gazit Aviv; Livnah Oded; Levitzki Alexander
AN 2003094802 MEDLINE

L25 ANSWER 68 OF 181 MEDLINE on STN
TI G-protein-coupled muscarinic acetylcholine receptor activation up-regulates Bcl-2 and phospho-bad via Ras-ERK-1/2 signaling pathway.
SO Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica, (2003 Jan) 35 (1) 41-8.
Journal code: 20730160R. ISSN: 0582-9879.
AU Li Jian-Ling; Zhu Jian-Hua; Jing Zhao-Zheng; Chen Zhu-Chu; Xiao Zhi-Qiang
AN 2003012059 MEDLINE

L25 ANSWER 69 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 41
TI Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling.
SO Journal of Biological Chemistry, (29 Nov 2002) 277/48 (45892-45897).
Refs: 40
ISSN: 0021-9258 CODEN: JBCHA3
AU Krug A.W.; Schuster C.; Gassner B.; Freudinger R.; Mildenberger S.; Troppmair J.; Gekle M.
AN 2002440458 EMBASE

L25 ANSWER 70 OF 181 MEDLINE on STN DUPLICATE 42
TI Inhibitor scaffolds as new allele specific kinase substrates.
SO Journal of the American Chemical Society, (2002 Oct 16) 124 (41) 12118-28.
Journal code: 7503056. ISSN: 0002-7863.
AU Kraybill Brian C; Elkin Lisa L; Blethrow Justin D; Morgan David O; Shokat Kevan M
AN 2002636231 MEDLINE

L25 ANSWER 71 OF 181 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts: relevance to intracellular

signaling pathways
SO Journal of Biological Chemistry (2002), 277(10), 7865-7874
CODEN: JBCHA3; ISSN: 0021-9258
AU Onodera, Shin; Nishihira, Jun; Iwabuchi, Kazuya; Koyama, Yoshikazu; Yoshida, Kazuhiko; Tanaka, Sakae; Minami, Akio
AN 2002:218500 HCAPLUS
DN 137:198829

L25 ANSWER 72 OF 181 MEDLINE on STN
TI Early events in the activation of Fc gamma RIIA in human neutrophils: stimulated insolubilization, translocation to detergent-resistant domains, and degradation of Fc gamma RIIA.
SO Journal of immunology (Baltimore, Md. : 1950), (2002 Apr 15) 168 (8) 4042-9.
Journal code: 2985117R. ISSN: 0022-1767.
AU Barabe Frederic; Rollet-Labelle Emmanuelle; Gilbert Caroline; Fernandes Maria J G; Naccache Samia N; Naccache Paul H
AN 2002215475 MEDLINE

L25 ANSWER 73 OF 181 MEDLINE on STN DUPLICATE 43
TI ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases.
SO American journal of physiology. Heart and circulatory physiology, (2002 Dec) 283 (6) H2322-30.
Journal code: 100901228. ISSN: 0363-6135.
AU Krieg Thomas; Qin Qining; McIntosh Elizabeth C; Cohen Michael V; Downey James M
AN 2002666883 MEDLINE

L25 ANSWER 74 OF 181 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2002272062 ESBIOBASE
TI ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases
AU Krieg T.; Qin Q.; McIntosh E.C.; Cohen M.V.; Downey J.M.
CS J.M. Downey, Dept. of Physiology, Univ. of South Alabama, College of Medicine, Mobile, AL 36688, United States.
E-mail: jdowney@usouthal.edu
SO American Journal of Physiology - Heart and Circulatory Physiology, (01 DEC 2002), 283/6 52-6 (H2322-H2330), 44 reference(s)
CODEN: AJPPDI ISSN: 0363-6135
DT Journal; Article
CY United States
LA English
SL English

L25 ANSWER 75 OF 181 MEDLINE on STN
TI Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells.
SO American journal of pathology, (2002 Dec) 161 (6) 2209-18.
Journal code: 0370502. ISSN: 0002-9440.
AU Xu Jie; Jian Bo; Chu Richard; Lu Zhibin; Li Quanyi; Dunlop John; Rosenzweig-Lipson Sharon; McGonigle Paul; Levy Robert J; Liang Bruce
AN 2002704685 MEDLINE

L25 ANSWER 76 OF 181 MEDLINE on STN
TI Tyrosine kinases regulate intracellular calcium during alpha(2)-adrenergic contraction in rat aorta.
SO American journal of physiology. Heart and circulatory physiology, (2002 Oct) 283 (4) H1673-80.
Journal code: 100901228. ISSN: 0363-6135.
AU Carter Rebecca W; Kanagy Nancy L
AN 2002472719 MEDLINE

L25 ANSWER 77 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Chromium(III)-induced apoptosis of lymphocytes: Death decision by ROS and Src-family tyrosine kinases.
SO Free Radical Biology and Medicine, (15 Dec 2002) 33/12 (1622-1640). Refs: 78
ISSN: 0891-5849 CODEN: FRBMEH
AU Balamurugan K.; Rajaram R.; Ramasami T.; Narayanan S.
AN 2002455483 EMBASE

L25 ANSWER 78 OF 181 MEDLINE on STN DUPLICATE 44
TI Epidermal growth factor-induced activation of the insulin-like growth factor I receptor in rat hepatocytes.
SO Hepatology (Baltimore, Md.), (2002 Dec) 36 (6) 1509-18.
Journal code: 8302946. ISSN: 0270-9139.
AU Hallak Hazem; Moehren Giesla; Tang Jei; Kaou Mohamad; Addas Mouhamad; Hoek Jan B; Rubin Raphael
AN 2002687894 MEDLINE

L25 ANSWER 79 OF 181 MEDLINE on STN
TI Regulation of ionomycin-mediated granule release from rat basophil leukemia cells.
SO Molecular immunology, (2002 Sep) 38 (16-18) 1329-35.
Journal code: 7905289. ISSN: 0161-5890.
AU Hanson Dennis A; Ziegler Steven F
AN 2002460088 MEDLINE

L25 ANSWER 80 OF 181 MEDLINE on STN DUPLICATE 45
TI Src modulates serotonin-induced calcium signaling by regulating phosphatidylinositol 4,5-bisphosphate.
SO American journal of physiology. Lung cellular and molecular physiology, (2002 Jun) 282 (6) L1305-13.
Journal code: 100901229. ISSN: 1040-0605.
AU Tolloczko Barbara; Turkewitsch Petra; Choudry Sofia; Bisotto Sandra; Fixman Elizabeth D; Martin James G
AN 2002264273 MEDLINE

L25 ANSWER 81 OF 181 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2002139995 ESBIOBASE
TI Src modulates serotonin-induced calcium signaling by regulating phosphatidylinositol 4,5-bisphosphate
AU Tolloczko B.; Turkewitsch P.; Choudry S.; Bisotto S.; Fixman E.D.; Martin J.G.
CS J.G. Martin, Meakins-Christie Laboratories, McGill Univ., 3626 St. Urbain St., Montreal, Que. H2X 2P2, Canada.
E-mail: james.martin@mcgill.ca
SO American Journal of Physiology - Lung Cellular and Molecular Physiology, (2002), 282/6 26-6 (L1305-L1313), 30 reference(s)
CODEN: APLPE7 ISSN: 1040-0605
DT Journal; Article
CY United States
LA English
SL English

L25 ANSWER 82 OF 181 MEDLINE on STN
TI Tyrosine kinases act directly on the alpha1 subunit to modulate Ca(v)2.2 calcium channels.
SO Biochemical and biophysical research communications, (2002 Feb 1) 290 (4) 1246-9.
Journal code: 0372516. ISSN: 0006-291X.
AU Wijetunge S; Dolphin A C; Hughes A D
AN 2002108788 MEDLINE

L25 ANSWER 83 OF 181 MEDLINE on STN DUPLICATE 46
TI Beta(2)-adrenergic receptor lacking the cyclic AMP-dependent protein kinase consensus sites fully activates extracellular signal-regulated kinase 1/2 in human embryonic kidney 293 cells: lack of evidence for G(s)/G(i) switching.
SO Molecular pharmacology, (2002 Nov) 62 (5) 1094-102.
Journal code: 0035623. ISSN: 0026-895X.
AU Friedman Jacqueline; Babu Bonita; Clark Richard B
AN 2002645571 MEDLINE

L25 ANSWER 84 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Selective pharmacological inhibitors reveal the role of Syk tyrosine kinase, phospholipase C, phosphatidylinositol-3'-kinase, and p38 mitogen-activated protein kinase in Fc receptor-mediated signaling of chicken heterophil degranulation.
SO International Immunopharmacology, (2002) 2/7 (963-973).
Refs: 52
ISSN: 1567-5769 CODEN: IINMBA
AU Kogut M.; Lowry V.K.; Farnell M.
AN 2002251244 EMBASE

L25 ANSWER 85 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Stimulation of β(3)-adrenoceptors causes phosphorylation of p38 mitogen-activated protein kinase via a stimulatory G protein-dependent pathway in 3T3-L1 adipocytes.
SO British Journal of Pharmacology, (2002) 135/4 (951-960).
Refs: 49
ISSN: 0007-1188 CODEN: BJPCBM
AU Mizuno K.; Kanda Y.; Kuroki Y.; Nishio M.; Watanabe Y.
AN 2002097834 EMBASE

L25 ANSWER 86 OF 181 MEDLINE on STN DUPLICATE 47
TI Peroxynitrite enhances astrocytic volume-sensitive excitatory amino acid release via a src tyrosine kinase-dependent mechanism.
SO Journal of neurochemistry, (2002 Aug) 82 (4) 903-12.
Journal code: 2985190R. ISSN: 0022-3042.
AU Haskew Renee E; Mongin Alexander A; Kimelberg Harold K
AN 2002495972 MEDLINE

L25 ANSWER 87 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Activation of extracellular-regulated kinase by 5-hydroxytryptamine(2A) receptors in PC12 cells is protein kinase C-independent and requires calmodulin and tyrosine kinases.
SO Journal of Pharmacology and Experimental Therapeutics, (1 Nov 2002) 303/2 (746-752).
Refs: 41
ISSN: 0022-3565 CODEN: JPETAB
AU Quinn J.C.; Johnson-Farley N.N.; Yoon J.; Cowen D.S.
AN 2002383127 EMBASE

L25 ANSWER 88 OF 181 MEDLINE on STN
TI Lysophosphatidic acid stimulates p21-activated kinase in vascular smooth muscle cells.
SO Biochemical and biophysical research communications, (2002 Mar 1) 291 (3) 687-91.
Journal code: 0372516. ISSN: 0006-291X.
AU Schmitz Udo; Thommes Kerstin; Beier Imke; Vetter Hans
AN 2002141669 MEDLINE

L25 ANSWER 89 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells.
SO British Journal of Pharmacology, (2002) 135/2 (511-519).
Refs: 43
ISSN: 0007-1188 CODEN: BJPCBM
AU Croxtall J.D.; Van Hal P.Th.W.; Choudhury Q.; Gilroy D.W.; Flower R.J.
AN 2002067735 EMBASE

L25 ANSWER 90 OF 181 MEDLINE on STN DUPLICATE 48
TI Implication of Galpha i proteins and Src tyrosine kinases in endotoxin-induced signal transduction events and mediator production.
SO Journal of endotoxin research, (2002) 8 (6) 427-35.
Journal code: 9433350. ISSN: 0968-0519.
AU Ferlito Marcella; Romanenko Olga G; Guyton Kelly; Ashton Sarah; Squadrito Francesco; Halushka Perry V; Cook James A
AN 2003182495 MEDLINE

L25 ANSWER 91 OF 181 MEDLINE on STN
TI Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators.
SO Circulation research, (2002 Sep 6) 91 (5) 406-13.
Journal code: 0047103. ISSN: 1524-4571.
AU Seshiah Puvi N; Weber David S; Rocic Petra; Valppu Liisa; Taniyama Yoshihiro; Griendling Kathy K
AN 2002456925 MEDLINE

L25 ANSWER 92 OF 181 MEDLINE on STN DUPLICATE 49
TI Glycoprotein IIb-IIIa-dependent aggregation by glycoprotein Ibalpha is reinforced by a **Src** family kinase **inhibitor** (PP1)-sensitive signalling pathway.
SO Biochemical journal, (2002 Jan 15) 361 (Pt 2) 297-305.
Journal code: 2984726R. ISSN: 0264-6021.
AU Marshall Stuart J; Asazuma Naoki; Best Denise; Wonerow Peter; Salmon Gary; Andrews Robert K; Watson Steve P
AN 2002050486 MEDLINE

L25 ANSWER 93 OF 181 MEDLINE on STN
TI Involvement of NMDA receptors and a p21Ras-like guanosine triphosphatase in the constitutive activation of nuclear factor-kappa-B in cortical neurons.
SO Experimental brain research. Experimentelle Hirnforschung. Experimentation cerebrale, (2002 Dec) 147 (3) 273-9.
Journal code: 0043312. ISSN: 0014-4819.
AU Burr P B; Morris B J
AN 2002667276 MEDLINE

L25 ANSWER 94 OF 181 MEDLINE on STN DUPLICATE 50
TI Phospholipase D1 is threonine-phosphorylated in human-airway epithelial cells stimulated by sphingosine-1-phosphate by a mechanism involving Src tyrosine kinase and protein kinase Cdelta.
SO Biochemical journal, (2002 Aug 15) 366 (Pt 1) 187-93.
Journal code: 2984726R. ISSN: 0264-6021.
AU Ghelli Anna; Porcelli Anna M; Facchini Annalisa; Hrelia Silvana; Flamigni Flavio; Rugolo Michela
AN 2002408845 MEDLINE

L25 ANSWER 95 OF 181 MEDLINE on STN DUPLICATE 51
TI Tyrosine phosphorylation of vascular endothelial cadherin and the regulation of microvascular permeability.
SO Surgery, (2002 Aug) 132 (2) 180-5.
Journal code: 0417347. ISSN: 0039-6060.
AU Nwariaku Fiemu E; Liu Zijuan; Zhu Xudong; Turnage Richard H; Sarosi George A; Terada Lance S
AN 2002460314 MEDLINE

L25 ANSWER 96 OF 181 MEDLINE on STN
TI Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells.
SO Experimental & molecular medicine, (2002 Jul 31) 34 (3) 177-83.
Journal code: 9607880. ISSN: 1226-3613.
AU Lee Hyuk-Joon; Kim Eunsook; Jee Bokeun; Hahn Jang-Hee; Han Kyuhyoung; Jung Kyeong Cheon; Park Seong Hoe; Lee Hansoo
AN 2002456513 MEDLINE

L25 ANSWER 97 OF 181 MEDLINE on STN DUPLICATE 52
TI Inducible expression of endothelial PAS domain protein-1 by hypoxia in human lung adenocarcinoma A549 cells. Role of Src family kinases-dependent pathway.
SO American journal of respiratory cell and molecular biology, (2002 Jan) 26 (1) 127-34.
Journal code: 8917225. ISSN: 1044-1549.
AU Sato Mahito; Tanaka Toru; Maeno Toshitaka; Sando Yoshichika; Suga Tatsuo; Maeno Yuri; Sato Hiroko; Nagai Ryozo; Kurabayashi Masahiko
AN 2002001299 MEDLINE

L25 ANSWER 98 OF 181 MEDLINE on STN
TI Src kinases regulate PKB activation and modulate cytokine and chemoattractant-controlled neutrophil functioning.
SO Journal of leukocyte biology, (2002 Jan) 71 (1) 115-24.
Journal code: 8405628. ISSN: 0741-5400.
AU Nijhuis Evert; Lammers Jan-Willem J; Koenderman Leo; Coffer Paul J
AN 2002055902 MEDLINE

L25 ANSWER 99 OF 181 MEDLINE on STN DUPLICATE 53
TI Coupling of M(2) muscarinic receptors to Src activation in cultured canine colonic smooth muscle cells.
SO American journal of physiology. Gastrointestinal and liver physiology, (2002 Jan) 282 (1) G61-8.
Journal code: 100901227. ISSN: 0193-1857.
AU Singer Cherie A; Vang Sa; Gerthoffer William T
AN 2002065823 MEDLINE

L25 ANSWER 100 OF 181 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2002138801 ESBIOBASE
TI Coupling of M.sub.2 muscarinic receptors to Src activation in cultured canine colonic smooth muscle cells
AU Singer C.A.; Vang S.; Gerthoffer W.T.
CS C.A. Singer, Dept. of Pharmacology/318, Univ. of Nevada School of Medicine, Reno, NV 89557-0046, United States.
E-mail: cas@med.unr.edu
SO American Journal of Physiology - Gastrointestinal and Liver Physiology, (2002), 282/1 45-1 (G61-G68), 39 reference(s)
CODEN: APGPDF ISSN: 0193-1857
DT Journal; Article
CY United States
LA English
SL English

L25 ANSWER 101 OF 181 MEDLINE on STN DUPLICATE 55
TI The **Src**-family tyrosine kinase **inhibitor** PP1 interferes with the activation of ribosomal protein S6 kinases.
SO Biochemical journal, (2002 Aug 15) 366 (Pt 1) 57-62.
Journal code: 2984726R. ISSN: 0264-6021.
AU Shah O Jameel; Kimball Scot R; Jefferson Leonard S
AN 2002408866 MEDLINE

L25 ANSWER 102 OF 181 MEDLINE on STN

TI Augmentation by zinc of NMDA receptor-mediated synaptic responses in CA1 of rat hippocampal slices: mediation by Src family tyrosine kinases.
SO Synapse (New York, N.Y.), (2002 Nov) 46 (2) 49-56.
Journal code: 8806914. ISSN: 0887-4476.
AU Kim Tae-Youn; Hwang Jung-Jin; Yun Sung Hwan; Jung Min Whan; Koh Jae-Young
AN 2002454673 MEDLINE

L25 ANSWER 103 OF 181 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI PEROXYNITRITE POTENTIATES VOLUME - SENSITIVE EXCITATORY AMINO ACID RELEASE IN ASTROCYTE CULTURES VIA A SRC KINASE - DEPENDENT MECHANISM.
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 96.7. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
AU Haskew, R. E. [Reprint Author]; Mongin, A. A. [Reprint Author]; Kimelberg, H. K. [Reprint Author]
AN 2003:269223 BIOSIS

L25 ANSWER 104 OF 181 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Involvement of the p38MAPK Pathway in the Inhibition of IL-10 Synthesis and Secretion by Rituximab in 2F7 NHL Cells: Role in Inhibition of Bcl-2 Expression and Sensitization to Chemotherapeutic Drugs.
SO Blood, (November 16 2002) Vol. 100, No. 11, pp. Abstract No. 2249. print. Meeting Info.: 44th Annual Meeting of the American Society of Hematology. Philadelphia, PA, USA. December 06-10, 2002. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
AU Vega, Mario I. [Reprint Author]; Huerta, Sara [Reprint Author]; Garban, Hermes [Reprint Author]; Jazirehi, Ali [Reprint Author]; Alas, Steve [Reprint Author]; Emmanouilides, Christos [Reprint Author]; Bonavida, Benjamin [Reprint Author]
AN 2003:336946 BIOSIS

L25 ANSWER 105 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 56
TI Ouabain-induced Signaling and Vascular Smooth Muscle Cell Proliferation.
SO Journal of Biological Chemistry, (7 Dec 2001) 276/49 (46605-46611).
Refs: 32
ISSN: 0021-9258 CODEN: JBCHA3
AU Aydemir-Koksoy A.; Abramowitz J.; Allen J.C.
AN 2003451815 EMBASE

L25 ANSWER 106 OF 181 MEDLINE on STN DUPLICATE 57
TI Voltage-independent inhibition of P/Q-type Ca2+ channels in adrenal chromaffin cells via a neuronal Ca2+ sensor-1-dependent pathway involves Src family tyrosine kinase.
SO Journal of biological chemistry, (2001 Nov 30) 276 (48) 44804-11.
Journal code: 2985121R. ISSN: 0021-9258.
AU Weiss J L; Burgoyne R D
AN 2001673440 MEDLINE

L25 ANSWER 107 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 58
TI Src Family Kinases Mediate Epithelial Na(+) Channel Inhibition by Endothelin.
SO Journal of Biological Chemistry, (9 Nov 2001) 276/45 (42610-42617).
Refs: 56
ISSN: 0021-9258 CODEN: JBCHA3
AU Gilmore E.S.; Stutts M.J.; Milgram S.L.
AN 2003452069 EMBASE

L25 ANSWER 108 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 59
TI Angiotensin II-induced Stimulation of p21-activated Kinase and c-Jun

NH(2)-terminal Kinase Is Mediated by Rac1 and Nck.
SO Journal of Biological Chemistry, (22 Jun 2001) 276/25 (22003-22010). Refs: 55
ISSN: 0021-9258 CODEN: JBCHA3
AU Schmitz U.; Thommes K.; Beier I.; Wagner W.; Sachinidis A.; Dusing R.; Vetter H.
AN 2003465876 EMBASE

L25 ANSWER 109 OF 181 MEDLINE on STN DUPLICATE 60
TI Protein-tyrosine kinase Pyk2 mediates endothelin-induced p38 MAPK activation in glomerular mesangial cells.
SO Journal of biological chemistry, (2001 Jun 15) 276 (24) 21521-8.
Journal code: 2985121R. ISSN: 0021-9258.
AU Sorokin A; Kozlowski P; Graves L; Philip A
AN 2001356367 MEDLINE

L25 ANSWER 110 OF 181 MEDLINE on STN DUPLICATE 61
TI Src family kinases are required for integrin-mediated but not for G protein-coupled receptor stimulation of focal adhesion kinase autophosphorylation at Tyr-397.
SO Journal of biological chemistry, (2001 May 25) 276 (21) 17788-95.
Journal code: 2985121R. ISSN: 0021-9258.
AU Salazar E P; Rozengurt E
AN 2001276167 MEDLINE

L25 ANSWER 111 OF 181 MEDLINE on STN DUPLICATE 62
TI c-Src tyrosine kinase binds the beta 2-adrenergic receptor via phospho-Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization.
SO Journal of biological chemistry, (2001 Apr 20) 276 (16) 13240-7.
Journal code: 2985121R. ISSN: 0021-9258.
AU Fan G; Shumay E; Malbon C C; Wang H
AN 2001308654 MEDLINE

L25 ANSWER 112 OF 181 MEDLINE on STN DUPLICATE 63
TI Zinc induces a Src family kinase-mediated up-regulation of NMDA receptor activity and excitotoxicity.
SO Proceedings of the National Academy of Sciences of the United States of America, (2001 Sep 25) 98 (20) 11055-61.
Journal code: 7505876. ISSN: 0027-8424.
AU Manzerra P; Behrens M M; Canzoniero L M; Wang X Q; Heidinger V; Ichinose T; Yu S P; Choi D W
AN 2001525789 MEDLINE

L25 ANSWER 113 OF 181 MEDLINE on STN DUPLICATE 64
TI Role of p190RhoGAP in beta 2 integrin regulation of RhoA in human neutrophils.
SO Journal of immunology (Baltimore, Md. : 1950), (2001 May 15) 166 (10) 6311-22.
Journal code: 2985117R. ISSN: 0022-1767.
AU Dib K; Melander F; Andersson T
AN 2001448629 MEDLINE

L25 ANSWER 114 OF 181 MEDLINE on STN
TI Association of FcgammaRII with low-density detergent-resistant membranes is important for cross-linking-dependent initiation of the tyrosine phosphorylation pathway and superoxide generation.
SO Journal of immunology (Baltimore, Md. : 1950), (2001 Nov 15) 167 (10) 5814-23.
Journal code: 2985117R. ISSN: 0022-1767.
AU Katsumata O; Hara-Yokoyama M; Sautes-Fridman C; Nagatsuka Y; Katada T; Hirabayashi Y; Shimizu K; Fujita-Yoshigaki J; Sugiya H; Furuyama S
AN 2001662578 MEDLINE

L25 ANSWER 115 OF 181 MEDLINE on STN
TI Rac, a small guanosine triphosphate-binding protein, and p21-activated kinase are activated during platelet spreading on collagen-coated surfaces: roles of integrin alpha(2)beta(1).
SO Blood, (2001 Dec 15) 98 (13) 3708-16.
Journal code: 7603509. ISSN: 0006-4971.
AU Suzuki-Inoue K; Yatomi Y; Asazuma N; Kainoh M; Tanaka T; Satoh K; Ozaki Y
AN 2001691052 MEDLINE

L25 ANSWER 116 OF 181 MEDLINE on STN DUPLICATE 65
TI Src family kinase and adenosine differentially regulate multiple MAP kinases in ischemic myocardium: modulation of MAP kinases activation by ischemic preconditioning.
SO Journal of molecular and cellular cardiology, (2001 Nov) 33 (11) 1989-2005.
Journal code: 0262322. ISSN: 0022-2828.
AU Takeishi Y; Huang Q; Wang T; Glassman M; Yoshizumi M; Baines C P; Lee J D; Kawakatsu H; Che W; Lerner-Marmarosh N; Zhang C; Yan C; Ohta S; Walsh R A; Berk B C; Abe J
AN 2001689186 MEDLINE

L25 ANSWER 117 OF 181 MEDLINE on STN
TI Leukotriene D(4) affects localisation of vinculin in intestinal epithelial cells via distinct tyrosine kinase and protein kinase C controlled events.
SO Journal of cell science, (2001 May) 114 (Pt 10) 1925-34.
Journal code: 0052457. ISSN: 0021-9533.
AU Massoumi R; Sjolander A
AN 2001515599 MEDLINE

L25 ANSWER 118 OF 181 MEDLINE on STN
TI Src family kinases and HER2 interactions in human breast cancer cell growth and survival.
SO Oncogene, (2001 Mar 22) 20 (12) 1465-75.
Journal code: 8711562. ISSN: 0950-9232.
AU Belsches-Jablonski A P; Biscardi J S; Peavy D R; Tice D A; Romney D A; Parsons S J
AN 2001247628 MEDLINE

L25 ANSWER 119 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI **Src inhibitors**: Genomics to therapeutics.
SO Expert Opinion on Investigational Drugs, (2001) 10/7 (1327-1344).
Refs: 176
ISSN: 1354-3784 CODEN: EOIDER
AU Sawyer T.; Boyce B.; Dalgarno D.; Iuliucci J.
AN 2001244891 EMBASE

L25 ANSWER 120 OF 181 MEDLINE on STN
TI Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning.
SO American journal of physiology. Heart and circulatory physiology, (2001 Sep) 281 (3) H1066-74.
Journal code: 100901228. ISSN: 0363-6135.
AU Hattori R; Otani H; Uchiyama T; Imamura H; Cui J; Maulik N; Cordis G A; Zhu L; Das D K
AN 2001468864 MEDLINE

L25 ANSWER 121 OF 181 MEDLINE on STN DUPLICATE 66
TI Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes.
SO Journal of pharmacology and experimental therapeutics, (2001 Mar) 296 (3) 931-8.
Journal code: 0376362. ISSN: 0022-3565.
AU Doolen S; Zahniser N R

AN 2001151494 MEDLINE

L25 ANSWER 122 OF 181 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Essential role of non-receptor tyrosine kinase Hck in vomitoxin-induced phosphorylation of JNK, ERK and p38 mitogen-activated protein kinases.
SO FASEB Journal, (March 8, 2001) Vol. 15, No. 5, pp. A905. print.
Meeting Info.: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001. Orlando, Florida, USA. March 31-April 04, 2001.
CODEN: FAJOEC. ISSN: 0892-6638.
AU Zhou, Hui-Ren [Reprint author]; Pestka, James J.
AN 2001:245174 BIOSIS

L25 ANSWER 123 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Role of the extracellular signal-regulated kinase (Erk) signal transduction cascade in α(2) adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein.
SO British Journal of Pharmacology, (2001) 133/6 (859-866).
Refs: 40
ISSN: 0007-1188 CODEN: BJPCBM
AU Roberts R.E.
AN 2001289328 EMBASE

L25 ANSWER 124 OF 181 MEDLINE on STN
TI Src family kinase involvement in muscarinic receptor-induced tyrosine phosphorylation in differentiated SH-SY5Y cells.
SO Neurochemical research, (2001 Jul) 26 (7) 809-16.
Journal code: 7613461. ISSN: 0364-3190.
AU Watcharasit P; Tucholski J; Jope R S
AN 2001519181 MEDLINE

L25 ANSWER 125 OF 181 MEDLINE on STN
TI Role of Src kinases and Syk in Fcgamma receptor-mediated phagocytosis and phagosome-lysosome fusion.
SO Journal of leukocyte biology, (2001 Nov) 70 (5) 801-11.
Journal code: 8405628. ISSN: 0741-5400.
AU Majeed M; Caveggion E; Lowell C A; Berton G
AN 2001646064 MEDLINE

L25 ANSWER 126 OF 181 MEDLINE on STN
TI Regulation of the very late antigen-4-mediated adhesive activity of normal and nonreleaser basophils: roles for Src, Syk, and phosphatidylinositol 3-kinase.
SO Journal of leukocyte biology, (2001 Nov) 70 (5) 776-82.
Journal code: 8405628. ISSN: 0741-5400.
AU Andrews R P; Kepley C L; Youssef L; Wilson B S; Oliver J M
AN 2001646061 MEDLINE

L25 ANSWER 127 OF 181 HCAPLUS COPYRIGHT 2004 ACS on STN
TI PI 3-kinases and Src kinases regulate spreading and migration of cultured VSMCs
SO American Journal of Physiology (2001), 281(2, Pt. 1), C709-C718
CODEN: AJPHAP; ISSN: 0002-9513
AU Yamboliev, Ilia A.; Chen, Jennifer; Gerthoffer, William T.
AN 2001:598603 HCAPLUS
DN 135:255073

L25 ANSWER 128 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor.
SO Journal of Pharmacology and Experimental Therapeutics, (2001) 296/2

(426-433).
Refs: 39
ISSN: 0022-3565 CODEN: JPETAB
AU Gao Y.; Tang S.; Zhou S.; Ware J.A.
AN 2001047197 EMBASE

L25 ANSWER 129 OF 181 MEDLINE on STN
TI The role of mitogen-activated protein kinase activation within focal adhesions in chemotaxis toward FGF-2 by murine brain capillary endothelial cells.
SO Experimental cell research, (2001 Apr 1) 264 (2) 275-83.
Journal code: 0373226. ISSN: 0014-4827.
AU Shono T; Kanetake H; Kanda S
AN 2001164123 MEDLINE

L25 ANSWER 130 OF 181 MEDLINE on STN DUPLICATE 67
TI Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells.
SO Biochemical journal, (2001 Nov 15) 360 (Pt 1) 255-64.
Journal code: 2984726R. ISSN: 0264-6021.
AU Abu-Ghazaleh R; Kabir J; Jia H; Lobo M; Zachary I
AN 2001643976 MEDLINE

L25 ANSWER 131 OF 181 MEDLINE on STN DUPLICATE 68
TI The tyrosine kinase c-Src is required for 1,25(OH)2-vitamin D3 signalling to the nucleus in muscle cells.
SO Biochimica et biophysica acta, (2001 Dec 19) 1541 (3) 179-87.
Journal code: 0217513. ISSN: 0006-3002.
AU Buitrago C; Boland R; de Boland A R
AN 2002044941 MEDLINE

L25 ANSWER 132 OF 181 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
TI The tyrosine kinase c-Src is required for 1,25(OH)(2)-vitamin D-3 signalling to the nucleus in muscle cells
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, (19 DEC 2001) Vol. 1541, No. 3, pp. 179-187.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
ISSN: 0167-4889.
AU Buitrago C; Boland R; de Boland A R (Reprint)
AN 2002:31733 SCISEARCH

L25 ANSWER 133 OF 181 MEDLINE on STN DUPLICATE 69
TI Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A(1) receptor in DDT(1)MF-2 cells.
SO European journal of pharmacology, (2001 Feb 16) 413 (2-3) 151-61.
Journal code: 1254354. ISSN: 0014-2999.
AU Robinson A J; Dickenson J M
AN 2001301888 MEDLINE

L25 ANSWER 134 OF 181 MEDLINE on STN
TI Phosphorylation of protein kinase Cdelta on distinct tyrosine residues regulates specific cellular functions.
SO Journal of biological chemistry, (2000 Nov 10) 275 (45) 35491-8.
Journal code: 2985121R. ISSN: 0021-9258.
AU Kronfeld I; Kazimirsky G; Lorenzo P S; Garfield S H; Blumberg P M; Brodie C
AN 2001069381 MEDLINE

L25 ANSWER 135 OF 181 MEDLINE on STN DUPLICATE 70
TI MAPK mediation of hypertonicity-stimulated cyclooxygenase-2 expression in renal medullary collecting duct cells.
SO Journal of biological chemistry, (2000 Jul 28) 275 (30) 23281-6.

Journal code: 2985121R. ISSN: 0021-9258.
AU Yang T; Huang Y; Heasley L E; Berl T; Schnermann J B; Briggs J P
AN 2000413015 MEDLINE

L25 ANSWER 136 OF 181 MEDLINE on STN
TI Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-**Src** to swap nucleotide and **inhibitor** specificities.
SO Biochemistry, (2000 Nov 28) 39 (47) 14400-8.
Journal code: 0370623. ISSN: 0006-2960.
AU Liu Y; Witucki L A; Shah K; Bishop A C; Shokat K M
AN 2001084704 MEDLINE

L25 ANSWER 137 OF 181 MEDLINE on STN DUPLICATE 71
TI A role for Src kinase in spontaneous epileptiform activity in the CA3 region of the hippocampus.
SO Proceedings of the National Academy of Sciences of the United States of America, (2000 Jul 18) 97 (15) 8653-7.
Journal code: 7505876. ISSN: 0027-8424.
AU Sanna P P; Berton F; Cammalleri M; Tallent M K; Siggins G R; Bloom F E; Francesconi W
AN 2000406963 MEDLINE

L25 ANSWER 138 OF 181 MEDLINE on STN
TI Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status.
SO Journal of biological chemistry, (2000 Mar 17) 275 (11) 7481-91.
Journal code: 2985121R. ISSN: 0021-9258.
AU Kim Y N; Wiepz G J; Guadarrama A G; Bertics P J
AN 2000179838 MEDLINE

L25 ANSWER 139 OF 181 MEDLINE on STN DUPLICATE 72
TI 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways.
SO Proceedings of the National Academy of Sciences of the United States of America, (2000 Mar 14) 97 (6) 2591-6.
Journal code: 7505876. ISSN: 0027-8424.
AU Nebigil C G; Launay J M; Hickel P; Tournois C; Maroteaux L
AN 2000183932 MEDLINE

L25 ANSWER 140 OF 181 MEDLINE on STN DUPLICATE 73
TI Pharmacology of IgE-mediated desensitization of human basophils: effects of protein kinase C and **src**-family kinase **inhibitors.**
SO Biochemical pharmacology, (2000 Dec 1) 60 (11) 1717-27.
Journal code: 0101032. ISSN: 0006-2952.
AU MacGlashan D Jr; Miura K; Lavens-Phillips S
AN 2001050286 MEDLINE

L25 ANSWER 141 OF 181 MEDLINE on STN
TI Effects of protein tyrosine kinase inhibitors on voltage-operated calcium channel currents in vascular smooth muscle cells and pp60(c-src) kinase activity.
SO British journal of pharmacology, (2000 Apr) 129 (7) 1347-54.
Journal code: 7502536. ISSN: 0007-1188.
AU Wijetunge S; Lymn J S; Hughes A D
AN 2000209009 MEDLINE

L25 ANSWER 142 OF 181 MEDLINE on STN DUPLICATE 74
TI Opposite effects of pressurized steady versus pulsatile perfusion on vascular endothelial cell cytosolic pH: role of tyrosine kinase and mitogen-activated protein kinase signaling.
SO Circulation research, (2000 Jun 23) 86 (12) 1230-6.
Journal code: 0047103. ISSN: 1524-4571.

AU Wittstein I S; Qiu W; Ziegelstein R C; Hu Q; Kass D A
AN 2000325061 MEDLINE

L25 ANSWER 143 OF 181 MEDLINE on STN DUPLICATE 75
TI c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells.
SO Journal of immunology (Baltimore, Md. : 1950), (2000 Feb 1) 164 (3) 1169-74.
Journal code: 2985117R. ISSN: 0022-1767.
AU Munshi N; Groopman J E; Gill P S; Ganju R K
AN 2000109065 MEDLINE

L25 ANSWER 144 OF 181 MEDLINE on STN DUPLICATE 76
TI Tyrosine phosphorylation of the delta-opioid receptor. Evidence for its role in mitogen-activated protein kinase activation and receptor internalization*.
SO Biochemical pharmacology, (2000 Sep 15) 60 (6) 781-92.
Journal code: 0101032. ISSN: 0006-2952.
AU Kramer H K; Andria M L; Esposito D H; Simon E J
AN 2000417236 MEDLINE

L25 ANSWER 145 OF 181 MEDLINE on STN DUPLICATE 77
TI Ceramide-mediated stimulation of inducible nitric oxide synthase (iNOS) and tumor necrosis factor (TNF) accumulation in murine macrophages requires tyrosine kinase activity.
SO Journal of leukocyte biology, (2000 May) 67 (5) 735-41.
Journal code: 8405628. ISSN: 0741-5400.
AU Knapp K M; English B K
AN 2000269152 MEDLINE

L25 ANSWER 146 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Small molecule **inhibitors** of **Src** family kinases.
SO Drugs of the Future, (2000) 25/7 (717-736).
Refs: 243
ISSN: 0377-8282 CODEN: DRFUD4
AU Boschelli D.H.; Boschelli F.
AN 2000341838 EMBASE

L25 ANSWER 147 OF 181 MEDLINE on STN DUPLICATE 78
TI Interleukin-1beta, Src- and non-Src tyrosine kinases, and nitric oxide synthase induction in rat aorta in vitro.
SO American journal of physiology. Heart and circulatory physiology, (2000 Aug) 279 (2) H566-76.
Journal code: 100901228. ISSN: 0363-6135.
AU Gui Y; Zheng X L; Hollenberg M D
AN 2000426825 MEDLINE

L25 ANSWER 148 OF 181 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2000202009 ESBIOBASE
TI Interleukin-1β, Src- and non-Src tyrosine kinases, and nitric oxide synthase induction in rat aorta in vitro
AU Gui Y.; Zheng X.-L.; Hollenberg M.D.
CS M.D. Hollenberg, Dept. of Pharmacology/Therapeutics, Department of Medicine, University of Calgary, 3330 Hospital Dr. N.W., Calgary, Alta. T2N 4N1, Canada.
E-mail: mhollenb@ucalgary.ca
SO American Journal of Physiology - Heart and Circulatory Physiology, (2000), 279/2 48-2 (H566-H576), 40 reference(s)
CODEN: AJPPDI ISSN: 0363-6135
DT Journal; Article
CY United States

LA English
SL English

L25 ANSWER 149 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Tyrosine kinase inhibition in bone metabolism.
SO Current Opinion in Drug Discovery and Development, (2000) 3/5 (541-548). Refs: 58
ISSN: 1367-6733 CODEN: CODDFF
AU Missbach M.; Altmann E.; Susa M.
AN 2000362286 EMBASE

L25 ANSWER 150 OF 181 MEDLINE on STN DUPLICATE 79
TI Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells.
SO Biochemical journal, (2000 Apr 15) 347 (Pt 2) 441-7.
Journal code: 2984726R. ISSN: 0264-6021.
AU Graness A; Hanke S; Boehmer F D; Presek P; Liebmann C
AN 2001132959 MEDLINE

L25 ANSWER 151 OF 181 MEDLINE on STN
TI Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
SO Cell growth & differentiation : molecular biology journal of the American Association for Cancer Research, (2000 Jun) 11 (6) 305-14.
Journal code: 9100024. ISSN: 1044-9523.
AU Bondzi C; Litz J; Dent P; Krystal G W
AN 2001013335 MEDLINE

L25 ANSWER 152 OF 181 MEDLINE on STN
TI An anti-Ras cancer potential of PP1, an **inhibitor** specific for **Src** family kinases: in vitro and in vivo studies.
SO Cancer journal (Sudbury, Mass.), (2000 Jul-Aug) 6 (4) 243-8.
Journal code: 100931981. ISSN: 1528-9117.
AU He H; Hirokawa Y; Levitzki A; Maruta H
AN 2000487886 MEDLINE

L25 ANSWER 153 OF 181 MEDLINE on STN
TI Lck is involved in interleukin-2 induced proliferation but not cell survival in human T cells through a MAP kinase-independent pathway.
SO European cytokine network, (2000 Jun) 11 (2) 225-31.
Journal code: 9100879. ISSN: 1148-5493.
AU Brockdorff J; Nielsen M; Kaltoft K; Mustelin T; Ropke C; Svejaard A; Geisler C; Odum N
AN 2000454823 MEDLINE

L25 ANSWER 154 OF 181 MEDLINE on STN
TI Association of Lyn tyrosine kinase to the GM-CSF and IL-3 receptor common betac subunit and role of Src tyrosine kinases in DNA synthesis and anti-apoptosis.
SO Genes to cells : devoted to molecular & cellular mechanisms, (2000 Feb) 5 (2) 143-53.
Journal code: 9607379. ISSN: 1356-9597.
AU Dahl M E; Arai K I; Watanabe S
AN 2000138539 MEDLINE

L25 ANSWER 155 OF 181 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI The selective **src** kinase **inhibitor** PP1 also **inhibits** c-kit and Bcr-Abl tyrosine kinases and induces apoptosis in mast cell leukaemia, CML and AML cells.
SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 1, pp. 81a. print.

Meeting Info.: 42nd Annual Meeting of the American Society of Hematology. San Francisco, California, USA. December 01-05, 2000. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
AU Tatton, Louise [Reprint author]; Chopra, Raj; Khwaja, Asim
AN 2001:311789 BIOSIS

L25 ANSWER 156 OF 181 MEDLINE on STN
TI Shear stress stimulation of p130(cas) tyrosine phosphorylation requires calcium-dependent c-Src activation.
SO Journal of biological chemistry, (1999 Sep 17) 274 (38) 26803-9.
Journal code: 2985121R. ISSN: 0021-9258.
AU Okuda M; Takahashi M; Suero J; Murry C E; Traub O; Kawakatsu H; Berk B C
AN 1999410412 MEDLINE

L25 ANSWER 157 OF 181 MEDLINE on STN DUPLICATE 80
TI Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade. Role of focal adhesions and receptor tyrosine kinases.
SO Journal of biological chemistry, (1999 May 14) 274 (20) 13978-84.
Journal code: 2985121R. ISSN: 0021-9258.
AU Della Rocca G J; Maudsley S; Daaka Y; Lefkowitz R J; Luttrell L M
AN 1999253951 MEDLINE

L25 ANSWER 158 OF 181 MEDLINE on STN
TI Cell shrinkage regulates Src kinases and induces tyrosine phosphorylation of cortactin, independent of the osmotic regulation of Na+/H+ exchangers.
SO Journal of biological chemistry, (1999 Mar 19) 274 (12) 8093-102.
Journal code: 2985121R. ISSN: 0021-9258.
AU Kapus A; Szaszi K; Sun J; Rizoli S; Rotstein O D
AN 1999175190 MEDLINE

L25 ANSWER 159 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Growth factor-mediated Fyn signaling regulates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor expression in rodent neocortical neurons.
SO Proceedings of the National Academy of Sciences of the United States of America, (2 Mar 1999) 96/5 (2461-2466).
Refs: 57
ISSN: 0027-8424 CODEN: PNASA6
AU Narisawa-Saito M.; Silva A.J.; Yamaguchi T.; Hayashi T.; Yamamoto T.; Nawa H.
AN 1999091661 EMBASE

L25 ANSWER 160 OF 181 MEDLINE on STN
TI Signaling via Src family kinases is required for normal internalization of the receptor c-Kit.
SO Blood, (1999 Sep 15) 94 (6) 1979-86.
Journal code: 7603509. ISSN: 0006-4971.
AU Broudy V C; Lin N L; Liles W C; Corey S J; O'Laughlin B; Mou S; Linnekin D
AN 1999408738 MEDLINE

L25 ANSWER 161 OF 181 MEDLINE on STN
TI Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
SO Journal of cell biology, (1999 Jun 14) 145 (6) 1209-18.
Journal code: 0375356. ISSN: 0021-9525.
AU Osterhout D J; Wolven A; Wolf R M; Resh M D; Chao M V
AN 1999296613 MEDLINE

L25 ANSWER 162 OF 181 MEDLINE on STN DUPLICATE 81
TI Differential regulation of p90 ribosomal S6 kinase and big mitogen-activated protein kinase 1 by ischemia/reperfusion and oxidative

stress in perfused guinea pig hearts.
SO Circulation research, (1999 Dec 3-17) 85 (12) 1164-72.
Journal code: 0047103. ISSN: 0009-7330.
AU Takeishi Y; Abe J i; Lee J D; Kawakatsu H; Walsh R A; Berk B C
AN 2000059658 MEDLINE

L25 ANSWER 163 OF 181 MEDLINE on STN
TI 'Outside-in' signalling mechanisms underlying CD11b/CD18-mediated NADPH oxidase activation in human adherent blood eosinophils.
SO British journal of pharmacology, (1999 Nov) 128 (6) 1149-58.
Journal code: 7502536. ISSN: 0007-1188.
AU Lynch O T; Giembycz M A; Barnes P J; Hellewell P G; Lindsay M A
AN 2000046973 MEDLINE

L25 ANSWER 164 OF 181 MEDLINE on STN
TI Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck.
SO Journal of immunology (Baltimore, Md. : 1950), (1999 Jan 15) 162 (2) 1120-6.
Journal code: 2985117R. ISSN: 0022-1767.
AU Mocsai A; Ligeti E; Lowell C A; Berton G
AN 1999113780 MEDLINE

L25 ANSWER 165 OF 181 MEDLINE on STN DUPLICATE 82
TI Crystal structure of Hck in complex with a **Src** family-selective tyrosine kinase **inhibitor.**
SO Molecular cell, (1999 May) 3 (5) 639-48.
Journal code: 9802571. ISSN: 1097-2765.
AU Schindler T; Sicheri F; Pico A; Gazit A; Levitzki A; Kuriyan J
AN 1999288452 MEDLINE

L25 ANSWER 166 OF 181 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN DUPLICATE 83
TI Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (3 FEB 1999) Vol. 121, No. 4, pp. 627-631.
Publisher: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036.
ISSN: 0002-7863.
AU Bishop A C; Kung C Y; Shah K; Witucki L; Shokat K M (Reprint); Liu Y
AN 1999:135338 SCISEARCH

L25 ANSWER 167 OF 181 MEDLINE on STN DUPLICATE 84
TI The **src** family-selective tyrosine kinase **inhibitor** PP1 blocks LPS and IFN-gamma-mediated TNF and iNOS production in murine macrophages.
SO Shock (Augusta, Ga.), (1999 Nov) 12 (5) 350-4.
Journal code: 9421564. ISSN: 1073-2322.
AU Orlicek S L; Hanke J H; English B K
AN 2000029339 MEDLINE

L25 ANSWER 168 OF 181 MEDLINE on STN DUPLICATE 85
TI **Inhibitors** of **Src**-family tyrosine kinases favour Th2 differentiation.
SO Cytokine, (1999 Mar) 11 (3) 208-15.
Journal code: 9005353. ISSN: 1043-4666.
AU Gimsa U; Mitchison A; Allen R
AN 1999227137 MEDLINE

L25 ANSWER 169 OF 181 MEDLINE on STN
TI Evidence for the involvement of p59fyn and p53/56lyn in collagen receptor signalling in human platelets.
SO Biochemical journal, (1999 Feb 15) 338 (Pt 1) 203-9.
Journal code: 2984726R. ISSN: 0264-6021.

AU Briddon S J; Watson S P
AN 1999132005 MEDLINE

L25 ANSWER 170 OF 181 MEDLINE on STN DUPLICATE 86
TI Src-family kinase-p53/ Lyn p56 plays an important role in TNF-alpha-stimulated production of O2- by human neutrophils adherent to fibrinogen.
SO Inflammation, (1999 Apr) 23 (2) 167-78.
Journal code: 7600105. ISSN: 0360-3997.
AU Yan S R; Novak M J
AN 1999228260 MEDLINE

L25 ANSWER 171 OF 181 MEDLINE on STN
TI The proto-oncogene p120(Cbl) is a downstream substrate of the Hck protein-tyrosine kinase.
SO Biochemical and biophysical research communications, (1999 Apr 2) 257 (1) 129-38.
Journal code: 0372516. ISSN: 0006-291X.
AU Howlett C J; Bisson S A; Resek M E; Tigley A W; Robbins S M
AN 1999194566 MEDLINE

L25 ANSWER 172 OF 181 MEDLINE on STN
TI A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
SO Circulation research, (1999 Jul 9) 85 (1) 12-22.
Journal code: 0047103. ISSN: 1524-4571.
AU Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge J D; Fujita D; Gazit A; Hombach V; Levitzki A; Bohmer F D
AN 1999330572 MEDLINE

L25 ANSWER 173 OF 181 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 87
TI **Inhibition** of the **Src** kinase family pathway as a method of treating hepatitis B virus infection and hepatocellular carcinoma
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
IN Schneider, Robert J.; Klein, Nicola
AN 1999:8208 HCAPLUS
DN 130:61060

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9857175	A1	19981217	WO 1998-US12279	19980612
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6420338	B1	20020716	US 1997-874430	19970613
AU 9878385	A1	19981230	AU 1998-78385	19980612
AU 757164	B2	20030206		
EP 988548	A1	20000329	EP 1998-926584	19980612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 2003032596	A1	20030213	US 2002-196344	20020715

L25 ANSWER 174 OF 181 MEDLINE on STN DUPLICATE 88
TI Bombesin, vasopressin, lysophosphatidic acid, and sphingosylphosphorylcholine induce focal adhesion kinase activation in intact Swiss 3T3 cells.
SO Journal of biological chemistry, (1998 Jul 24) 273 (30) 19321-8.
Journal code: 2985121R. ISSN: 0021-9258.
AU Rodriguez-Fernandez J L; Rozengurt E
AN 1998334673 MEDLINE

L25 ANSWER 175 OF 181 MEDLINE on STN DUPLICATE 89
TI The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells.
SO Journal of biological chemistry, (1998 Jul 17) 273 (29) 18268-72.
Journal code: 2985121R. ISSN: 0021-9258.
AU Tang H; Kerins D M; Hao Q; Inagami T; Vaughan D E
AN 1998325034 MEDLINE

L25 ANSWER 176 OF 181 MEDLINE on STN
TI Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the **Src** family kinase **inhibitor** PP1.
SO Cancer research, (1998 Oct 15) 58 (20) 4660-6.
Journal code: 2984705R. ISSN: 0008-5472.
AU Krystal G W; DeBerry C S; Linnekin D; Litz J
AN 1999002668 MEDLINE

L25 ANSWER 177 OF 181 MEDLINE on STN
TI Characterization of Cbl-Nck and Nck-Pak1 interactions in myeloid FcgammaRII signaling.
SO Experimental cell research, (1998 Dec 15) 245 (2) 330-42.
Journal code: 0373226. ISSN: 0014-4827.
AU Izadi K D; Erdreich-Epstein A; Liu Y; Durden D L
AN 1999069159 MEDLINE

L25 ANSWER 178 OF 181 MEDLINE on STN DUPLICATE 90
TI Tyrosine kinases of the Src family participate in signaling to MAP kinase from both Gq and Gi-coupled receptors.
SO Biochemical and biophysical research communications, (1998 Mar 6) 244 (1) 5-10.
Journal code: 0372516. ISSN: 0006-291X.
AU Igishi T; Gutkind J S
AN 1998183388 MEDLINE

L25 ANSWER 179 OF 181 MEDLINE on STN
TI Signal characteristics of G protein-transactivated EGF receptor.
SO EMBO journal, (1997 Dec 1) 16 (23) 7032-44.
Journal code: 8208664. ISSN: 0261-4189.
AU Daub H; Wallasch C; Lankenau A; Herrlich A; Ullrich A
AN 1998046033 MEDLINE

L25 ANSWER 180 OF 181 MEDLINE on STN DUPLICATE 91
TI **Src** family-selective tyrosine kinase **inhibitor**, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells.
SO European journal of immunology, (1997 Aug) 27 (8) 1881-6.
Journal code: 1273201. ISSN: 0014-2980.
AU Amoui M; Draber P; Draberova L
AN 97439466 MEDLINE

L25 ANSWER 181 OF 181 MEDLINE on STN DUPLICATE 92
TI Discovery of a novel, potent, and **Src** family-selective tyrosine kinase **inhibitor.** Study of Lck- and FynT-dependent T cell activation.
SO Journal of biological chemistry, (1996 Jan 12) 271 (2) 695-701.
Journal code: 2985121R. ISSN: 0021-9258.
AU Hanke J H; Gardner J P; Dow R L; Changelian P S; Brissette W H; Weringer E J; Pollok B A; Connelly P A
AN 96132796 MEDLINE

=> d ab 9,11,21,37,43,141

L25 ANSWER 9 OF 181 MEDLINE on STN DUPLICATE 5
AB New 4-**aminopyrazolo**[3,4-d]**pyrimidines** bearing various substituents at the position 1 and 6, were synthesized. The new compounds showed antiproliferative activity toward A431 cells, were found to be **inhibitors** of **Src** phosphorylation, and induced apoptotic cell death. In particular, 2h was a better **inhibitor** of **Src** phosphorylation than the reference compound PP2.

L25 ANSWER 11 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AB The cellular signaling machinery is a complex network of cross-talking proteins that enables dynamic communication between upstream causal factors and downstream effectors. Non-receptor tyrosine kinases, including Src, are the intermediates of signal transfer, controlling pathways as diverse as cell growth, death, differentiation, migration, and genome maintenance. When expressed as viral genes these proteins are potent carcinogens. Furthermore, analogous genetic alterations are observed, albeit not frequently, in human tumors. In a variety of tumors including those derived from the colon and breast, Src is either over expressed or constitutively active in a large percentage of patients. Increased expression or activity of Src correlates with the stage and metastatic potential of some neoplasia. The detailed knowledge of Src activation facilitates rational design of drugs that potentially interfere with either binding of ATP or substrate peptides. Several existing inhibitors are available as lead compounds for further development of **Src inhibitors.** .COPYRGT. 2004 Bentham Science Publishers Ltd.

L25 ANSWER 21 OF 181 MEDLINE on STN DUPLICATE 13
AB Reversible protein tyrosine phosphorylation, coordinately controlled by protein tyrosine kinases and phosphatases, is a critical element in signal transduction pathways regulating a wide variety of biological processes, including cell growth, differentiation, and tumorigenesis. We have previously reported that c-Src belonging to the Src family tyrosine kinase (SFK) becomes dephosphorylated at tyrosine 530 (Y530) and thereby activated during progestin-induced differentiation of human endometrial stromal cells (i.e., decidualization). In this study, to elucidate the role of decidual c-Src activation, we examined whether 4-amino-5-(4-methylphenyl)-7-(t-butyl)**pyrazolo**[3,4-d] **pyrimidine** (PP1) and 4-amino-5-(4-chlorophenyl)-7-(t-butyl) **pyrazolo**[3,4-d]**pyrimidine** (PP2), both potent and selective SFK inhibitors, affected the ovarian steroid-induced decidualization in vitro. Unexpectedly, PP1 paradoxically increased the kinase activity of decidual c-Src together with dephosphorylation of Y530 in the presence of ovarian steroids. Concomitantly, PP1 enhanced morphological and functional decidualization, as determined by induction of decidualization markers, such as insulin-like growth factor binding protein-1 and prolactin. PP2 also advanced decidualization along with up-regulation of the active form of c-Src whose Y-530 was dephosphorylated. In contrast to PP1 and PP2, herbimycin A, a tyrosine kinase inhibitor with less specificity for SFKs, showed little enhancing effect on the expression of both IGFBP-1 and active c-Src. These results suggest that SFKs, including c-Src, may play a significant role in stromal cell differentiation, providing a clue for a possible therapeutic strategy to modulate endometrial function by targeting signaling pathway(s) involving SFKs.

L25 ANSWER 37 OF 181 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 22

L25 ANSWER 43 OF 181 MEDLINE on STN DUPLICATE 24
AB Src tyrosine kinase is a therapeutic target for bone diseases that has been validated by gene knockout studies. Furthermore, in vitro cellular studies implicate that Src has a positive regulatory role in osteoclasts and a negative regulatory role in osteoblasts. The potential use of

Src inhibitors for osteoporosis therapy has been previously shown by novel bone-targeted ligands of the Src SH2 (e.g., AP22408) and non-bone-targeted, ATP-based **inhibitors** of **Src** kinase. Significant to this study, compounds 2-12 exemplify novel analogues of known pyrrolopyrimidine and **pyrazolopyrimidine** template-based **Src** kinase **inhibitors** that incorporate bone-targeting group modifications designed to provide tissue (bone) selectivity and diminished side effects. Accordingly, we report here the structure-based design, synthetic chemistry and biological testing of these compounds and proof-of-concept studies thereof.

L25 ANSWER 141 OF 181 MEDLINE on STN

AB 1. Tyrosine kinases have been proposed as regulators of voltage-operated calcium channels. The effects of a range of structurally different inhibitors of protein tyrosine kinases (PTK) were examined on voltage-operated calcium channel currents (I(Ba)) and pp60(c-src) kinase (c-src) activity in vitro. 2. I(Ba) was measured in single myocytes isolated from rabbit ear artery by conventional whole cell voltage-clamp techniques. The activity of purified human c-src was measured in vitro using a non-radioactive assay. 3. Bath application of tyrphostin-23 and genistein (non-selective PTK inhibitors), bistyrphostin (a receptor-PTK-selective **inhibitor**) and PP1 (a **src** family-selective **inhibitor**) **inhibited** I(Ba) in a concentration-dependent manner over a range of test membrane potentials. Intracellular application of peptide-A, a peptide **inhibitor** of c-**src** also **inhibited** currents. Inhibitor potency series against I(Ba) was PP1 > genistein > tyrphostin 23 > bistyrphostin. 4. Tyrphostin-23, genistein, PP1, and peptide-A shifted the steady-state inactivation curves in a hyperpolarized direction without altering their slope. The inhibitors had no significant effects on I(Ba) activation calculated from current-voltage relationships. 5. The agents **inhibited** c-**src** activity in a concentration-dependent manner. The order of potency was PP1 > genistein > peptide-A > tyrphostin-23 > bistyrphostin. The IC(50) for **inhibition** of c-**src** activity was similar to the IC(50) for inhibition of I(Ba) in all cases. 6. Western blot analysis with a specific antibody to c-src showed the presence of this cytoplasmic tyrosine kinase in rabbit ear artery cells. 7. A range of structurally dissimilar inhibitors of PTKs **inhibit** I(Ba) and c-**src** activity with similar potency. These data provide further evidence implicating endogenous c-src in the modulation of L-type calcium channels in vascular smooth muscle cells.

=> d 146

L25 ANSWER 146 OF 181 EMBASE on STN

TI Small molecule **inhibitors** of **Src** family kinases.

SO Drugs of the Future, (2000) 25/7 (717-736).
Refs: 243
ISSN: 0377-8282 CODEN: DRFUD4

AU Boschelli D.H.; Boschelli F.

AN 2000341838 EMBASE

=> d ab 146

L25 ANSWER 146 OF 181 EMBASE on STN

=> log y
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION

```
FULL ESTIMATED COST                                    199.07     199.28

STN INTERNATIONAL LOGOFF AT 10:21:11 ON 30 JUL 2004

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:23:18 ON 30 JUL 2004

=> fil .bec
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42       0.42

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,
       ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 14:24:41 ON 30 JUL 2004
ALL COPYRIGHTS AND RESTRICTIONS APPLY.  SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s aminopyrazolopyrimidine? or pyrazolopyrimidine? or (aminopyrazolo or
pyrazolo)(3w)pyrimidine?
FILE 'MEDLINE'
            50 AMINOPYRAZOLOPYRIMIDINE?
            87 PYRAZOLOPYRIMIDINE?
           140 AMINOPYRAZOLO
           854 PYRAZOLO
         27194 PYRIMIDINE?
           502 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L1         591 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'SCISEARCH'
            34 AMINOPYRAZOLOPYRIMIDINE?
           133 PYRAZOLOPYRIMIDINE?
            99 AMINOPYRAZOLO
          2284 PYRAZOLO
         20620 PYRIMIDINE?
           760 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L2         891 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'LIFESCI'
            12 AMINOPYRAZOLOPYRIMIDINE?
            31 PYRAZOLOPYRIMIDINE?
            14 AMINOPYRAZOLO
           145 PYRAZOLO
          5660 PYRIMIDINE?
            77 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L3         109 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOTECHDS'
             0 AMINOPYRAZOLOPYRIMIDINE?
             4 PYRAZOLOPYRIMIDINE?
             3 AMINOPYRAZOLO
            20 PYRAZOLO
           755 PYRIMIDINE?
            19 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L4          22 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOSIS'
            57 AMINOPYRAZOLOPYRIMIDINE?
           146 PYRAZOLOPYRIMIDINE?
```

```
          139 AMINOPYRAZOLO
         1751 PYRAZOLO
        21362 PYRIMIDINE?
          656 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L5        805 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'EMBASE'
           47 AMINOPYRAZOLOPYRIMIDINE?
          181 PYRAZOLOPYRIMIDINE?
          174 AMINOPYRAZOLO
         2292 PYRAZOLO
        17694 PYRIMIDINE?
          674 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L6        833 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'HCAPLUS'
          184 AMINOPYRAZOLOPYRIMIDINE?
         1402 PYRAZOLOPYRIMIDINE?
          409 AMINOPYRAZOLO
         5413 PYRAZOLO
        61580 PYRIMIDINE?
         1686 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L7       2301 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'NTIS'
            1 AMINOPYRAZOLOPYRIMIDINE?
            1 PYRAZOLOPYRIMIDINE?
            0 AMINOPYRAZOLO
            5 PYRAZOLO
          526 PYRIMIDINE?
            1 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L8          3 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'ESBIOBASE'
            2 AMINOPYRAZOLOPYRIMIDINE?
           28 PYRAZOLOPYRIMIDINE?
           10 AMINOPYRAZOLO
          290 PYRAZOLO
         4646 PYRIMIDINE?
          129 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L9        156 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOTECHNO'
           15 AMINOPYRAZOLOPYRIMIDINE?
           27 PYRAZOLOPYRIMIDINE?
           42 AMINOPYRAZOLO
          260 PYRAZOLO
         5965 PYRIMIDINE?
           85 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L10       119 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
              O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'WPIDS'
            2 AMINOPYRAZOLOPYRIMIDINE?
          126 PYRAZOLOPYRIMIDINE?
           50 AMINOPYRAZOLO
         2380 PYRAZOLO
        12648 PYRIMIDINE?
          515 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
```

```
L11          596 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
                 O OR PYRAZOLO)(3W)PYRIMIDINE?

TOTAL FOR ALL FILES
L12         6426 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
                 O OR PYRAZOLO)(3W) PYRIMIDINE?

=> s l12 and hirst?/au
FILE 'MEDLINE'
          1636 HIRST?/AU
L13          2 L1 AND HIRST?/AU

FILE 'SCISEARCH'
          2451 HIRST?/AU
L14          2 L2 AND HIRST?/AU

FILE 'LIFESCI'
           438 HIRST?/AU
L15          0 L3 AND HIRST?/AU

FILE 'BIOTECHDS'
            57 HIRST?/AU
L16          0 L4 AND HIRST?/AU

FILE 'BIOSIS'
          1953 HIRST?/AU
L17          3 L5 AND HIRST?/AU

FILE 'EMBASE'
          1414 HIRST?/AU
L18          3 L6 AND HIRST?/AU

FILE 'HCAPLUS'
          2228 HIRST?/AU
L19          7 L7 AND HIRST?/AU

FILE 'NTIS'
           288 HIRST?/AU
L20          0 L8 AND HIRST?/AU

FILE 'ESBIOBASE'
           546 HIRST?/AU
L21          2 L9 AND HIRST?/AU

FILE 'BIOTECHNO'
           358 HIRST?/AU
L22          0 L10 AND HIRST?/AU

FILE 'WPIDS'
           228 HIRST?/AU
L23          5 L11 AND HIRST?/AU

TOTAL FOR ALL FILES
L24         24 L12 AND HIRST?/AU

=> dup rem l24
PROCESSING COMPLETED FOR L24
L25          11 DUP REM L24 (13 DUPLICATES REMOVED)

=> d tot

L25  ANSWER 1 OF 11     MEDLINE on STN                  DUPLICATE 1
TI   A-420983: a potent, orally active inhibitor of lck with efficacy in a
     model of transplant rejection.
```

SO Bioorganic & medicinal chemistry letters, (2004 May 17) 14 (10) 2613-6.
Journal code: 9107377. ISSN: 0960-894X.
AU Borhani David W; Calderwood David J; Friedman Michael M; **Hirst Gavin C**; Li Biqin; Leung Adelaine K W; McRae Brad; Ratnofsky Sheldon; Ritter Kurt; Waegell Wendy
AN 2004212362 IN-PROCESS

L25 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
TI **Pyrazolopyrimidine** and furopyrimidine protein kinase inhibitors and their therapeutic use
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
IN **Hirst, Gavin C.**; Arnold, Lee D.; Burchat, Andrew; Wishart, Neil; Calderwood, David; Wada, Carol K.; Michaelides, Michael R.; Ji, Zhiqin; Muckey, Melanie
AN 2003:777596 HCAPLUS
DN 139:272922

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080064	A1	20031002	WO 2003-US8950	20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003199525	A1	20031023	US 2002-103098	20020321

L25 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
TI Preparation of **pyrazolopyrimidine** and furopyrimidine protein kinase inhibitors and their therapeutic use
SO U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
IN **Hirst, Gavin C.**; Arnold, Lee D.; Burchat, Andrew; Wishart, Neil; Calderwood, David; Wada, Carol K.; Michaelides, Michael R.; Ji, Zhiqin; Muckey, Melanie
AN 2003:950055 HCAPLUS
DN 140:5065

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225098	A1	20031204	US 2003-394965	20030321

L25 ANSWER 4 OF 11 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI **Pyrazolopyrimidines** as therapeutic agents.
SO Official Gazette of the United States Patent and Trademark Office Patents, (Dec 9 2003) Vol. 1277, No. 2. http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133 (ISSN print).
AU **Hirst, Gavin C.** [Inventor, Reprint Author]; Rafferty, Paul [Inventor]; Ritter, Kurt [Inventor]; Calderwood, David [Inventor]; Wishart, Neil [Inventor]; Arnold, Lee D. [Inventor]; Friedman, Michael M. [Inventor]
AN 2004:58341 BIOSIS

L25 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
SO PCT Int. Appl., 867 pp.
CODEN: PIXXD2

IN **Hirst, Gavin C.**; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
AN 2002:793426 HCAPLUS
DN 137:310925

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002156081	A1	20021024	US 2001-815310	20010322
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2003004176	A	20031121	NO 2003-4176	20030919

L25 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
SO U.S. Pat. Appl. Publ., 426 pp., Cont.-in-part of U.S. Ser. No. 663,780.
CODEN: USXXCO
IN **Hirst, Gavin C.**; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
AN 2002:814851 HCAPLUS
DN 137:310930

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156081	A1	20021024	US 2001-815310	20010322
US 6660744	B1	20031209	US 2000-663780	20000915
WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2003004176	A	20031121	NO 2003-4176	20030919

L25 ANSWER 7 OF 11 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **pyrazolopyrimidine** derivatives as kinase inhibitors useful for treating e.g. ulcers.
PI WO 2002076986 A1 20021003 (200305)* EN 440 C07D487-04
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
NO 2003004177 A 20031121 (200382) C07D487-04

US 2004006083 A1 20040108 (200404) A61K031-519
EP 1379528 A1 20040114 (200410) EN C07D487-04
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
KR 2003088114 A 20031117 (200420) C07D487-04
SK 2003001312 A3 20040406 (200427) C07D487-04
CZ 2003002837 A3 20040114 (200429) C07D487-04
AU 2002258590 A1 20021008 (200432) C07D487-04
BR 2002005890 A 20040629 (200444) C07D487-04
IN ARNOLD, L D; CALDERWOOD, D J; FRIEDMAN, M M; **HIRST, G C**; RAFFERTY, P; RITTER, K; WISHART, N; CALDERWOOD, D

L25 ANSWER 8 OF 11 MEDLINE on STN DUPLICATE 5
TI **Pyrazolo**[3,4-d]**pyrimidines** containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight.
SO Bioorganic & medicinal chemistry letters, (2002 Jun 17) 12 (12) 1687-90. Journal code: 9107377. ISSN: 0960-894X.
AU Burchat Andrew F; Calderwood David J; Friedman Michael M; **Hirst Gavin C**; Li Biqin; Rafferty Paul; Ritter Kurt; Skinner Barbara S
AN 2002298771 MEDLINE

L25 ANSWER 9 OF 11 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Design, synthesis and brief SAR of pyrazolo(3,4-d) and pyrrolo(2,3-d)pyrimidines as potent inhibitors of lck.
SO Abstracts of Papers American Chemical Society, (2002) Vol. 224, No. 1-2, pp. MEDI 109. print.
Meeting Info.: 224th National Meeting of the American Chemical Society. Boston, MA, USA. August 18-22, 2002.
CODEN: ACSRAL. ISSN: 0065-7727.
AU Burchat, Andrew F. [Reprint author]; Calderwood, David J. [Reprint author]; Deng, Bojuan [Reprint author]; Friedman, Michael [Reprint author]; **Hirst, Gavin** [Reprint author]; Li, Biqin [Reprint author]; Ritter, Kurt [Reprint author]; Skinner, Barbara [Reprint author]
AN 2002:510877 BIOSIS

L25 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6
TI Preparation of **pyrazolopyrimidines** as protein kinase inhibitors
SO PCT Int. Appl., 527 pp.
CODEN: PIXXD2
IN **Hirst, Gavin C.**; Calderwood, David; Wishart, Neil; Rafferty, Paul; Ritter, Kurt; Arnold, Lee D.; Friedman, Michael M.
AN 2001:208278 HCAPLUS
DN 134:252353

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019829	A2	20010322	WO 2000-US25468	20000915
WO 2001019829	A3	20010927		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000074950	A5	20010417	AU 2000-74950	20000915
EP 1212327	A2	20020612	EP 2000-963554	20000915
EP 1212327	B1	20030820		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

BR 2000014073	A	20020716	BR 2000-14073	20000915
JP 2003509428	T2	20030311	JP 2001-523406	20000915
AT 247657	E	20030915	AT 2000-963554	20000915

```
     ZA 2002002123      A     20030617       ZA 2002-2123      20020314
     NO 2002001328      A     20020521       NO 2002-1328      20020318
     BG 106586          A     20030131       BG 2002-106586    20020405

L25  ANSWER 11 OF 11  EMBASE  COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
TI   Lck inhibitors as a therapeutic approach to autoimmune disease and
     transplant rejection.
SO   Current Opinion in Investigational Drugs, (2001) 2/9 (1213-1219).
     Refs: 67
     ISSN: 0967-8298  CODEN: CIDREE
AU   Kamens J.S.; Ratnofsky S.E.; Hirst G.C.
AN   2001329775  EMBASE


=> s l12 and calderwood?/au
FILE 'MEDLINE'
           341 CALDERWOOD?/AU
L26          2 L1 AND CALDERWOOD?/AU

FILE 'SCISEARCH'
           540 CALDERWOOD?/AU
L27          2 L2 AND CALDERWOOD?/AU

FILE 'LIFESCI'
           127 CALDERWOOD?/AU
L28          0 L3 AND CALDERWOOD?/AU

FILE 'BIOTECHDS'
            17 CALDERWOOD?/AU
L29          0 L4 AND CALDERWOOD?/AU

FILE 'BIOSIS'
           450 CALDERWOOD?/AU
L30          3 L5 AND CALDERWOOD?/AU

FILE 'EMBASE'
           280 CALDERWOOD?/AU
L31          2 L6 AND CALDERWOOD?/AU

FILE 'HCAPLUS'
           570 CALDERWOOD?/AU
L32          7 L7 AND CALDERWOOD?/AU

FILE 'NTIS'
            23 CALDERWOOD?/AU
L33          0 L8 AND CALDERWOOD?/AU

FILE 'ESBIOBASE'
           144 CALDERWOOD?/AU
L34          2 L9 AND CALDERWOOD?/AU

FILE 'BIOTECHNO'
           136 CALDERWOOD?/AU
L35          0 L10 AND CALDERWOOD?/AU

FILE 'WPIDS'
            50 CALDERWOOD?/AU
L36          5 L11 AND CALDERWOOD?/AU

TOTAL FOR ALL FILES
L37         23 L12 AND CALDERWOOD?/AU

=> dup rem l37
```

PROCESSING COMPLETED FOR L37
L38 10 DUP REM L37 (13 DUPLICATES REMOVED)

=> d tot

L38 ANSWER 1 OF 10 MEDLINE on STN DUPLICATE 1
TI A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.
SO Bioorganic & medicinal chemistry letters, (2004 May 17) 14 (10) 2613-6. Journal code: 9107377. ISSN: 0960-894X.
AU Borhani David W; **Calderwood David J**; Friedman Michael M; Hirst Gavin C; Li Biqin; Leung Adelaine K W; McRae Brad; Ratnofsky Sheldon; Ritter Kurt; Waegell Wendy
AN 2004212362 IN-PROCESS

L38 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
TI **Pyrazolopyrimidine** and furopyrimidine protein kinase inhibitors and their therapeutic use
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
IN Hirst, Gavin C.; Arnold, Lee D.; Burchat, Andrew; Wishart, Neil; **Calderwood, David**; Wada, Carol K.; Michaelides, Michael R.; Ji, Zhiqin; Muckey, Melanie
AN 2003:777596 HCAPLUS
DN 139:272922

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080064	A1	20031002	WO 2003-US8950	20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003199525	A1	20031023	US 2002-103098	20020321

L38 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
TI Preparation of **pyrazolopyrimidine** and furopyrimidine protein kinase inhibitors and their therapeutic use
SO U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
IN Hirst, Gavin C.; Arnold, Lee D.; Burchat, Andrew; Wishart, Neil; **Calderwood, David**; Wada, Carol K.; Michaelides, Michael R.; Ji, Zhiqin; Muckey, Melanie
AN 2003:950055 HCAPLUS
DN 140:5065

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225098	A1	20031204	US 2003-394965	20030321

L38 ANSWER 4 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI **Pyrazolopyrimidines** as therapeutic agents.
SO Official Gazette of the United States Patent and Trademark Office Patents, (Dec 9 2003) Vol. 1277, No. 2. http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133 (ISSN print).
AU Hirst, Gavin C. [Inventor, Reprint Author]; Rafferty, Paul [Inventor]; Ritter, Kurt [Inventor]; **Calderwood, David** [Inventor]; Wishart, Neil [Inventor]; Arnold, Lee D. [Inventor]; Friedman, Michael M.

[Inventor]
AN 2004:58341 BIOSIS

L38 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
SO PCT Int. Appl., 867 pp.
CODEN: PIXXD2
IN Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; **Calderwood, David** ; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
AN 2002:793426 HCAPLUS
DN 137:310925

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002156081	A1	20021024	US 2001-815310	20010322
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2003004176	A	20031121	NO 2003-4176	20030919

L38 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
SO U.S. Pat. Appl. Publ., 426 pp., Cont.-in-part of U.S. Ser. No. 663,780.
CODEN: USXXCO
IN Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; **Calderwood, David** ; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
AN 2002:814851 HCAPLUS
DN 137:310930

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002156081	A1	20021024	US 2001-815310	20010322
US 6660744	B1	20031209	US 2000-663780	20000915
WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2003004176	A	20031121	NO 2003-4176	20030919

L38 ANSWER 7 OF 10 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **pyrazolopyrimidine** derivatives as kinase inhibitors useful for treating e.g. ulcers.
PI WO 2002076986 A1 20021003 (200305)* EN 440 C07D487-04

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

NO	2003004177	A	20031121	(200382)	C07D487-04
US	2004006083	A1	20040108	(200404)	A61K031-519
EP	1379528	A1	20040114	(200410) EN	C07D487-04

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

KR	2003088114	A	20031117	(200420)	C07D487-04
SK	2003001312	A3	20040406	(200427)	C07D487-04
CZ	2003002837	A3	20040114	(200429)	C07D487-04
AU	2002258590	A1	20021008	(200432)	C07D487-04
BR	2002005890	A	20040629	(200444)	C07D487-04

IN ARNOLD, L D; **CALDERWOOD, D J**; FRIEDMAN, M M; HIRST, G C; RAFFERTY, P; RITTER, K; WISHART, N; **CALDERWOOD, D**

L38 ANSWER 8 OF 10 MEDLINE on STN DUPLICATE 5
TI **Pyrazolo**[3,4-d]**pyrimidines** containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight.
SO Bioorganic & medicinal chemistry letters, (2002 Jun 17) 12 (12) 1687-90. Journal code: 9107377. ISSN: 0960-894X.
AU Burchat Andrew F; **Calderwood David J**; Friedman Michael M; Hirst Gavin C; Li Biqin; Rafferty Paul; Ritter Kurt; Skinner Barbara S
AN 2002298771 MEDLINE

L38 ANSWER 9 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Design, synthesis and brief SAR of pyrazolo(3,4-d) and pyrrolo(2,3-d)pyrimidines as potent inhibitors of lck.
SO Abstracts of Papers American Chemical Society, (2002) Vol. 224, No. 1-2, pp. MEDI 109. print.
Meeting Info.: 224th National Meeting of the American Chemical Society. Boston, MA, USA. August 18-22, 2002.
CODEN: ACSRAL. ISSN: 0065-7727.
AU Burchat, Andrew F. [Reprint author]; **Calderwood, David J.** [Reprint author]; Deng, Bojuan [Reprint author]; Friedman, Michael [Reprint author]; Hirst, Gavin [Reprint author]; Li, Biqin [Reprint author]; Ritter, Kurt [Reprint author]; Skinner, Barbara [Reprint author]
AN 2002:510877 BIOSIS

L38 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6
TI Preparation of **pyrazolopyrimidines** as protein kinase inhibitors
SO PCT Int. Appl., 527 pp.
CODEN: PIXXD2
IN Hirst, Gavin C.; **Calderwood, David**; Wishart, Neil; Rafferty, Paul; Ritter, Kurt; Arnold, Lee D.; Friedman, Michael M.
AN 2001:208278 HCAPLUS
DN 134:252353

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019829	A2	20010322	WO 2000-US25468	20000915
WO 2001019829	A3	20010927		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

```
AU 2000074950     A5   20010417       AU 2000-74950    20000915
EP 1212327        A2   20020612       EP 2000-963554   20000915
EP 1212327        B1   20030820
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL
BR 2000014073     A    20020716       BR 2000-14073    20000915
JP 2003509428     T2   20030311       JP 2001-523406   20000915
AT 247657         E    20030915       AT 2000-963554   20000915
ZA 2002002123     A    20030617       ZA 2002-2123     20020314
NO 2002001328     A    20020521       NO 2002-1328     20020318
BG 106586         A    20030131       BG 2002-106586   20020405


=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    66.18      66.60

STN INTERNATIONAL LOGOFF AT 14:37:51 ON 30 JUL 2004

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:02:57 ON 30 JUL 2004

=> fil hcapl
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'HCAPLUS' ENTERED AT 15:03:07 ON 30 JUL 2004

=> s hirst?/au and calderwood?/au and 2002/py
          2228 HIRST?/AU
           570 CALDERWOOD?/AU
       1129905 2002/PY
L1           10 HIRST?/AU AND CALDERWOOD?/AU AND 2002/PY

=> s l1 and lck
          1633 LCK
L2           10 L1 AND LCK

=> d tot

L2   ANSWER 1 OF 10  HCAPLUS  COPYRIGHT 2004 ACS on STN
TI   Preparation of pyrrolopyrimidines as tyrosine kinase inhibitors
SO   U.S. Pat. Appl. Publ., 166 pp., Cont.-in-part of Appl. No. PCT/US99/21560.
     CODEN: USXXCO
IN   Hirst, Gavin C.; Calderwood, David; Munschauer,
     Rainer; Arnold, Lee D.; Johnston, David N.; Rafferty, Paul
AN   2003:633320  HCAPLUS
DN   139:180075
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   US 2003153752      A1   20030814       US 2000-537167   20000329
     US 6713474         B2   20040330
     WO 2000017203      A1   20000330       WO 1999-US21560  19990917
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
```

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
ZA 2001002204 A 20020318 ZA 2001-2204 20010316 <--

L2 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
SO U.S. Pat. Appl. Publ., 426 pp., Cont.-in-part of U.S. Ser. No. 663,780.
CODEN: USXXCO
IN **Hirst, Gavin C.**; Rafferty, Paul; Ritter, Kurt; **Calderwood, David**; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
AN 2002:814851 HCAPLUS
DN 137:310930

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 2002156081	A1	20021024	US 2001-815310	20010322	<--
US 6660744	B1	20031209	US 2000-663780	20000915	
WO 2002080926	A1	20021017	WO 2002-US9104	20020322	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1385524	A1	20040204	EP 2002-746301	20020322	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
NO 2003004176	A	20031121	NO 2003-4176	20030919	

L2 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
SO PCT Int. Appl., 867 pp.
CODEN: PIXXD2
IN **Hirst, Gavin C.**; Rafferty, Paul; Ritter, Kurt; **Calderwood, David**; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
AN 2002:793426 HCAPLUS
DN 137:310925

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 2002080926	A1	20021017	WO 2002-US9104	20020322	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2002156081	A1	20021024	US 2001-815310	20010322	<--
EP 1385524	A1	20040204	EP 2002-746301	20020322	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
NO 2003004176	A	20031121	NO 2003-4176	20030919	

L2 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
SO PCT Int. Appl., 440 pp.

CODEN: PIXXD2

IN **Hirst, Gavin C.**; Rafferty, Paul; Ritter, Kurt; **Calderwood, David**; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.

AN 2002:754390 HCAPLUS

DN 137:263056

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076986	A1	20021003	WO 2002-US8996	20020322 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1379528	A1	20040114	EP 2002-728546	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002005890	A	20040629	BR 2002-5890	20020322
US 2004006083	A1	20040108	US 2002-104140	20020719
NO 2003004177	A	20031121	NO 2003-4177	20030919

L2 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Synthesis and SAR of pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of **lck**

SO Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002 (**2002**), MEDI-110 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69CZPZ

AU **Calderwood, David J.**; Deng, Bojuan; **Hirst, Gavin**; Konopacki, Donald B.; Lee, Soo Jung; Ritter, Kurt; Skinner, Barbara

AN 2002:617963 HCAPLUS

L2 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Design, synthesis and brief SAR of pyrazolo[3,4-d] and pyrrolo[2,3-d]pyrimidines as potent inhibitors of **lck**

SO Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002 (**2002**), MEDI-109 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69CZPZ

AU Burchat, Andrew F.; **Calderwood, David J.**; Deng, Bojuan; Friedman, Michael; **Hirst, Gavin**; Li, Biqin; Ritter, Kurt; Skinner, Barbara

AN 2002:617962 HCAPLUS

L2 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of **Lck** - a selectivity insight

SO Bioorganic & Medicinal Chemistry Letters (**2002**), 12(12), 1687-1690
CODEN: BMCLE8; ISSN: 0960-894X

AU Burchat, Andrew F.; **Calderwood, David J.**; Friedman, Michael M.; **Hirst, Gavin C.**; Li, Biqin; Rafferty, Paul; Ritter, Kurt; Skinner, Barbara S.

AN 2002:407945 HCAPLUS

DN 138:49367

L2 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Preparation of pyrazolopyrimidines as protein kinase inhibitors

SO PCT Int. Appl., 527 pp.
CODEN: PIXXD2

IN **Hirst, Gavin C.**; **Calderwood, David**; Wishart, Neil; Rafferty, Paul; Ritter, Kurt; Arnold, Lee D.; Friedman, Michael M.

AN 2001:208278 HCAPLUS

DN 134:252353

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 2001019829	A2	20010322	WO 2000-US25468	20000915	
WO 2001019829	A3	20010927			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2000074950	A5	20010417	AU 2000-74950	20000915	
EP 1212327	A2	20020612	EP 2000-963554	20000915	<--
EP 1212327	B1	20030820			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
BR 2000014073	A	20020716	BR 2000-14073	20000915	<--
JP 2003509428	T2	20030311	JP 2001-523406	20000915	
AT 247657	E	20030915	AT 2000-963554	20000915	
ZA 2002002123	A	20030617	ZA 2002-2123	20020314	
NO 2002001328	A	20020521	NO 2002-1328	20020318	<--
BG 106586	A	20030131	BG 2002-106586	20020405	

L2 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Preparation of pyrrolopyrimidines as protein kinase inhibitors

SO PCT Int. Appl., 304 pp.
CODEN: PIXXD2

IN **Hirst, Gavin C.**; **Calderwood, David**; Wishart, Neil; Ritter, Kurt; Arnold, Lee D.

AN 2000:210172 HCAPLUS

DN 132:251160

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 2000017203	A1	20000330	WO 1999-US21560	19990917	
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2344249	AA	20000330	CA 1999-2344249	19990917	
AU 9960484	A1	20000410	AU 1999-60484	19990917	<--
AU 753555	B2	20021024			
EP 1114053	A1	20010711	EP 1999-969415	19990917	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200101186	T2	20011022	TR 2001-20010118619990917		
BR 9913887	A	20011023	BR 1999-13887	19990917	
JP 2002526500	T2	20020820	JP 2000-574112	19990917	<--
NZ 510588	A	20030829	NZ 1999-510588	19990917	
US 2003153752	A1	20030814	US 2000-537167	20000329	
US 6713474	B2	20040330			
BG 105346	A	20011231	BG 2001-105346	20010315	
NO 2001001356	A	20010516	NO 2001-1356	20010316	
ZA 2001002204	A	20020318	ZA 2001-2204	20010316	<--

L2 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 4-aminopyrrolopyrimidines as protein kinase inhibitors
SO PCT Int. Appl., 242 pp.
CODEN: PIXXD2
IN **Calderwood, David**; Arnold, Lee D.; Mazdiyasni, Hormoz; **Hirst, Gavin**; Deng, Bojuan B.
AN 2000:210171 HCAPLUS
DN 132:251159

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000017202	A1	20000330	WO 1999-US21536	19990917
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2344262	AA	20000330	CA 1999-2344262	19990917
AU 9960475	A1	20000410	AU 1999-60475	19990917 <--
AU 752474	B2	20020919		
EP 1114052	A1	20010711	EP 1999-969414	19990917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101395	T2	20011121	TR 2001-20010139519990917	
BR 9913888	A	20020108	BR 1999-13888	19990917 <--
JP 2002527359	T2	20020827	JP 2000-574111	19990917 <--
NZ 510587	A	20031128	NZ 1999-510587	19990917
NO 2001001357	A	20010514	NO 2001-1357	20010316
BG 105355	A	20011130	BG 2001-105355	20010316
ZA 2001002201	A	20020315	ZA 2001-2201	20010316 <--

=> d all 7

L2 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:407945 HCAPLUS
DN 138:49367
ED Entered STN: 31 May 2002
TI Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of **Lck** - a selectivity insight
AU Burchat, Andrew F.; **Calderwood, David J.**; Friedman, Michael M.; **Hirst, Gavin C.**; Li, Biqin; Rafferty, Paul; Ritter, Kurt; Skinner, Barbara S.
CS Abbott Bioresearch Center, Worcester, MA, 01605-5314, USA
SO Bioorganic & Medicinal Chemistry Letters (**2002**), 12(12), 1687-1690
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
CC 1-3 (Pharmacology)
Section cross-reference(s): 28
OS CASREACT 138:49367
AB A series of para-substituted 3-Ph pyrazolopyrimidines was synthesized and evaluated as inhibitors of **lck**. The nature of the substitution affected enzyme selectivity and potency for **lck**, src, kdr, and tie-2. One of the para-phenoxyphenyl pyrazolopyrimidine analog is an orally active **lck** inhibitor with a bioavailability of 69% and exhibits an extended duration of action in animal models of T cell inhibition.

ST pyrazolopyrimidine prepn bioavailability structure activity **Lck** kinase T lymphocyte

IT Cell activation
(T cell; structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT T cell (lymphocyte)
(activation; structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT T cell (lymphocyte)
(inhibition of; structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT Drug bioavailability
Human
Hydrogen bond
Molecular modeling
Molecular structure
Structure-activity relationship
(structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT Interleukin 2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT 114051-78-4, **Lck** kinase 141349-89-5, Src kinase 148047-29-4, Tie-2 kinase 150977-45-0, Kinase (phosphorylating) gene kdr protein
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT 330786-01-1
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT 330786-32-8 330786-44-2 330786-46-4 330786-56-6 330787-02-5
330789-32-7 330791-29-2 330791-36-1 330791-47-4 364042-47-7
461698-29-3 479546-21-9 479546-22-0 479546-23-1 479546-24-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT 109-01-3, N-Methyl piperazine 16617-46-2 22428-87-1, 1-Hydroxy-4-cyclohexanone ethylene ketal 262433-02-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

IT 151266-23-8P 330792-72-8P 330792-74-0P 330792-81-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(structure-activity relationship of substituted pyrazolopyrimidines as potent inhibitors of **Lck**)

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Arnold, L; Bioorg Med Chem Lett 2000, V10, P2167 HCAPLUS
(2) Bolen, J; Annu Rev Immunol 1997, V15, P37
(3) Calderwood, D; Bioorg Med Chem Lett 2002, V12, P1683 HCAPLUS
(4) Dowden, J; Expert Opin Ther Pat 2001, V11, P295
(5) Gribble, F; J Biol Chem 2000, V275, P30046 HCAPLUS
(6) Hirst, G; WO 119829 2001 HCAPLUS
(7) Kolb, A; Drug Discov Today 1998, V3, P333 HCAPLUS
(8) Marth, J; Cell 1985, V43, P393 HCAPLUS
(9) Molina, T; Nature (London) 1992, V357, P161 HCAPLUS
(10) Neumeister, E; Mol Cell Biol 1995, V15, P3171 HCAPLUS
(11) Ohmi, N; J Biomol Screening 2000, V5, P463 HCAPLUS
(12) Sicheri, F; Curr Opin Struct Biol 1997, V7, P777 HCAPLUS

(13) Weil, R; Curr Top Microbiol Immunol 1996, V205, P63 HCAPLUS
(14) Wen, T; Eur J Immunol 1995, V25, P3155 HCAPLUS

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.03	24.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.74	-0.74

FILE 'REGISTRY' ENTERED AT 15:05:39 ON 30 JUL 2004

=> S 330786-32-8/RN

L3 1 330786-32-8/RN

=> D L3 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **330786-32-8** REGISTRY
CN Methanone, [4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]phenyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H33 N7 O
CI COM
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
                1 REFERENCES IN FILE CA (1907 TO DATE)
                1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> log y
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         5.13      29.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -0.74

STN INTERNATIONAL LOGOFF AT 15:10:40 ON 30 JUL 2004

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:53:26 ON 02 AUG 2004

=> fil uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'USPATFULL' ENTERED AT 07:53:53 ON 02 AUG 2004

=> s 20020156081/pn
L1            0 20020156081/PN

=> s hirst?/in
L2          186 HIRST?/IN

=> s rafferty?/in
L3          170 RAFFERTY?/IN

=> s wishart?/in
L4           41 WISHART?/IN

=> s l2 and l3 and l4
L5            3 L2 AND L3 AND L4

=> d 1-3

L5   ANSWER 1 OF 3  USPATFULL on STN
AN     2004:7843  USPATFULL
TI     Pyrazolopyrimidines as therapeutic agents
IN     Hirst, Gavin C., Marlborough, MA, UNITED STATES
         Rafferty, Paul, Westborough, MA, UNITED STATES
       Ritter, Kurt, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
       Calderwood, David, Framingham, MA, UNITED STATES
         Wishart, Neil, Holden, MA, UNITED STATES
       Arnold, Lee D., Westborough, MA, UNITED STATES
       Friedman, Michael M., Newton, MA, UNITED STATES
PI     US 2004006083      A1   20040108
AI     US 2002-104140     A1   20020719 (10)
PRAI   US 2001-278047P     20010322 (60)
DT     Utility
FS     APPLICATION
LN.CNT 14812
INCL   INCLM: 514/248.000
       INCLS: 514/249.000; 514/259.100; 514/264.100; 544/235.000; 544/262.000
NCL    NCLM:  514/248.000
       NCLS:  514/249.000; 514/259.100; 514/264.100; 544/235.000; 544/262.000
```

IC [7]
ICM: A61K031-519
ICS: C07D487-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 3 USPATFULL on STN
AN 2003:321522 USPATFULL
TI Pyrazolopyrimidines as therapeutic agents
IN **Hirst, Gavin C.**, Marlborough, MA, United States
Rafferty, Paul, Westborough, MA, United States
Ritter, Kurt, Newton, MA, United States
Calderwood, David, Framingham, MA, United States
Wishart, Neil, Jefferson, MA, United States
Arnold, Lee D., Westborough, MA, United States
Friedman, Michael M., Newton, MA, United States
PA Abbott GmbH & Co. KG, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6660744 B1 20031209
AI US 2000-663780 20000915 (9)
PRAI US 1999-154620P 19990917 (60)
DT Utility
FS GRANTED
LN.CNT 17542
INCL INCLM: 514/258.000
INCLS: 544/262.000
NCL NCLM: 514/262.100
NCLS: 514/210.210; 544/262.000
IC [7]
ICM: C07D487-04
ICS: A61K031-519; A61P003-10; A61P009-10; A61P035-02
EXF 544/262; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 3 USPATFULL on STN
AN 2002:280635 USPATFULL
TI Pyrazolopyrimidines as therapeutic agents
IN **Hirst, Gavin C.**, Marlborough, MA, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES
Ritter, Kurt, Newton, GERMANY, FEDERAL REPUBLIC OF
Calderwood, David, Framingham, UNITED KINGDOM
Wishart, Neil, Jefferson, MA, UNITED STATES
Arnold, Lee D., Westborough, CANADA
Friedman, Michael M., Newton, MA, UNITED STATES
PA Abbott Laboratories, Abbott Park, IL, UNITED STATES (U.S. corporation)
PI US 2002156081 A1 20021024
AI US 2001-815310 A1 20010322 (9)
RLI Continuation-in-part of Ser. No. US 2000-663780, filed on 15 Sep 2000, PENDING
PRAI US 1999-154620P 19990917 (60)
DT Utility
FS APPLICATION
LN.CNT 30126
INCL INCLM: 514/247.000
INCLS: 514/249.000; 514/258.000; 544/237.000; 544/262.000
NCL NCLM: 514/247.000
NCLS: 514/249.000; 514/258.000; 544/237.000; 544/262.000
IC [7]
ICM: A61K031-519
ICS: C07D487-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ind 3

L5 ANSWER 3 OF 3 USPATFULL on STN

INCL INCLM: 514/247.000
INCLS: 514/249.000; 514/258.000; 544/237.000; 544/262.000
NCL NCLM: 514/247.000
NCLS: 514/249.000; 514/258.000; 544/237.000; 544/262.000
IC [7]
ICM: A61K031-519
ICS: C07D487-04

CHEMICAL ABSTRACTS INDEXING COPYRIGHT 2004 ACS on STN

		PATENT	KIND	DATE
OS	CA 134:252353	WO 0119829	A2	20010322
	CA 137:310930 *	US 20020156081	A1	20021024
	CA 137:310925	WO 02080926	A1	20021017

* CA Indexing for this record included

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

ST azaheteroaryl aryl pyrazolopyrimidinamine prepn protein kinase inhibitor antiangiogenic

IT Cell activation
(B cell; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Intestine, disease
(Crohn's; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Sarcoma
(Kaposi's; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Bone, disease
(Paget's; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Cell activation
(T cell; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Tyrosine kinase receptors
(Tie, TIE-2; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Tyrosine kinase receptors
(Tie-1; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
(VEGF, VEGF-B, VEGF-C, VEGF-D, or VEGF-E, combination therapy agent; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Antibodies and Immunoglobulins
(antiiodotypic, combination therapy agent; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Infection
(bacterial; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Edema
(burn-related; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
(c-fgr; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Artery, disease
(carotid, occlusion; preparation of [(hetero)aryl]pyrazolo[3,4-

d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Lung, disease
(chronic obstructive; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Inflammation
(chronic; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Angiogenic factors
Hepatocyte growth factor
(combination therapy agent; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Eye, disease
(conjunctivitis; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Eye, disease
(diabetic retinopathy; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Burn
(edema from; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Uterus, disease
(endometriosis; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Sarcoma
(fibrosarcoma; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
(fyn; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Necrosis
(gangrene; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
(gene hck; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins
(gene lyn; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Neuroglia, neoplasm
(glioblastoma; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Kidney, disease
(glomerulonephritis; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Capillary vessel, disease
(hereditary hemorrhagic telangiectasia; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Human herpesvirus 3
(herpes zoster from; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Ovary, disease
(hyperstimulation syndrome; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Intestine, disease
(inflammatory; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Cell proliferation
(inhibition; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Reperfusion
(injury; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Diabetes mellitus
(insulin-dependent; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Eye, disease
(macula, degeneration; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Cell degranulation
(mast cell; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Menstrual disorder
(menorrhagia; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Cell activation
(monocyte; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Vision
(myopia; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Angiogenesis
(neovascularization, eye; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Eye, disease
(neovascularization; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Nerve, neoplasm
(neuroblastoma; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Blood vessel, disease
(occlusion; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Proteins
(p62c-yes; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Skin, disease
(pemphigoid; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Kidney, disease
(polycystic; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
IT Anemia (disease)
Angiogenesis
Angiogenesis inhibitors
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antibacterial agents
Antidiabetic agents
Antiglaucoma agents
Antirheumatic agents
Antitumor agents
Antiulcer agents
Asthma
Atherosclerosis

Cardiovascular agents
Cardiovascular system, disease
Cirrhosis
Contraceptives
Eye, disease
Fibrosis
Fungicides
Glaucoma (disease)
Hematopoiesis
Hodgkin's disease
Human
Human herpesvirus
Human immunodeficiency virus 1
Hypoxia, animal
Ischemia
Leukemia
Lyme disease
Lymphoma
Melanoma
Multiple myeloma
Multiple sclerosis
Mycosis
Necrosis
Neoplasm
Osteoarthritis
Parapoxvirus
Preeclampsia
Protozoa
Protozoacides
Psoriasis
Radiation
Rheumatoid arthritis
Sarcoidosis
Sarcoma
Sepsis
Sickle cell anemia
Transplant rejection
Ulcer
Wound
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Hepatocyte growth factor receptors
Insulin-like growth factor I receptors
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Drug delivery systems
(prodrugs; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Eye
(radial keratotomy; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Artery, disease
(restenosis; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Eye, disease
(retina, detachment; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Eye, neoplasm
(retinoblastoma; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Eye, disease
(retinopathy; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as

protein kinase inhibitors with antiangiogenic properties)

IT Myoma
(rhabdomyosarcoma; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Brain, disease
(stroke; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Synovial membrane, disease
(synovitis; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Lupus erythematosus
(systemic; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Carcinoma
(teratocarcinoma; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Multiple sclerosis
(therapeutic agents; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Thyroid gland, disease
(thyroiditis; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Toxoplasma gondii
(toxoplasmosis from; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Injury
(trauma; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Fibroblast growth factor receptors
(type 1; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
(type VEGFR-1; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
(type VEGFR-2; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors
(type VEGFR-3; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Intestine, disease
(ulcerative colitis; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Eye, disease
(uveitis; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Nervous system agents
(von Hippel Lindau disease; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Nervous system, neoplasm
(von Hippel-Lindau disease; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Platelet-derived growth factor receptors
(α; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Platelet-derived growth factor receptors
(β; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as

protein kinase inhibitors with antiangiogenic properties)

IT 106096-92-8, FGF-1 106096-93-9, FGF-2
(combination therapy agent; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461699-44-5P, 1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-59-4P, 3-(4-Amino-3-fluorophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(intermediate; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 527-62-8P, 2-Amino-4,6-dichlorophenol 567-19-1P, 3-Chloro-1H-benzo[d]isothiazole-1,1-dione 614-30-2P, N-Benzyl-N-methyl-N-phenylamine 2380-63-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-ylamine 4094-64-8P, 3-Methyl-3-phenylbutanoyl chloride 4160-52-5P, 1-(4-Methylphenyl)-1-butanone 4746-97-8P, 1,4-Cyclohexanedione monoethylene ketal 4831-21-4P, 2-(4-Bromoanilino)-1-phenyl-1-ethanone 5213-16-1P, 4-Bromo-2-methoxy-1-benzenecarbonyl chloride 5669-14-7P, 2,2-Dimethyl-3-phenylpropanoic acid 6278-86-0P, N-(4-Bromophenyl)-1,3-benzothiazol-2-amine 6846-12-4P, N-Phenyl-4-bromobenzamide 14543-43-2P, 3-Amino-4-hydroxybenzonitrile 17672-22-9P, 2-Amino-6-methylphenol 18213-90-6P, 2-Phenoxypyrimidine 19541-99-2P, 1H-Benzimidazol-1-ylmethanol 20949-84-2P, 2-Methyl-1,3-thiazole-4-carboxaldehyde 21943-50-0P, 2-Bromocyclopentanone 22428-87-1P, 1,4-Dioxaspiro[4.5]decan-8-ol 23511-05-9P 25216-74-4P, tert-Butyl N-(3-bromophenyl)carbamate 29078-20-4P, 2-Amino-6-isopropylphenol 32587-79-4P, (R)-3-Phenylbutanoyl chloride 35863-45-7P, 2,2-Dimethyl-3-phenylpropanenitrile 38191-33-2P, 2-Amino-6-chlorophenol 41717-28-6P, Benzofuran-2-carbonyl chloride 51067-38-0P, 4-Phenoxyphenylboronic acid 54738-73-7P 55095-17-5P 56520-98-0P, 4-Ethyl-2-nitrophenol 56759-58-1P, 2,6-Dibromo-3,5-dimethyl-1-cyclohexanone 58881-45-1P, 1H-2-Indolecarbonyl chloride 59557-91-4P, 4-Bromo-2-methoxyaniline 59717-96-3P, 5-Bromo-2-phenoxypyridine 62931-24-2P, 2,2-Dimethyl-3-phenylpropanoyl chloride 63290-62-0P, 1-(4-Bromophenyl)-3-phenyl-2,5-pyrrolidinedione 68679-84-5P, (S)-3-Phenylbutanoyl chloride 72135-36-5P, 4-Bromo-2-methoxybenzoic acid 73798-61-5P 74965-38-1P, tert-Butyl N-(2-formylphenyl)carbamate 84016-98-8P 90914-41-3P, 3-Bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine 91851-17-1P, 2-(4-Bromoanilino)-1-phenyl-1-ethanol 93186-69-7P, N-(1,3-Benzoxazol-2-yl)-N-(4-bromophenyl)amine 94109-11-2P, 2-Amino-4-ethylphenol 96980-62-0P 100709-10-2P, N-Benzyl-N-(4-bromophenyl)-N-methylamine 103057-44-9P, tert-Butyl 3-hydroxy-1-pyrrolidinecarboxylate 107965-78-6P 109384-19-2P, tert-Butyl 4-hydroxy-1-piperidinecarboxylate 118618-61-4P, 1-Methyl-1H-2-indolecarbonyl chloride 126884-70-6P, N-(4-Bromophenyl)-N-(2,3-dihydrobenzo[b]furan-3-yl)amine 129644-56-0P, 2-Nitro-4-(trifluoromethoxy)phenol 131818-17-2P, tert-Butyl N-(4-bromophenyl)carbamate 141699-55-0P 141699-58-3P, tert-Butyl 3-[(methylsulfonyl)oxy]azetane-1-carboxylate 143900-43-0P, (R)-tert-Butyl 3-hydroxy-1-piperidinecarboxylate 146137-74-8P, 2-Fluoro-6-methoxybenzaldehyde 146137-80-6P, 2-Fluoro-4-methylbenzaldehyde 147804-30-6P, tert-Butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate 151266-23-8P 156682-54-1P, 3-(Benzyloxy)phenylboronic acid 164226-32-8P, tert-Butyl N-[2-(hydroxymethyl)phenyl]carbamate 174671-44-4P, 5-Phenoxy-1,3-dihydro-2,1-benzoxaborol-1-ol 175204-11-2P, 2-Fluoro-6-[(4-methylphenyl)sulfanyl]benzonitrile 209958-42-9P 257280-25-4P, 5-Bromo-2-phenoxypyrimidine 262444-42-8P, tert-Butyl N-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 269410-03-9P, Phenyl[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanone 312754-72-6P, 3-(4-Bromoanilino)-1H-benzo[d]isothiazole-1,1-dione 328931-56-2P, N-Phenethyl-4-bromobenzamide 330785-91-6P, 1-[1-(1-Methyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330785-95-0P, 1-[1-(1-Isopropyl-4-piperidyl)-4-piperidyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330785-97-2P,

1-[1-(4-Piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-01-1P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-05-5P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 330786-07-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide 330786-35-1P, cis-3-(4-Anilinophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-39-5P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-42-0P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-44-2P, trans-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330786-46-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzamide 330786-48-6P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-phenylsulfamide 330786-50-0P 330786-54-4P 330786-60-2P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-65-7P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-92-0P, cis-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330787-98-9P, cis-1-(Aminomethyl)-4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanol 330788-00-6P, cis-1-(2-Aminoethyl)-4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanol 330789-01-0P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide 330789-05-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide 330789-07-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 330789-10-1P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 330789-14-5P, 1-[1-(1-Methyl-4-piperidyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-25-8P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(4-methylphenyl)sulfanyl]benzonitrile 330789-27-0P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-(2-pyridylsulfanyl)benzonitrile 330789-30-5P, trans-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile 330789-36-1P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino](4-methylpiperazino)methanone 330789-38-3P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide 330791-29-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 330791-31-6P 330791-36-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-3-phenylbutanamide 330791-47-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide 330791-49-6P 330791-53-2P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenylcyclopropane-1-carboxamide 330791-82-7P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide 330791-84-9P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-

1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide 330791-86-1P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3S)-3-phenylbutanamide 330791-90-7P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 330791-92-9P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide 330792-57-9P, 1-(1-Benzyl-4-piperidinyl)-3-bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine 330792-58-0P, 1-(1-Benzyl-4-piperidinyl)-3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-59-1P 330792-60-4P, 1-[cis-4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-61-5P, 1-(1,4-Dioxaspiro[4.5]dec-8-yl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 330792-62-6P, tert-Butyl N-[4-[4-amino-1-(1,4-dioxaspiro[4.5]dec-8-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]carbamate 330792-63-7P, 4-[4-Amino-3-(4-amino-3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanone 330792-64-8P, cis-3-(4-Amino-3-fluorophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-65-9P, trans-3-(4-Amino-3-fluorophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-66-0P, 3-Bromo-4-chloro-1-(1,4-dioxaspiro[4.5]dec-8-yl)-1H-pyrazolo[3,4-d]pyrimidine 330792-67-1P, 3-Bromo-1-(1,4-dioxaspiro[4.5]dec-8-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 330792-68-2P, 1,1-Dicyano-2-hydroxy-2-(4-phenoxyphenyl)ethene 330792-69-3P, 1,1-Dicyano-2-methoxy-2-(4-phenoxyphenyl)ethene 330792-70-6P, 3-Amino-4-cyano-5-(4-phenoxyphenyl)pyrazole 330792-72-8P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-cyclohexanone 330792-73-9P, cis-3-Iodo-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-74-0P, trans-3-Iodo-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-75-1P, N-Phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330792-76-2P, 2-Phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 330792-77-3P, 1-(1,4-Dioxaspiro[4.5]dec-8-yl)-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-78-4P, 4-[4-Amino-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanone 330792-79-5P, Benzyl N-(4-bromo-2-methoxyphenyl)carbamate 330792-80-8P, Benzyl N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330792-81-9P, trans-3-(4-Amino-3-methoxyphenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-82-0P 330792-83-1P 330792-84-2P, Phenyl[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanone oxime 330792-85-3P, 2-Phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine 330792-86-4P, 2-(4-Iodophenoxy)pyrimidine 330792-87-5P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrimidine 330792-88-6P, 1-(1,4-Dioxaspiro[4.5]dec-8-yl)-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-89-7P, 4-[4-Amino-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexanone 330792-90-0P, tert-Butyl N-[(4-bromophenyl)(phenyl)methyl]carbamate 330792-91-1P, tert-Butyl N-[phenyl[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]carbamate 330792-92-2P 330792-93-3P, 4-(4-Bromophenoxy)benzonitrile 330792-94-4P, 4-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]benzonitrile 330792-95-5P, cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzonitrile 330792-96-6P, cis-3-[4-[4-(Aminomethyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-97-7P, 3-(4-Bromophenoxy)benzonitrile 330792-98-8P, 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]benzonitrile 330792-99-9P, cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzonitrile 330793-00-5P, cis-3-[4-[3-(Aminomethyl)phenoxy]phenyl]-1-[4-(4-

methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-01-6P, tert-Butyl N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330793-02-7P, cis-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]carbamate 330793-03-8P, Cis-3-(4-Aminophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-04-9P, trans-3-(4-Aminophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-05-0P, N-Benzyl-N-methyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-06-1P, N-Benzyl-N-(4-bromophenyl)-N-ethylamine 330793-07-2P, N-Benzyl-N-ethyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-08-3P, 4-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol 330793-09-4P, tert-Butyl N-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330793-10-7P, cis-tert-Butyl N-[3-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]carbamate 330793-11-8P, Cis-3-(3-Aminophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-12-9P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]benzonitrile 330793-14-1P, (2-Bromo-5-phenoxyphenyl)methanol 330793-15-2P 330793-16-3P, Cis-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]methyl cyanide 330793-17-4P 330793-18-5P, 3-Propylidenecyclobutyl methanesulfonate 330793-20-9P, 3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanone 330793-21-0P, Trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclobutyl 4-nitrobenzoate 330793-22-1P, Cis-3-[(Benzyloxy)methyl]cyclobutyl methanesulfonate 330793-23-2P, tert-Butyl 4-[4-amino-3-(4-amino-3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330793-24-3P 330793-25-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea dihydrochloride 330793-26-5P, 3-[(tert-Butoxycarbonyl)(2-hydroxyethyl)amino]propanoic acid 330793-27-6P 330793-28-7P 330793-29-8P, 2-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3-pyridyl cyanide 330793-30-1P, 2-[4-Amino-3-(4-amino-3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-3-pyridyl cyanide 330793-31-2P 330793-32-3P, tert-Butyl 4-[4-amino-3-[4-[(tert-butoxycarbonyl)amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330793-33-4P, 3-(4-Amino-3-fluorophenyl)-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-35-6P, Ethyl 2-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)acetate 330793-36-7P, Ethyl 2-[4-amino-3-[4-[(tert-butoxycarbonyl)amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330793-38-9P, 4-Bromo-2-methoxybenzonitrile 330793-39-0P, N-Phenyl-4-bromo-2-methoxybenzamide 330793-40-3P 330793-41-4P, N-Benzyl-4-bromo-2-methoxybenzamide 330793-42-5P 330793-43-6P, N-Phenethyl-4-bromo-2-methoxybenzamide 330793-44-7P 330793-45-8P, 4-(Anilinocarbonyl)phenylboronic acid 330793-46-9P 330793-47-0P, trans-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330793-48-1P, tert-Butyl 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 330793-49-2P, 3-Iodo-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-50-5P, 3-Iodo-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-51-6P, tert-Butyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinecarboxylate 330793-52-7P, 3-(4-Phenoxyphenyl)-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-56-1P, cis-4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenol 330793-57-2P, trans-4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenol 330793-58-3P, N-(4-Bromo-2-methoxyphenyl)-3-phenylpropanamide 330793-59-4P 330793-60-7P, N-(4-Bromo-2-methoxyphenyl)-N-methyl-3-phenylpropanamide 330793-61-8P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-

methyl-3-phenylpropanamide 330793-62-9P, 3-(4-Amino-3-methoxyphenyl)-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-63-0P, N-(4-Bromophenyl)-N-(1-phenylethyl)amine 330793-64-1P, N-(1-Phenylethyl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-65-2P, N-(2,3-Dihydrobenzo[b]furan-3-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-66-3P, 3-(4-Bromophenyl)-5-phenyl-1,3-oxazolan-2-one 330793-67-4P, 5-Phenyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-oxazolan-2-one 330793-68-5P, 1-(4-Bromoanilino)-3-phenyl-2-propanol 330793-69-6P, 5-Benzyl-3-(4-bromophenyl)-1,3-oxazolan-2-one 330793-70-9P, 5-Benzyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-oxazolan-2-one 330793-71-0P, 3-Phenyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2,5-pyrrolidinedione 330793-72-1P 330793-73-2P, N-(1,3-Benzoxazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-74-3P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]benzaldehyde 330793-75-4P, cis-tert-Butyl 2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetate 330793-76-5P, trans-tert-Butyl 2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetate 330793-77-6P, Diethyl 3-[(methylsulfonyl)oxy]-1,1-cyclobutanedicarboxylate 330793-78-7P, Diethyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1,1-cyclobutanedicarboxylate 330793-79-8P, 3-Iodo-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dihydrochloride 330793-80-1P, 1-[4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidino]-2-(dimethylamino)-1-ethanone 330793-81-2P, N-(4-Bromo-2-fluorophenyl)-1,3-benzoxazol-2-amine 330793-82-3P, N-(4-Bromo-2-fluorophenyl)-1,3-benzothiazol-2-amine 330793-83-4P 330793-84-5P 330793-85-6P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-benzothiazol-2-amine 330793-86-7P 330793-87-8P 330793-88-9P, cis-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330793-89-0P, cis-3-(4-Amino-3-methoxyphenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330793-90-3P
(intermediate; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330793-91-4P, cis-4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzaldehyde 330793-95-8P, N-(6-Chloro-1,3-benzothiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-96-9P 330793-97-0P, N-(4-Bromophenyl)-N-(4-ethyl-1,3-thiazol-2-yl)amine 330793-98-1P, N-(4-Ethyl-1,3-thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 330793-99-2P, 4-Amino-1-(4-nitrophenyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 330794-00-8P, 3-Iodo-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-01-9P, 4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzaldehyde 330794-02-0P, 1-Bromo-2-fluoro-5-methoxy-4-nitrobenzene 330794-03-1P, 4-Bromo-5-fluoro-2-methoxyaniline 330794-04-2P, tert-Butyl N-(4-bromo-5-fluoro-2-methoxyphenyl)carbamate 330794-05-3P, tert-Butyl N-[5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330794-06-4P, 3-Iodo-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-08-6P, trans-tert-Butyl N-[2-[[[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]]anilino]methyl]phenyl]carbamate acetate 330794-09-7P, tert-Butyl N-(4-bromo-2-chlorophenyl)carbamate 330794-10-0P, tert-Butyl N-[2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 330794-11-1P, Trans-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]carbamate 330794-12-2P, Trans-3-(4-Amino-3-chlorophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-13-3P, 1-(4-Bromophenyl)-3-methyl-5-phenyl-4,5-dihydro-1H-pyrazole 330794-14-4P, 3-Methyl-5-phenyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-4,5-dihydro-1H-pyrazole 330794-15-5P

330794-17-7P, tert-Butyl N-[3-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-oxopropyl]-N-(2-hydroxyethyl)carbamate 330794-18-8P, tert-Butyl N-[3-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-oxopropyl]-N-(2-hydroxyethyl)carbamate 330794-19-9P, tert-Butyl 2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 330794-20-2P, Benzyl 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 330794-21-3P, Benzyl 4-[4-amino-3-[4-[(tert-butoxycarbonyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-22-4P, Benzyl 4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-23-5P, Trans-Benzyl 4-[4-amino-3-[3-methoxy-4-[[(2-phenylcyclopropyl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-24-6P, Benzyl 4-[4-amino-3-[3-methoxy-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-25-7P, tert-Butyl 4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-4-hydroxy-1-piperidinecarboxylate 330794-26-8P, tert-Butyl 4-[[4-amino-3-[4-[[(benzyloxy)carbonyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-27-9P, tert-Butyl 4-[[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-28-0P, Trans-tert-Butyl 4-[[4-amino-3-[3-methoxy-4-[[(2-phenylcyclopropyl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-29-1P 461696-99-1P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde 461697-00-7P 461697-02-9P, 2-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-ethanol 461697-03-0P, [2-[4-Amino-3-[3-methoxy-4-[[(1-methyl-1H-indol-2-yl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl] methanesulfonate 461697-30-3P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-methyl-1H-2-indolecarboxamide 461697-31-4P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-34-7P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-36-9P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-38-1P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-40-5P, N-[4-[4-Amino-1-[2-(1H-1-imidazolyl)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-53-0P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-cyclopenten-1-ol 461697-57-4P, tert-Butyl 4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461697-66-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-98-3P, 3-Iodo-1-(1-methyl-3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-01-1P, 3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-02-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide 461698-04-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethoxy)benzamide 461698-10-2P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylcarbonyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 461698-14-6P 461698-21-5P 461698-24-8P 461698-45-3P, tert-Butyl 4-[4-amino-3-(4-aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-46-4P, tert-Butyl 4-[4-amino-3-[4-[[(benzyloxy)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-79-3P, 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1H-benzo[d]isothiazole-1,1-dione 461698-84-0P, N-(4-Bromophenyl)-2-fluoro-

1-benzenecarbothioamide 461698-85-1P 461698-86-2P, N-(Benzo[d]isoxazol-3-yl)-N-(4-bromophenyl)amine 461698-87-3P, N-(Benzo[d]isoxazol-3-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-94-2P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-, hydrazide 461698-95-3P, N-(4-Bromophenyl)-N-(1H-3-indazolyl)amine 461698-96-4P, N-(1H-3-Indazolyl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-99-7P, N-(4-Bromophenyl)-2-fluoro-4-(trifluoromethyl)benzamide 461699-00-3P, N-(4-Bromophenyl)-2-fluoro-4-(trifluoromethyl)-1-benzenecarbothioamide 461699-01-4P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-4-(trifluoromethyl)-, hydrazide 461699-02-5P, N-(4-Bromophenyl)-N-[6-(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-03-6P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-[6-(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-05-8P, 3-Iodo-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-06-9P 461699-09-2P, 3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 461699-13-8P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 461699-14-9P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461699-18-3P, 3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dihydrochloride 461699-19-4P, 9H-Fluoren-9-ylmethyl N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidino]-1,1-dimethyl-2-oxoethyl]-N-methylcarbamate 461699-20-7P 461699-22-9P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)azetane-1-carboxylate 461699-23-0P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]azetane-1-carboxylate 461699-27-4P, 1-(3-Azetanyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-28-5P, 3-Iodo-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-30-9P, 2-(4-Bromoanilino)-1,3-benzoxazole-5-carbonitrile 461699-31-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1,3-benzoxazole-5-carbonitrile 461699-34-3P, 2-Amino-4-(trifluoromethoxy)phenol 461699-35-4P, N-(4-Bromophenyl)-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-36-5P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-38-7P, N-(4-Bromophenyl)-5-ethyl-1,3-benzoxazol-2-amine 461699-39-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-41-2P, Cis-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-42-3P, trans-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-46-7P, N-(4-Bromophenyl)-5-chloro-1,3-benzoxazol-2-amine 461699-47-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-chloro-1,3-benzoxazol-2-amine 461699-48-9P, N-(4-Bromophenyl)-5-methyl-1,3-benzoxazol-2-amine 461699-49-0P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-methyl-1,3-benzoxazol-2-amine 461699-50-3P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-51-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-52-5P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(methylamino)cyclohexyl]- 461699-61-6P, N-(4-Bromophenyl)-N-(5,7-dimethyl-1,3-benzothiazol-2-yl)amine 461699-78-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461699-82-1P, 2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline bismaleate 461701-01-9P, 3-Iodo-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monohydrochloride 461701-02-0P, 3-Iodo-1-(1-methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-03-1P, N-(4-Bromophenyl)-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-05-3P, 3-Iodo-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-07-5P, N-(4-Bromo-2-fluorophenyl)-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-08-6P, N-[2-Fluoro-4-(4,4,5,5-

tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-10-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]imidazo[1,2-a]pyridine 461701-12-2P, 1-[3-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-14-4P, 9H-Fluoren-9-ylmethyl N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-1,1-dimethyl-2-oxoethyl]-N-methylcarbamate 461701-15-5P 461701-17-7P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinecarboxylate 461701-18-8P, tert-Butyl 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinecarboxylate 461701-21-3P, N-(4-Bromophenyl)-7-isopropyl-1,3-benzoxazol-2-amine 461701-22-4P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461701-38-2P, 4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzaldehyde 461701-54-2P 461702-08-9P, 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole 461702-16-9P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-21-6P 461702-22-7P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-24-9P, N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-39-6P, 1-(3-Bromopropyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-40-9P, 3-Iodo-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-42-1P, 3-Iodo-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-44-3P, 1-[3-(1H-1-Imidazolyl)propyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-55-6P, Cyclohexanecarboxylic acid, 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-, ethyl ester, cis- 461702-59-0P, N-(4-Bromophenyl)-N-(2-pyrimidinyl)amine 461702-62-5P, 1-(2-Chloro-4-pyridyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-63-6P 461702-66-9P, (S)-tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 461702-68-1P 461702-69-2P, (S)-3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-98-7P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-3-indolecarboxamide 471925-68-5P, 3-(4-Phenoxyphenyl)-1-(3-propylidenecyclobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-82-3P 471925-83-4P, N-[4-[4-Amino-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]aniline 471925-90-3P, 1-[1-(1H-2-Imidazolylmethyl)-4-piperidyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-91-4P, tert-Butyl N-[4-[4-amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 471925-92-5P, 3-(4-Amino-3-methoxyphenyl)-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-99-2P, 2-Fluoro-6-[(2-methoxyethyl)amino]benzonitrile 471927-37-4P, 5-Ethoxy-3-methyl-1-[4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl]-1H-pyrazole
(intermediate; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 144697-17-6 144941-35-5, Blk protein kinase
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 471926-01-9P 471926-92-8P
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 4114-28-7P, Diethyl 1,2-hydrazinedicarboxylate
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 51-17-2, 1H-Benzimidazole 62-23-7, 4-Nitrobenzoic acid 62-53-3, Aniline, reactions 64-04-0, Phenethylamine 70-11-1, Bromoacetophenone 76-83-5, Triphenylmethyl chloride 78-82-0, Isobutyronitrile 81-07-2,

Saccharin 90-02-8, Salicylaldehyde, reactions 90-04-0, o-Anisidine 90-82-4, (+)-Pseudoephedrine 90-90-4, 4-Bromobenzophenone 92-59-1, N-Benzyl-N-phenyl-N-ethylamine 93-91-4 95-55-6, 2-Aminophenol 95-84-1, 2-Amino-4-methylphenol 95-85-2, 2-Amino-4-chlorophenol 96-09-3, Styrene oxide 96-30-0, N-Methyl-2-chloroacetamide 96-32-2, Methyl 2-bromoacetate 98-01-1, 2-Furaldehyde, reactions 98-09-9, Benzenesulfonyl chloride 98-80-6, Phenylboronic acid 98-88-4, Benzoyl chloride 100-36-7, N,N-Diethylethylenediamine 100-46-9, Benzylamine, reactions 100-52-7, Benzaldehyde, reactions 101-55-3, 4-Phenoxybromobenzene 103-32-2, N-Phenyl-N-benzylamine 103-76-4, N-(2-Hydroxyethyl)piperazine 103-80-0, Phenylacetyl chloride 105-36-2, Ethyl bromoacetate 106-40-1, 4-Bromoaniline 106-41-2, 4-Bromophenol 106-45-6, p-Thiocresol 108-00-9 108-01-0, N,N-Dimethylethanolamine 108-94-1, Cyclohexanone, reactions 108-95-2, Phenol, reactions 109-01-3, N-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propane diamine 109-77-3, Malononitrile 109-85-3, 2-Methoxyethylamine 110-91-8, Morpholine, reactions 120-92-3, Cyclopentanone 122-78-1, Phenylacetaldehyde 123-00-2, 4-Morpholinepropanamine 123-07-9, 4-Ethylphenol 137-43-9, Bromocyclopentane 141-75-3, Butyryl chloride 141-97-9, Ethyl acetoacetate 142-25-6, N,N,N'-Trimethyl-1,2-ethanediamine 156-87-6, 3-Amino-1-propanol 288-32-4, Imidazole, reactions 315-30-0, 1H-Pyrazolo[3,4-d]pyrimidin-4-ol 329-15-7, 4-(Trifluoromethyl)-1-benzenecarbonyl chloride 349-88-2, 4-Fluorobenzenesulfonyl chloride 350-46-9, p-Fluoronitrobenzene 352-70-5, 3-Fluorotoluene 367-24-8, 4-Bromo-2-fluoroaniline 387-45-1, 2-Chloro-6-fluorobenzaldehyde 393-52-2, 2-Fluorobenzoyl chloride 456-49-5, 3-Fluoroanisole 459-57-4, 4-Fluorobenzaldehyde 475-11-6 495-40-9, Butyrophenone 496-41-3, Benzo[b]furan-2-carboxylic acid 501-53-1, Benzyl chloroformate 535-11-5, Ethyl 2-bromopropionate 582-62-7, Isovalerophenone 586-75-4, 4-Bromo-1-benzenecarbonyl chloride 589-15-1, 1-Bromo-4-(bromomethyl)benzene 591-19-5, 3-Bromoaniline 603-86-1, 2-Chloro-6-nitrophenol 609-89-2, 2,4-Dichloro-6-nitrophenol 615-18-9, 2-Chlorobenzoxazole 615-20-3, 2-Chlorobenzothiazole 616-30-8, 3-Amino-1,2-propanediol 619-41-0, 2-Bromo-4'-methylacetophenone 620-02-0, 5-Methyl-2-furfural 621-29-4, m-Tolyl isocyanate 622-26-4, 4-Piperidineethanol 622-88-8, 4-Bromophenylhydrazine hydrochloride 627-18-9, 3-Bromo-1-propanol 645-45-4, Hydrocinnamoyl chloride 762-49-2, 1-Bromo-2-fluoroethane 771-50-6, Indole-3-carboxylic acid 772-14-5, (R)-3-Phenylbutanoic acid 772-15-6, (S)-3-Phenylbutyric acid 780-20-1, N-(4-Bromophenyl)-N-(1-phenylmethylidene)amine 814-75-5, 3-Bromo-2-butanone 816-40-0, 1-Bromo-2-butanone 826-55-1, α,α-Dimethylphenylacetic acid 828-27-3, 4-(Trifluoromethoxy)phenol 872-31-1, 3-Bromothiophene 886-34-0, 2-[[(4-Bromophenyl)imino]methyl]phenol 939-87-7, trans-2-Phenyl-1-cyclopropanecarbonyl chloride 1009-14-9, Valerophenone 1010-48-6, 3-Methyl-3-phenylbutyric acid 1074-59-5, 3-(1H-4-Imidazolyl)propanoic acid 1118-68-9, Dimethylglycine 1124-33-0, 4-Nitropyridine-N-oxide 1131-15-3, Phenylsuccinic anhydride 1194-02-1, 4-Fluorobenzonitrile 1195-42-2, N-Isopropylcyclohexylamine 1423-26-3, 3-(Trifluoromethylphenyl)boronic acid 1440-61-5, 2-Chloro-1-morpholino-1-ethanone 1445-73-4, 1-Methyl-4-piperidone 1477-50-5, Indole-2-carboxylic acid 1493-27-2, 2-Fluoronitrobenzene 1709-01-9, N-(3-Hydroxypropyl)-2-chloroacetamide 1722-12-9, 2-Chloropyrimidine 1765-93-1, 4-(Fluorophenyl)boronic acid 1849-02-1, 2-Chloro-1-methylbenzimidazole 1874-23-3, Methyl 5-nitro-2-furoate 1878-68-8, 4-Bromophenylacetic acid 1897-52-5, 2,6-Difluorobenzonitrile 1985-12-2, 4-Bromophenyl isothiocyanate 2038-03-1, N-(2-Aminoethyl)morpholine 2081-44-9 2114-00-3, 2-Bromopropiophenone 2215-77-2, 4-Phenoxybenzoic acid 2320-30-1, 3,5-Dimethylcyclohexanone 2420-26-0, 2-Hydroxy-4-chlorobenzaldehyde 2564-06-9, N-Benzyl-2-chloroacetamide 2605-14-3, 2-Chloro-6-methoxybenzothiazole 2675-89-0, N,N-Dimethyl-2-chloroacetamide 2799-21-5, (R)-3-Pyrrolidinol 2835-97-4, 2-Amino-m-cresol 2895-21-8, N-Isopropyl-2-chloroacetamide

2969-81-5, Ethyl 4-bromobutyrate 3034-50-2, 1H-4-Imidazolecarboxaldehyde 3173-56-6, Benzyl isocyanate 3272-08-0, 4-Hydroxy-3-nitrobenzonitrile 3433-37-2, 2-Piperidinemethanol 3622-23-9, 2,6-Dichlorobenzothiazole 4265-16-1, Benzofuran-2-carboxaldehyde 4436-24-2, 2,3-Epoxypropylbenzene 4606-65-9, 3-Piperidinemethanol 4727-72-4, 1-Benzyl-4-piperidinol 4755-50-4, 4-(Dimethylamino)benzoyl chloride 4795-29-3 4897-50-1, 4-Piperidinopiperidine 5036-48-6, 1-(3-Aminopropyl)imidazole 5292-43-3, tert-Butyl 2-bromoacetate 5332-73-0, 3-Methoxypropylamine 5344-90-1, 2-Aminobenzyl alcohol 5355-68-0, 1-Isopropyl-4-piperidone 5382-16-1, 4-Hydroxypiperidine 5458-99-1, 3-[(2-Hydroxyethyl)amino]propanoic acid 5720-05-8, p-Tolylboronic acid 6457-49-4, 4-Piperidinemethanol 6482-24-2, 2-Bromoethyl methyl ether 6602-54-6, 2-Chloro-3-cyanopyridine 6851-99-6, 2-Bromo-2'-nitroacetophenone 7129-41-1, 6-Oxabicyclo[3.1.0]hex-2-ene 7305-71-7, 2-Amino-5-methylthiazole 7389-87-9, L-Histidine methyl ester dihydrochloride 7545-71-3, 6-Isopropyl-2-nitrophenol 7663-77-6, 1-(3-Aminopropyl)-2-pyrrolidinone 10111-08-7, 1H-2-Imidazolecarboxaldehyde 10365-98-7, 3-Methoxyphenylboronic acid 13073-29-5, 2-Methyl-6-nitrophenol 13325-10-5, 4-Amino-1-butanol 13331-27-6, 3-Nitrophenylboronic acid 13484-40-7, 1-(2-Methoxyethyl)piperazine 13734-36-6, 2-[(tert-Butoxycarbonyl)(methyl)amino]acetic acid 13750-81-7, 1-Methyl-2-imidazolecarboxaldehyde 13826-35-2, 3-Phenoxyphenyl methanol 15674-67-6, 3-(Diethylamino)propionic acid hydrochloride 15761-39-4 16136-58-6, 1-Methylindole-2-carboxylic acid 16419-60-6, o-Tolylboronic acid 16617-46-2, 3-Amino-4-pyrazole carbonitrile 17159-80-7, Ethyl 4-hydroxycyclohexanecarboxylate 17180-94-8, 5-Chloropyrimidine 17933-03-8, m-Tolylboronic acid 18621-17-5, 1-Benzhydryl-3-azetanol 18908-07-1, 3-Methoxyphenyl isocyanate 19005-93-7, 2-Formylindole 20485-43-2, 1-Methyl-1H-2-imidazolecarboxylic acid 23056-36-2, 2-Chloro-4-nitropyridine 23356-96-9, (S)-2-Pyrrolidinemethanol 24221-86-1, (+)-Ephedrine hydrochloride 24424-99-5, Di-tert-butyl dicarbonate 26329-57-7 27578-60-5, 2-Piperidino-1-ethanamine 31301-45-8, 3,5-Dimethyl-4-isoxazolecarbonyl chloride 32779-36-5, 5-Bromo-2-chloropyrimidine 33268-46-1 34658-66-7, 2-(4-Bromophenyl)imidazo[1,2-a]pyridine 35034-22-1, 2-Methyl-1H-4-imidazolecarboxaldehyde 36635-61-7, (p-Tolylsulfonyl)methyl isocyanide 36823-88-8, 4-(Trifluoromethoxy)-1-benzenecarbonyl chloride 37784-17-1 38762-41-3, 4-Bromo-2-chloroaniline 39238-07-8, 4-Chloromethyl-2-methyl-1,3-thiazole 39499-34-8, 5-Methyl-3-isoxazolecarbonyl chloride 39856-50-3, 5-Bromo-2-nitropyridine 40499-83-0, 3-Pyrrolidinol 41458-65-5, 6-Amino-2,4-xylenol 41602-50-0, Ethyl 2-[(2-chloroacetyl)amino]acetate 42383-61-9, 2-Aminoimidazole sulfate 53087-13-1, 3-Benzyloxybromobenzene 53525-65-8, 5H,10H-Diimidazo[1,5-a:1',5'-d]pyrazine-5,10-dione 54149-17-6, 1-Bromo-2-(2-methoxyethoxy)ethane 54446-36-5 55112-42-0, 4-Methyl-1-piperazinecarbonyl chloride hydrochloride 56368-58-2, Sodium 2-(1H-4-imidazolyl)acetate 57044-25-4, (R)-(+)-Glycidol 57260-71-6 58530-53-3, 2,4-Dibromopyridine 59025-55-7, 2,4-Difluorophenyl isocyanate 60260-49-3, N-Phenylsulfamoyl chloride 60456-23-7, (S)-(-)-Glycidol 64248-64-2, 2,5-Difluorobenzonitrile 68641-49-6, Bis(2-oxo-3-oxazolidinyl)phosphinic chloride 68832-13-3, (R)-2-Pyrrolidinemethanol 69000-39-1, N-(3-Methyl-5-isoxazolyl)-2-chloroacetamide 71255-09-9 73183-34-3 73579-08-5, N-Methyl-N-(1-methyl-4-piperidyl)amine 76874-79-8 78443-72-8 79099-07-3, 1-tert-Butoxycarbonyl-4-piperidone 82417-45-6, 2,3-Dichlorobenzenesulfonyl chloride 85275-45-2, tert-Butyl 3-hydroxy-1-piperidinecarboxylate 86069-86-5 87199-17-5, 4-Formylphenylboronic acid 90071-62-8 97986-34-0, Tetrahydropyran-4-yl tosylate 99974-66-0, Diethyl 3-hydroxy-1,1-cyclobutanedicarboxylate 100243-39-8, (S)-3-Hydroxypyrrolidine 102368-13-8, 1,1'-Thiocarbonyldi-2(1H)-pyridone 103057-45-0, tert-Butyl 3-[[(4-methylphenyl)sulfonyl]oxy]-1-pyrrolidinecarboxylate 105942-08-3,

4-Bromo-2-fluorobenzonitrile 112758-40-4 126917-10-0, 2-Fluoro-4-trifluoromethyl-1-benzenecarbonyl chloride 139301-27-2, 4-Trifluoromethoxyphenylboronic acid
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 146631-00-7, 4-(Benzyloxy)phenylboronic acid 159419-77-9, 3-Propylidene-1-cyclobutanol 167415-27-2, 1-Bromo-2,5-difluoro-4-nitrobenzene 172324-68-4, cis-3-[(Benzyloxy)methyl]-1-cyclobutanol 198976-43-1, (R)-3-Hydroxypiperidine hydrochloride 199915-38-3 214343-15-4 262433-02-3, tert-Butyl N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 262433-36-3, 2-Fluoro-6-(2-pyridylsulfanyl)benzonitrile 262444-19-9, 2-(4-Iodophenoxy)benzaldehyde 330787-02-5, Trans-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-94-5, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-17-5, cis-3-[4-(Benzylamino)-3-fluorophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-33-5, cis-3-[4-[(4-Bromobenzyl)amino]-3-fluorophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-51-0, Trans-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-45-2 330794-30-4 330794-31-5, 1-Cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-32-6 330794-35-9, tert-Butyl N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]carbamate 330794-36-0 330794-37-1, 2-[4-Amino-3-(4-amino-3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-5-(4-methylpiperazino)benzonitrile 330794-38-2, 4-[4-Amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanone 330794-39-3, trans-2-Benzylcyclopropane-1-carbonyl chloride 363186-06-5, Benzyl N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate 400779-65-9, 2-[[(9H-Fluoren-9-ylmethoxy)carbonyl](methyl)amino]-2-methylpropanoic acid 461697-01-8, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-70-1, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide 461699-32-1, 3-Iodo-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-43-4, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-cyclohexanone monohydrochloride 461699-81-0, 2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 461701-31-5, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-18-1, 3-Iodo-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride 461702-70-5, (S)-3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461702-73-8, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carbonitrile triacetate 461702-74-9, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(benzyloxy)-1H-2-indolecarboxamide 471925-61-8, 3-(4-Amino-3-methoxyphenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-66-3, [2-(4-Bromophenoxy)phenyl](methylidyne)ammonium 471925-67-4, 4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenol 471925-85-6, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 471926-24-6, N,N-Methoxymethyl-2-chloroacetamide
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330792-45-5P, trans-N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330792-71-7P, 1-Cyclopentyl-4-(cyclopentylamino)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-88-1P, 1-(1-Benzyl-4-piperidinyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(protein kinase inhibitor.; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330788-71-1P 330788-72-2P 330788-73-3P 330788-74-4P 330788-75-5P
330788-76-6P 330788-77-7P 330788-78-8P 330788-79-9P 330788-80-2P
330788-81-3P 330788-82-4P 330788-83-5P 330788-84-6P 330788-85-7P
330788-86-8P 330788-87-9P 330788-88-0P 471925-84-5P
(protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-90-5P, 3-(4-Phenoxyphenyl)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-11-3P 330786-13-5P, 4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanone 330786-15-7P, tert-Butyl cis-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-16-8P, tert-Butyl trans-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-24-8P, 3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-58-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-63-5P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-67-9P 330787-59-2P 330787-63-8P 330787-67-2P, 3-[4-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-88-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzonitrile 330787-91-2P, Cis-3-[4-[2-(Aminomethyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-01-7P 330788-03-9P, 1-(3-Azetanyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-11-9P, Cis-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 330788-15-3P, Trans-1-[3-[(Benzyloxy)methyl]cyclobutyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-68-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide 330788-92-6P, Ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330789-03-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 330789-23-6P, cis-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-29-2P, trans-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-32-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-75-8P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1-phenyl-1-ethanone diacetate 330790-07-3P, Methyl 5-[4-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoate 330790-15-3P, Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzaldehyde 330790-20-0P 330790-21-1P 330790-70-0P, Trans-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetic acid 330790-74-4P 330790-88-0P, Methyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-98-2P, Ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330790-99-3P, Methyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-

pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-04-3P, Methyl 4-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-51-0P, tert-Butyl N-[4-[4-amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-57-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine dihydrochloride 330791-68-9P 330791-88-3P, tert-Butyl N-[4-[4-amino-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-99-6P, trans-3-(4-Amino-2-fluoro-5-methoxyphenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-01-3P, tert-Butyl N-[4-[4-amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330792-23-9P, Trans-3-[4-[(2-Aminobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-33-1P, Trans-3-[4-(5-Ethoxy-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-43-3P, 2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetic acid 330792-49-9P, 3-[3-Methoxy-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461697-04-1P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-42-7P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-45-0P, Cis-Ethyl 3-[[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-46-1P, Trans-Ethyl 3-[[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-49-4P, N-[4-(4-Amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-50-7P, N-[4-(4-Amino-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-52-9P, N-[4-[4-Amino-1-(4-hydroxy-2-cyclopentenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461698-20-4P 461698-28-2P, trans-3-[4-[[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-12-7P 461701-33-7P, 3-(4-Amino-3-methoxyphenyl)-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-35-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide 461702-45-4P, N-[4-[4-Amino-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-54-5P, cis-Ethyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 471926-42-8P 471927-18-1P, trans-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]carbamate
(protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-92-7P, 1-[1-(1-Methyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330785-96-1P, 1-[1-(1-Isopropyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330785-98-3P, 1-[1-(4-Piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-02-2P, 1-[trans-4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-06-6P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-08-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleate 330786-18-0P,

Cis-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-20-4P, Trans-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-25-9P, 4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine 330786-27-1P, 3-(4-Phenoxyphenyl)-1-(tetrahydropyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 330786-29-3P 330786-30-6P 330786-33-9P 330786-36-2P, Cis-3-(4-Anilinophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-40-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-45-3P, Trans-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate 330786-47-5P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzamide dimaleate 330786-49-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-phenylsulfamide dimaleate 330786-51-1P 330786-53-3P 330786-55-5P 330786-57-7P 330786-59-9P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-61-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-64-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-66-8P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-69-1P 330786-71-5P 330786-72-6P 330786-73-7P 330786-75-9P 330786-77-1P 330786-78-2P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide 330786-79-3P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-81-7P 330786-83-9P 330786-85-1P, cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide diacetate 330786-86-2P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-88-4P 330786-89-5P, Cis-N-[3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzyl]benzamide 330786-91-9P 330786-93-1P, Cis-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo-[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate 330786-95-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-benzylurea acetate 330786-97-5P, Cis-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330786-99-7P 330787-03-6P, Trans-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330787-05-8P, Trans-3-[4-[(2,6-Dimethoxybenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-07-0P, Trans-3-[4-[(2-Chloro-6-fluorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-09-2P, Cis-3-[4-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-11-6P, Cis-3-[4-[(2-Methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-13-8P 330787-14-9P, Cis-3-[4-[(2-Chlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-15-0P, Cis-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-16-1P, Cis-3-[4-[(2-Ethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-17-2P, Cis-3-[4-[[2-(Difluoromethoxy)benzyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-19-4P 330787-21-8P 330787-23-0P, Cis-2-[[4-[4-Amino-1-[4-(4-

methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]benzonitrile diacetate 330787-24-1P, Cis-3-[4-[(2,6-Difluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-26-3P, Cis-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330787-27-4P, Cis-3-[4-[[2-Fluoro-6-(trifluoromethyl)benzyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-29-6P, Cis-3-[4-[(2-Fluoro-6-methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-30-9P, Cis-3-[4-[(2,6-Dichlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-32-1P, Cis-3-[4-[(2,6-Dimethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-34-3P, Cis-3-[4-[(2-Fluoro-4-methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-38-7P, Cis-3-[4-[[(1-Methyl-1H-indol-2-yl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-40-1P, Trans-3-[4-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330787-42-3P, Trans-3-[4-[(2-Methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-44-5P, Trans-3-[4-[(2,6-Dimethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-46-7P, Trans-3-[4-[(2-Chlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-48-9P, Trans-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330787-50-3P 330787-52-5P 330787-53-6P 330787-55-8P, Cis-3-[4-[Benzyl(methyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-57-0P, Cis-3-[4-[Benzyl(ethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-61-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(phenethylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-65-0P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-phenylpropyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-66-1P, 1-Cyclopentyl-3-[4-(3-methoxyphenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-68-3P, 1-Cyclopentyl-3-[4-(4-fluorophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-69-4P, 1-Cyclopentyl-3-[4-[3-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-70-7P, 1-Cyclopentyl-3-[4-(3-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-71-8P, 1-Cyclopentyl-3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-72-9P, 1-Cyclopentyl-3-[4-[4-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-73-0P, 3-[3-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-75-2P, Cis-3-[4-[(3-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-77-4P, Cis-3-[4-[(2-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-79-6P, Cis-3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-81-0P, Cis-3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-83-2P, Cis-3-[4-[(4-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-84-3P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-pyridylmethyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-85-4P, Cis-3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-87-6P, Cis-3-[3-(Benzylamino)phenyl]-1-[4-(4-

methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-90-1P, Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide triacetate 330787-93-4P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-95-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-96-7P, Cis-3-[4-(2-Aminophenoxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-97-8P, [2-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-phenoxyphenyl]methanol 330787-99-0P 330788-02-8P 330788-04-0P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanol 330788-06-2P, 1-[1-(2-Methoxyethyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330788-07-3P, 1-[1-[2-(2-Methoxyethoxy)ethyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-08-4P, 1-[1-(1-Methyl-4-piperidyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-09-5P, 1-[1-[(1-Methyl-1H-imidazol-2-yl)methyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-10-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone 330788-12-0P, Trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 330788-14-2P 330788-16-4P, trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclobutanemethanol 330788-18-6P 330788-19-7P 330788-20-0P 330788-21-1P 330788-23-3P 330788-24-4P 330788-25-5P 330788-26-6P 330788-27-7P 330788-28-8P 330788-29-9P 330788-30-2P 330788-31-3P 330788-32-4P 330788-34-6P, cis-3-[4-[(4-Bromobenzyl)amino]-3-fluorophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330788-46-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(2,4-difluorophenyl)urea 330788-47-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea 330788-48-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea monoacetate 330788-50-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-51-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-52-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-ethyl-N'-(3-methylphenyl)urea 330788-53-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-benzyl-N'-(2,4-difluorophenyl)urea 330788-54-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-N'-(3-methylphenyl)urea 330788-55-1P, N-[4-[4-Amino-1-[1-[2-(dimethylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-57-3P, N-[4-[4-Amino-1-[1-[3-(diethylamino)propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-58-4P, N-[4-[4-Amino-1-[1-[2-(methylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-60-8P, N-[4-[4-Amino-1-[1-[3-[(2-hydroxyethyl)amino]propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-61-9P 330788-62-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-2-carboxamide 330788-63-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-1H-indene-2-carboxamide 330788-64-2P 330788-65-3P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 330788-66-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-3-carboxamide 330788-67-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330788-69-7P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330788-70-0P 330788-89-1P 330788-90-4P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(phenethylamino)(phenyl)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-91-5P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-93-7P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-94-8P, N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-95-9P, cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-96-0P, trans-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-97-1P, cis-N-Benzyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-98-2P, cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-99-3P, cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-00-9P, cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-02-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide trimaleate 330789-04-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 330789-06-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 330789-08-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-09-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-13-4P, 1-[1-(1H-Imidazol-2-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-15-6P, 1-[1-(1-Methyl-4-piperidyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330789-16-7P, N-[4-[4-Amino-1-[1-(1H-imidazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-24-7P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile 330789-26-9P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(4-methylphenyl)sulfanyl]benzonitrile trimaleate 330789-28-1P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-(2-pyridylsulfanyl)benzonitrile dimaleate 330789-31-6P, trans-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile trimaleate 330789-33-8P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide trimaleate 330789-34-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N-methyl-3-phenylpropanamide 330789-35-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-37-2P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-

yl]piperidino](4-methylpiperazino)methanone dimaleate 330789-39-4P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330789-40-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)benzamide 330789-41-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)benzamide 330789-42-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethoxy)benzamide 330789-43-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 330789-44-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 330789-46-3P 330789-48-5P, Cis-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-50-9P 330789-52-1P, Trans-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330789-56-5P, Cis-2-[2-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]phenoxy]acetic acid diacetate 330789-58-7P, Cis-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-60-1P

, Cis-3-[4-[[(5-Methyl-2-furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-62-3P, Cis-3-[4-[(3-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-64-5P 330789-66-7P, Trans-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-68-9P, 3-[4-[[(5-Methyl-2-furyl)methyl]amino]phenyl]-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-70-3P 330789-71-4P 330789-77-0P 330789-79-2P 330789-81-6P 330789-83-8P 330789-85-0P 330789-86-1P 330789-88-3P 330789-90-7P 330789-92-9P 330789-93-0P 330789-96-3P 330789-98-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-2-methyl-2-phenylpropanamide diacetate 330790-00-6P 330790-02-8P 330790-03-9P 330790-05-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzoxazol-2-amine diacetate 330790-06-2P, 2-[4-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]acetamide 330790-08-4P, 5-[4-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoic acid 330790-09-5P, 1-Cyclopentyl-3-[4-(3-thienyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330790-11-9P 330790-12-0P, Cis-3-[3-[Di(2-furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330790-14-2P 330790-18-6P, (2S)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]propane-1,2-diol 330790-19-7P, (2R)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]propane-1,2-diol 330790-22-2P 330790-23-3P, N-Methyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-24-4P, N,N-Dimethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-25-5P, N-Isopropyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-26-6P, N-(3-Hydroxypropyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-27-7P 330790-28-8P, N-Benzyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-30-2P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-morpholino-1-ethanone

330790-31-3P, N-(3-Methyl-5-isoxazolyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-34-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-hydroxyethyl)amino]-1-ethanone 330790-35-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-methoxyethyl)amino]-1-ethanone 330790-36-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-hydroxypropyl)amino]-1-ethanone 330790-37-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2,3-dihydroxypropyl)amino]-1-ethanone 330790-38-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(tetrahydro-2-furanylmethyl)amino]-1-ethanone 330790-39-1P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-piperidinoethyl)amino]-1-ethanone 330790-40-4P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[2-(dimethylamino)ethyl](methyl)amino]-1-ethanone 330790-42-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[2-(dimethylamino)ethyl]amino]-1-ethanone acetate 330790-43-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[methyl(1-methyl-4-piperidyl)amino]-1-ethanone 330790-44-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-morpholinoethyl)amino]-1-ethanone 330790-45-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-morpholinopropyl)amino]-1-ethanone (protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330790-46-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[3-(1H-1-imidazolyl)propyl]amino]-1-ethanone 330790-47-1P, 1-[3-[[2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-oxoethyl]amino]propyl]-2-pyrrolidinone 330790-48-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(4-hydroxypiperidino)-1-ethanone 330790-49-3P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(hydroxymethyl)piperidino]-1-ethanone 330790-51-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-morpholino-1-ethanone 330790-52-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(4-methylpiperazino)-1-ethanone 330790-53-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(piperid-1-yl)piperidino]-1-ethanone 330790-54-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(1H-4-imidazolyl)-1-ethanone 330790-56-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(methylamino)-1-ethanone acetate 330790-58-4P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(dimethylamino)-1-ethanone acetate 330790-59-5P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(diethylamino)-1-propanone 330790-61-9P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(methylamino)-1-ethanone acetate 330790-62-0P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-64-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-(diethylamino)-1-propanone acetate 330790-66-4P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-morpholino-1-ethanone acetate 330790-68-6P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(4-methylpiperazino)-1-ethanone acetate 330790-69-7P, Cis-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetic acid 330790-71-1P, [3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-(hydroxymethyl)cyclobutyl]methanol 330790-72-2P 330790-73-3P

330790-75-5P 330790-76-6P 330790-77-7P 330790-79-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-5-chloro-2-thiophenesulfonamide maleate 330790-80-2P, 1-[4-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-81-3P, 1-[4-[4-Amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-82-4P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-83-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-84-6P, N-((1R,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-85-7P, N-((1S,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-86-8P 330790-87-9P 330790-89-1P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetic acid 330790-90-4P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-91-5P, N-[2-(Diethylamino)ethyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-92-6P, 2-(Dimethylamino)ethyl 2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-93-7P, N-[3-(Dimethylamino)propyl]-2-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-94-8P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-96-0P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330790-97-1P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-00-9P, 2-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-01-0P 330791-02-1P 330791-03-2P, Ethyl 4-[4-amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-05-4P, 4-[4-Amino-3-[4-[[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanamide 330791-06-5P 330791-07-6P 330791-08-7P, 2-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-5-(4-methylpiperazino)benzonitrile 330791-09-8P, Ethyl 2-[4-amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-10-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-11-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzothiazol-2-amine 330791-12-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzothiazol-2-amine 330791-13-4P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzoxazol-2-amine 330791-14-5P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-15-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzothiazol-2-amine 330791-16-7P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-methyl-1,3-benzoxazol-2-amine 330791-17-8P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine 330791-18-9P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-

pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine 330791-19-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 330791-20-3P 330791-21-4P 330791-23-6P 330791-24-7P 330791-25-8P 330791-26-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzyl]-N'-(3-methylphenyl)urea 330791-27-0P 330791-28-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 330791-30-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide trimaleate 330791-32-7P 330791-33-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 330791-34-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-thiophenecarboxamide 330791-35-0P 330791-37-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-3-phenylbutanamide trimaleate 330791-38-3P 330791-39-4P 330791-40-7P 330791-43-0P 330791-44-1P 330791-46-3P 330791-48-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide trimaleate 330791-50-9P 330791-52-1P, 3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[1-(1-methyl-4-piperidinyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-54-3P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenylcyclopropane-1-carboxamide dimaleate 330791-58-7P 330791-59-8P 330791-60-1P 330791-61-2P 330791-62-3P 330791-63-4P 330791-64-5P 330791-65-6P 330791-66-7P 330791-67-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzyl]-5-methyl-1,3-thiazol-2-amine 330791-69-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dichloro-1,3-benzoxazol-2-amine 330791-70-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-methyl-1,3-benzoxazol-2-amine 330791-71-4P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-chloro-1,3-benzoxazol-2-amine 330791-72-5P 330791-73-6P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-74-7P, N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-75-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-chloro-1,3-benzothiazol-2-amine 330791-76-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-methoxy-1,3-benzothiazol-2-amine 330791-77-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-ethyl-1,3-thiazol-2-amine 330791-78-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5-dimethyl-1,3-thiazol-2-amine 330791-79-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-1,3-thiazol-2-amine 330791-80-5P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(4-methylphenyl)-1,3-thiazol-2-amine 330791-81-6P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-4-phenyl-1,3-thiazol-2-amine 330791-83-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide trimaleate 330791-85-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamidetrimaleat 330791-87-2P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3S)-3-phenylbutanamide trimaleate 330791-89-4P,

4-Amino-3-(4-amino-3-methoxyphenyl)-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidine 330791-91-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 330791-93-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide dimaleate 330791-94-1P, 3-Phenyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-95-2P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide 330791-96-3P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methanol 330791-97-4P, 1-[4-[(4-Methylpiperazino)methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-00-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 330792-03-5P, Trans-3-[4-[(2-Chlorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-05-7P, Trans-3-[3-Methoxy-4-[(1,3-thiazol-2-ylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-09-1P, Trans-3-[3-Methoxy-4-[(2-thienylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-11-5P, Trans-3-[3-Methoxy-4-[[(5-methyl-2-thienyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-13-7P, Trans-3-[4-[[(5-Chloro-2-thienyl)methyl]amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-15-9P, Trans-3-[3-Methoxy-4-[[(2-methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-19-3P, Trans-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-25-1P 330792-27-3P 330792-29-5P 330792-31-9P, Trans-3-[4-(3-Methyl-5-phenyl-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-35-3P 330792-37-5P, 2-(2-Amino-1H-1-imidazolyl)-1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone acetate 330792-38-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-40-0P, 2-(2-Amino-1H-1-imidazolyl)-1-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-1-ethanone acetate 330792-41-1P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-[(2-hydroxyethyl)amino]-1-ethanone 330792-42-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-46-6P, Trans-N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide maleate 330792-48-8P, trans-N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 330792-50-2P, 3-[3-Methoxy-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-52-4P, trans-N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylcyclopropane-1-carboxamide 330792-54-6P 330792-55-7P 330792-56-8P, 1-(Aminomethyl)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 461697-05-2P, N-[4-[4-Amino-1-[4-(morpholinomethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-07-4P, N-[4-[4-Amino-1-[4-[(4-hydroxypiperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-08-5P, N-[4-[4-Amino-1-[4-[[4-(2-hydroxyethyl)piperazino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-

(trifluoromethyl)benzamide 461697-10-9P, N-[4-[4-Amino-1-[4-[[4-(2-hydroxyethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461697-12-1P, N-[4-[4-Amino-1-[4-[[3-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-14-3P, N-[4-[4-Amino-1-[4-[[2-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-15-4P, N-[4-[4-Amino-1-[4-[[(2-morpholinoethyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-17-6P, N-[4-[4-Amino-1-[4-[[4-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461697-18-7P, N-[4-[4-Amino-1-[4-[[4-(2-methoxyethyl)piperazino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-19-8P 461697-20-1P 461697-21-2P, N-[4-[4-Amino-1-[4-[[[3-(1H-1-imidazolyl)propyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-22-3P, N-[4-[4-Amino-1-[4-[[(4-hydroxybutyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-23-4P, N-[4-[4-Amino-1-[4-[[(3-methoxypropyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-25-6P, N-[4-[4-Amino-1-[4-[[[3-(dimethylamino)propyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-26-7P, L-Histidine, N-[[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methyl]-, methyl ester 461697-27-8P, N-[4-[4-Amino-1-[4-[[(2-methoxyethyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-28-9P, N-[4-[4-Amino-1-[4-[[[2-(dimethylamino)ethyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-29-0P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-32-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 461697-35-8P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461697-37-0P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-39-2P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-41-6P 461697-43-8P, Cis-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-44-9P, Trans-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-47-2P, Cis-3-[[4-[4-Amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-48-3P, Trans-3-[[4-[4-Amino-3-[3-methoxy-4-[(2-methoxy-4-trifluoromethylbenzoyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-51-8P, N-[4-(4-Amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-54-1P, N-[4-[4-Amino-1-(3-hydroxycyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-56-3P, 1H-Indole-1-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461697-59-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(trifluoromethoxy)-, monoacetate

461697-61-0P, Benzenebutanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-63-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methyl-, monoacetate 461697-65-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxy-, monoacetate 461697-67-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, monoacetate 461697-69-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)-, monoacetate 461697-71-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-73-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxy-, monoacetate 461697-75-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-fluoro-, monoacetate 461697-77-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-chloro-, monoacetate 461697-79-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-chloro-, monoacetate 461697-81-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-methoxy-, monoacetate 461697-83-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-ethyl-, monoacetate 461697-85-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, monoacetate 461697-87-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-nitro-, monoacetate 461697-89-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenyl-, monoacetate 461697-91-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-ethyl-, monoacetate 461697-93-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-(2-propenyl)-, monoacetate 461697-95-0P, 1H-Indole-1-acetic acid, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461697-97-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1-methyl-3-piperidinyl)-3-(4-phenoxyphenyl)-, acetate 461698-00-0P, 1-[1-(2-Methoxyethyl)-3-piperidyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-03-3P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazol[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide dimaleate 461698-05-5P 461698-07-7P, Trans-3-[3-Chloro-4-[[(5-methyl-2-furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-09-9P 461698-11-3P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylcarbonyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide monomaleate 461698-13-5P, Cyclopropanecarboxamide, N-[4-[4-amino-1-[cis-4-(2-aminoethyl)-4-hydroxycyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-, (1R,2R)-rel-, acetate (salt) 461698-15-7P 461698-17-9P 461698-19-1P, 2-Pyrrolidinecarboxamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, (2R)-, monoacetate 461698-22-6P, 3-(4-Phenoxyphenyl)-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-23-7P, N-[4-[4-Amino-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461698-25-9P, 1-(6-Amino-3-pyridyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-26-0P, 3-(4-Phenoxyphenyl)-1-(2-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-30-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(1H-indol-2-ylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-32-8P, Trans-3-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-

yl]anilino]methyl]-1,2-dihydro-2-pyridinone diacetate 461698-34-0P, Trans-5-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]methyl]-4-chloro-1,3-thiazol-2-amine diacetate 461698-36-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[[(5-methyl-3-isoxazolyl)methyl]amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-38-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[(4-thiazolylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-40-8P, Trans-3-[4-[(4,6-Dichloro-2,3-dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 461698-42-0P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4-chloro-2,3-dihydro-3-benzofuranyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-44-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4,6-dichloro-2,3-dihydro-3-benzofuranyl)amino]-3-methoxyphenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-48-6P, 3-[4-[[(Benzo[b]furan-2-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-50-0P, 3-[4-[[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-52-2P, 3-[4-[[(5-Methyl-2-thienyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-54-4P, 3-[4-[(2-Furylmethyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-56-6P, 3-[4-(Benzylamino)phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-58-8P, 3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-60-2P, 3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-62-4P, 3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-64-6P 461698-66-8P 461698-68-0P, 3-[4-[[(2-Methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-70-4P, 3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-72-6P 461698-74-8P, 3-[4-[[(Benzo[b]furan-2-yl)methyl]amino]-3-methoxyphenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-76-0P, 3-[4-[(2,3-Dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate
(protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461698-78-2P, trans-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione monoacetate 461698-81-7P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione diacetate 461698-83-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine monoacetate 461698-89-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine diacetate 461698-91-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(1,2-benzisoxazol-3-ylamino)phenyl]-1-(4-piperidinyl)-, acetate 461698-93-1P, Trans-3-[4-(1H-3-Indazolylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-98-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-(trifluoromethyl)benzo[d]isoxazol-3-amine monoacetate 461699-04-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-07-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-08-1P, N-[4-[4-Amino-1-(1-methyl-3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine

461699-10-5P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-16-1P, Piperidine, 3-[4-amino-3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-[(dimethylamino)acetyl]-, acetate 461699-17-2P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-methyl-2-(methylamino)-1-propanone 461699-21-8P, N-4-[4-Amino-1-(3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-24-1P, N-[4-[4-Amino-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-29-6P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carbonitrile 461699-33-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-37-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-40-1P, Cis-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-45-6P, trans-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-53-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-54-7P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-55-8P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-56-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-57-0P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5-chloro-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-58-1P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(methylamino)cyclohexyl]- 461699-59-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(2-nitrophenyl)-1,3-thiazol-2-amine 461699-60-5P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzothiazol-2-amine 461699-62-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,6-dihydro-4H-cyclopenta[d][1,3]thiazol-2-amine 461699-63-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-phenyl-1,3-thiazol-2-amine 461699-64-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine 461699-65-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-isopropyl-4-phenyl-1,3-thiazol-2-amine 461699-66-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-5-propyl-1,3-thiazol-2-amine 461699-67-2P, 3-[4-(1,3-Benzoxazol-2-ylmethyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-68-3P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 461699-69-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(4-methylphenyl)-1,3-thiazol-2-amine 461699-71-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(2-methylphenyl)-1,3-thiazol-2-amine 461699-72-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(3-methylphenyl)-1,3-thiazol-2-amine 461699-73-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide bismaleate 461699-76-3P 461699-79-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-

4-(trifluoromethyl)-, acetate 461699-84-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-fluoro-4-(trifluoromethyl)-, acetate 461699-86-5P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-88-7P, Benzenepropanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-90-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-cyclopentylpropanamide diacetate 461699-92-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1,3-dimethyl-1H-5-pyrazolecarboxamide diacetate 461699-94-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide diacetate 461699-95-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylacetamide 461699-96-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(3,4-dimethoxyphenyl)acetamide 461699-97-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenoxypropanamide 461699-99-0P, 5-Isoxazolecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-01-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-pyridinecarboxamide triacetate 461700-03-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,4-difluorobenzamide diacetate 461700-05-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,5-difluoro-, acetate 461700-07-2P, 2-Furancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-08-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethylpropanamide 461700-09-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyanobenzamide 461700-11-8P, Cyclopropanecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-13-0P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methyl-, acetate 461700-14-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluoro-3-methylbenzamide 461700-15-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(dimethylamino)benzamide 461700-16-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,3-difluoro-4-methylbenzamide 461700-18-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]isonicotinamide diacetate 461700-20-9P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-22-1P, 1H-Pyrrole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461700-24-3P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-methyl-, acetate 461700-26-5P, Pyrazinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-28-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-iodobenzamide diacetate 461700-29-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-bromobenzamide 461700-30-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-phenoxybenzamide 461700-31-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluorobenzamide 461700-32-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chlorobenzamide 461700-33-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxybenzamide 461700-34-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461700-35-6P, N-[4-[4-Amino-1-(4-piperidyl)-

1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-nitrobenzamide 461700-36-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 461700-37-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide 461700-38-9P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methylbenzamide 461700-40-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(1,1-dimethylethyl)-, acetate 461700-42-5P, Benzoic acid, 4-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, methyl ester, acetate 461700-43-6P, 4-[[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]carbonyl]benzoic acid 461700-45-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-chloro-, acetate 461700-47-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-bromo-, acetate 461700-49-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methoxy-, acetate 461700-50-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylbenzamide 461700-52-7P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)-, acetate 461700-54-9P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)-, acetate 461700-55-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methoxybenzamide 461700-56-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 461700-58-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-3-(trifluoromethyl)-, acetate 461700-60-7P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-6-(trifluoromethyl)-, acetate 461700-62-9P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-(trifluoromethyl)-, acetate 461700-63-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-methylbenzamide 461700-64-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chloro-2-fluorobenzamide 461700-65-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-benzoylbenzamide 461700-66-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-acetylbenzamide 461700-67-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-isopropylbenzamide 461700-69-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethyl-, acetate 461700-71-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-propyl-, acetate 461700-73-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyclohexyl-, acetate 461700-75-4P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethoxy-, acetate 461700-77-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(methylsulfonyl)-, acetate 461700-79-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-isopropoxybenzamide diacetate 461700-81-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(1H-imidazol-1-yl)-, acetate 461700-83-4P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-, acetate 461700-84-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxybenzo[b]furan-2-carboxamide 461700-86-7P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-bromo-, acetate 461700-87-8P,

N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methylbenzo[b]furan-2-carboxamide 461700-88-9P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methylbenzo[b]furan-2-carboxamide 461700-89-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-nitrobenzo[b]furan-2-carboxamide 461700-91-4P, 2-Benzofurancarboxamide, 5-amino-N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-93-6P, 2-Benzofurancarboxamide, 5-(acetylamino)-N-[4-[4-(acetylamino)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-95-8P, 2-Benzofurancarboxamide, 5-(acetylamino)-N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-97-0P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, acetate 461700-99-2P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methoxy-, acetate 461701-00-8P, N-[4-[4-Amino-1-(1-methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-04-2P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-06-4P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-09-7P, Cis-3-[4-(Imidazo[1,2-a]pyridin-2-yl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-11-1P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-13-3P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-pyrrol-1-yl]-2-methyl-2-(methylamino)-1-propanone 461701-16-6P, N-[4-[4-Amino-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-20-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-amine diacetate 461701-23-5P 461701-25-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine monoacetate 461701-26-8P 461701-28-0P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine monoacetate 461701-30-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine monoacetate 461701-32-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimesylate 461701-34-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]trans-2-phenyl-1-cyclopropanecarboxamide 461701-36-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461701-37-1P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(1,3-oxazol-5-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-39-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 461701-40-6P 461701-41-7P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-ethanol 461701-42-8P , 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-2-methyl-1-propanol 461701-43-9P, 4-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-butanol 461701-44-0P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N',N'-dimethyl-1,2-ethanediamine 461701-45-1P, 1-[4-[[(3-Methoxypropyl)amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-46-2P, 1-[4-[[(2-Methoxyethyl)amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-47-3P, 3-(4-Phenoxyphenyl)-1-[4-(1,3-

thiazolan-3-ylmethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-48-4P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl](2-hydroxyethyl)amino]-1-ethanol 461701-49-5P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,2-ethanediamine 461701-50-8P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidinol 461701-51-9P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,3-propanediamine 461701-52-0P, [1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidyl]methanol 461701-53-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide dimaleate 461701-55-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-56-4P, N-[4-[4-Amino-1-[1-(cyclopropylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-58-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-pyrrol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-59-7P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-61-1P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-63-3P, Benzamide, N-[4-[4-amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-65-5P, Benzamide, N-[4-[4-amino-1-[1-[(4-methyl-1H-imidazol-5-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-66-6P, N-[4-[4-Amino-1-[1-(1,3-thiazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-67-7P, N-[4-[4-Amino-1-[1-[[5-(hydroxymethyl)-2-furyl]methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-68-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-69-9P, N-[4-[4-Amino-1-(1-isopropyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-71-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methylpropyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-72-4P, N-[4-[4-Amino-1-[1-(2-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-73-5P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-74-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-imidazol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-75-7P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-76-8P, tert-Butyl 4-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]-1-piperidinecarboxylate 461701-77-9P, N-[4-[4-Amino-1-[1-(tetrahydrothiophen-3-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-78-0P, N-[4-[4-Amino-1-(1-benzyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-80-4P, Benzamide, N-[4-[4-amino-1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-81-5P 461701-82-6P 461701-84-8P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-pyrrol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-

4-(trifluoromethyl)-, acetate 461701-86-0P, Benzamide, N-[4-[4-amino-1-[1-[(5-methyl-2-furanyl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-87-1P, N-[4-[4-Amino-1-[1-(2-thienylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-89-3P 461701-91-7P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461701-92-8P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-thiopyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-93-9P, 4-[[4-[4-Amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]methyl]-1-pyridine-N-oxide 461701-94-0P, N-[4-[4-Amino-1-[1-(2-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-95-1P, N-[4-[4-Amino-1-[1-(3-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-96-2P, N-[4-[4-Amino-1-[1-(4-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-97-3P, N-[4-[4-Amino-1-[1-[3-(methylsulfanyl)propyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-98-4P, N-[4-[4-Amino-1-[1-[(5-methyl-2-thienyl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-99-5P, N-[4-[4-Amino-1-[1-(3-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-00-1P, N-[4-[4-Amino-1-[1-(4-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-01-2P, N-[4-[4-Amino-1-[1-(2-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-02-3P, N-[4-[4-Amino-1-[1-(4-methoxybenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-03-4P, N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-05-6P, Benzamide, N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461702-06-7P, Methyl 2-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 461702-07-8P 461702-10-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methoxyethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461702-11-4P, N-[4-[4-Amino-1-[1-(cyanomethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-13-6P, 1-Piperidineacetamide, 4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-, acetate 461702-15-8P 461702-17-0P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-20-5P 461702-23-8P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-25-0P, N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-28-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-31-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461702-33-0P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-

pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-35-2P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide

(protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461702-36-3P, N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 461702-37-4P 461702-38-5P, N-[4-[4-Amino-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-41-0P, N-[4-[4-Amino-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-43-2P, N-[4-[4-Amino-1-[3-(1H-1-imidazolyl)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-46-5P, N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-47-6P, N-[4-[4-Amino-1-(1-isopropyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-48-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-49-8P, N-[4-[4-Amino-1-[1-(1H-imidazol-4-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-50-1P, N-[4-[4-Amino-1-[1-[(3-methyl-1H-pyrazol-4-yl)methyl]tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-51-2P 461702-52-3P 461702-53-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461702-56-7P, cis-Methyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 461702-57-8P, cis-4-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylic acid 461702-58-9P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-61-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461702-64-7P 461702-65-8P, (S)-N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461702-72-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carboxamide triacetate 461702-75-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate 461702-77-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(methylsulfonyl)-, monoacetate 461702-79-4P, 1H-Indole-5-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-81-8P, 1H-Indole-6-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-83-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate 461702-85-2P, β-Alanine, N-[3-[4-[(1H-indol-2-ylcarbonyl)amino]-3-methoxyphenyl]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, monoacetate 461702-87-4P, 1H-Indole-1-propanoic acid, 2-[[[4-[4-[(2-carboxyethyl)amino]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461702-89-6P, 1H-Indole-1-acetamide, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-N,N-dimethyl-, monoacetate 461702-91-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-hydroxy-1H-2-

indolecarboxamide monoacetate 461702-93-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-hydroxy-1H-2-indolecarboxamide monoacetate 461702-95-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-amino-1H-2-indolecarboxamide monoacetate 461702-97-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-3-indolecarboxamide monoacetate 461703-00-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-4-indolecarboxamide monoacetate 471925-60-7P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine maleate 471925-63-0P, Cis-3-[4-[(1H-4-Imidazolylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 471925-65-2P, Cis-3-[4-[(1H-2-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471925-69-6P 471925-70-9P 471925-71-0P 471925-72-1P 471925-73-2P 471925-74-3P 471925-75-4P 471925-76-5P 471925-77-6P 471925-78-7P 471925-79-8P 471925-80-1P 471925-81-2P 471925-87-8P 471925-88-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 471925-93-6P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(2-methoxyphenyl)propanamide 471925-94-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methoxyphenyl)propanamide 471925-95-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3-methoxyphenyl)propanamide 471925-96-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methylphenyl)propanamide 471925-97-0P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-fluorophenyl)propanamide 471925-98-1P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3,4-difluorophenyl)propanamide 471926-08-6P, Trans-3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]aminophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 471926-09-7P 471926-14-4P, Cis-3-[3-[2-(1H-2-Imidazolyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471926-16-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-anilinoacetamide 471926-23-5P, N,N-Methoxymethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 471926-25-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(1H-4-imidazolyl)-1-propanone 471926-26-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(2-methoxyethyl)piperidino]-1-ethanone 471926-61-1P 471926-74-6P 471926-76-8P 471926-82-6P 471927-20-5P, Trans-3-[3-Methoxy-4-[[(3-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-25-0P, Trans-3-[4-[(1H-7-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-28-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[[(5-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-44-3P, N-(1H-2-Imidazolyl)-2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetamide 471927-45-4P, trans-N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 471927-46-5P, Trans-N-[4-[4-Amino-1-[(4-hydroxy-4-piperidyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide (protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)